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ABSTRACT
Inhibition of CDK2 activity in G1 and S phases of the cell cycle can promote
selective apoptosis of cancer cells through the E2F1 pathway. Currently available CDK
inhibitors target the ATP binding pocket and result in lack of specificity for the cell cycle
vs. the transcriptional CDKs. It has been shown that a peptide HAKRRLIF derived from
the tumor suppressor p21 binds to the cyclin binding groove (CBG) and selectively
inhibits cell cycle CDKs (CDK2/Cyclin A, CDK2/Cyclin E and CDK4/Cyclin D). The
CBG is unique to cell cycle CDKs hence targeting this site avoids the inhibition of
transcriptional CDKs can potentially lead to toxicity. The goal of this project is to
iteratively convert potent cyclin groove inhibitory (CGI) peptides into more drug like
molecules called FLIPs (Fragment ligated inhibitory peptides) using the REPLACE
strategy (Replacement with Partial Ligand Alternatives through Computational
Enrichment).
FLIPs were constructed by sequentially replacing key peptide binding
determinants for RRLIF with fragment like small molecules in order to obtain a non-ATP
competitive inhibitor of cell cycle CDKs with improved drug like properties. Fragment
alternative capping groups were evaluated by docking, synthesis and testing of FLIPs in
competitive binding and cellular viability assays.

Partial Ligand Alternatives were

identified which interacted with the main subsites of the N-terminal tetrapeptide of
HAKRRLIF and were derivatives of phenyl heterocyclic carboxylic acids, furoic,
picolinic and benzoic acids. The most effective Ncap was found to be 1-(3,5v

dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (35DCPT) ligated to RLIF.
In a further iteration of REPLACE, the C-terminal motif was modified with βhomoleucine (βLeu) and N-Methyl Phe or 3-Thienylalanine in order to improve
metabolic stability. The lead compound after Ncap and Ccap optimization was found to
be 35DCPT-R{βLeu}{3TA}-NH2 (SCCP5964) which has respectable antiproliferative
activity and is also capable of inducing a G1 cell cycle arrest. The REPLACE strategy
has therefore been further validated in the development of FLIPs molecules as non-ATP
competitive CDK inhibitors. These cyclin groove inhibitors represent next generation
CDK therapeutics having anti-tumor activity consistent with on target inhibition and
demonstrated potential for drug development.
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CHAPTER 1
INTRODUCTION
1.1.Cancer
Cancer is a group of diseases caused by uncontrolled proliferation of cells. There
are more than 200 types of tumors originating from various types of cells affecting
different organs. The major types of cancer are classified into broad categories including
carcinomas, sarcomas, leukemias, lymphomas and cancers of the central nervous system.
Carcinomas are types of cancer affecting skin or tissues covering internal organs,
sarcomas originate in bones, cartilage, fat, muscle, blood vessels or connective tissues,
leukemias arise in blood and bone marrow, lymphomas affects lympocytes and the CNS
cancers are related to the brain and spinal cord1. Cancer is one of the greatest burdens on
society and is one of the leading causes of death worldwide. In 2008, the global cancer
mortality incidence was estimated to be 7.6 million and where this accounted for 13% of
all deaths in that year. It has been predicted that annually, 13.1 million deaths will occur
by 2030 due to cancer2. In the United States, one in four deaths is due to cancer and more
than 1.66 million new cases and more than 0.56 million deaths occurred in 20142,3,4.
The most frequent deaths arise from the cancers of lung, stomach, liver, colon and
breast. Cancer is caused by various factors which include among others chemicals,
radiation, food, aging, hormones, infections, and tobacco. Some of the common
preventable contributing factors include high body mass index, low fiber intake, lack of
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physical activity, alcohol and smoking account which combined represent 30% of
cancerdeaths. Tobacco alone contributes to 22% of global cancer deaths and 71% of all
lung cancers. Cancer treatment methods include surgery, radiation and chemotherapy all
of which are associated with significant negative outcomes. Surgery is generally not
useful when cancer has metastasized to various parts of the body whereas chemotherapy
and radiation therapy are not specific for cancer cells which results in side effects from
toxicity on normal cells2,3,5.
1.2 History of chemotherapy
Currently, there are about 200 drugs approved for cancer and hundreds more in
clinical development6. Anti-cancer drug development has undergone many advances
since the initial development of cytotoxic agents leading to the sophisticated targeted
therapeutics available now7,8. The development of chemotherapeutic agents started in the
era of World War II in 1940s with the nitrogen mustards. At the outset, cancer drugs were
based on cytotoxics that kill rapidly dividing cells and many of these drugs are widely
used. The nitrogen mustards were studied and developed at Yale School of Medicine to
treat non-Hodgkin’s lymphoma. These compounds alkylate DNA on purine bases leading
to crosslinking of strands and as a result inducing apoptosis9. The next step in
chemotherapeutic agents was the development of antifolate treatments by Sidney Farber
at the Harvard Medical School and at the Children’s hospital at Boston. Methotrexate is
an effective drug in the antimetabolite class and which was initially used in the treatment
of acute lymphoblastic leukemia10. Later this drug was found to be effective in breast,
ovary, bladder and head and neck cancers7,11,12. The antifolates bind to and inhibit
dihydrofolate reductase which acts at the level of the building blocks of DNA and inhibits
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the synthesis of thymidylate and purines leading to apoptosis13. Another example in this
class is 6-Mercaptopurine (immunosuppressive agent)14. Vinca alkaloids are another class
of drugs that act in mitosis causing spindle poisoning and also inhibit microtubule
polymerization. These were developed by Eli Lilly and approved by the FDA in 1963.
Prednisone (modifies gene transcription and affects the synthesis of various proteins) was
developed in the 1950s and used for acute lymphoblastic leukemia, Non-Hodgkin
lymphomas and multiple myeloma7,8.
Drug resistance is major problem in cancer treatment as cancer cells mutate and
become resistant to a single agent. Hence combination therapies were developed through
the use of multiple drugs with different mechanism of action in attempts to overcome
drug resistance problem. Combination therapies such as POMP (combination of
methotrexate, vincristine, 6-MP and prednisone) and MOPP (combination of nitrogen
mustard, vincristine, procarbazine and prednisone) regimens were validated in
1960s15,16,17. During the era of combination therapies, several natural product drugs such
as the taxanes18 (e.g. paclitaxel, an antimitotic agent) and camphothecins (topoisomerase
inhibitor) were discovered which were later used for the treatment of ovarian and colon
cancer respectively. Taxanes were discovered in the 1960s however not approved by the
FDA until the 1990s19. Cisplatin, a platinum based drug was a serendipitous discovery in
1960s that was then approved for testicular cancer. Carboplatin was later developed as an
improved and less toxic version of cisplatin. These drugs bind to DNA and interfere with
DNA transcription and replication20. Many of the cancer therapeutics developed in early
years of chemotherapy had serious drawbacks due to acute and long term toxicities
affecting various parts of the body. These arise from the non-selectivity of conventional
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therapeutics in targeting both cancer and normal cells. Molecular biology and genetics
approaches helped in understanding the deregulation of signaling pathways and
molecular defects in tumors. This lead to the development of drugs that target molecular
pathways specific for cancer cells which marked the beginning of the new generation of
targeted therapeutics in 1980s7.
1.3 Targeted therapy
In targeted therapy, drugs are designed to specifically block the function of
protein molecules that cause molecular defects ultimately leading to tumor growth and
progression. Such defects are considered as important hallmarks of cancer and are mainly
observed in proteins involved in signaling pathways and those responsible for regulating
growth and division of cells. These include regulation of proliferative signaling, control
of apoptotic pathways, angiogenesis, enabling of replicative immortality, activation of
invasion and metastasis, deregulation of cellular energetics, control of genome stability
and processes of tumor promoting inflammation21,22. Some examples of targeted drug
discovery directed towards these pathways are shown in figure 1.1.
Clinically validated drugs in the category of targeted therapeutics are mostly
based on small molecule enzyme inhibitors and biologic agents such as monoclonal
antibodies and vaccines. A number of drugs targeting pathways mentioned above (figure
1.2) have been approved by the FDA. The first targeted therapeutics approved were the
estrogen receptor modulators including tamoxifen and toremifene. Trastuzumab
(Herceptin) was developed in 1998 acts at HER2/neu receptor, used in the treatment of
breast cancer23. Imatinib Mesylate (Gleevac) developed by Novartis was the first small
molecule drug and the first kinase inhibitor approved for use as targeted therapy and
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which is capable of killing cancer cells specifically. Imatinib was approved by the FDA
in 2001 for the treatment of chronic myeloid Leukemia (CML) acting on the tyrosine
kinase (TYK) BCR-ABL which occurs only in the tumor and therefore provides a
window of opportunity for selective targeting. Remarkable success was obtained with this
drug when treating this disease in its early stages and further was shown to be effective in
treating gastrointestinal tumors. Unfortunately cancers treated with imatinib develop
resistance due to mutations in the catalytic site of BCR-ABL and which no longer bind
the drug24. Subsequent advances in kinase targeted drug development include the
epidermal growth factor receptor (EGFR) inhibitors gefitinib (Iressa) and the antibody
cetuximab were approved by FDA in 2003 for the treatment of non-small cell lung cancer
(NSCLC) and colon cancer. Erlotinib was then approved in 2005 following the failure of
gefitinib for NSCLC25.

Figure 1.1 Therapeutic Targeting of the Hallmarks of Cancer
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Additional drugs based on inhibition of tyrosine kinase inhibitors developed and
approved by the FDA later include sorafenib (TYK- VEGFR (vascular endothelial
growth factor receptor), PGDFR (Platelet derived growth factor)), sunitinib (TYKVEGF, PGDFR, renal carcinoma), nilotinib (CML), pazopanib (VEGF) , vandetanib
(inhibits EGFR, VEGF and RET), crizotinib (inhibits EML4-ALK), and axtitinib (VEGF,
renal cell carcinoma). A common feature of these drugs is that they target different
protein kinases which are deregulated in cancer26,

27

. There are 519 proteins in this

family, lack of drug selectivity, emergence of drug resistance may be problematic.
Furthermore difficulty in drug target validation for particular disease settings may also be
an issue28, 29,30.

Figure 1.2 FDA approved drugs for targeted cancer therapy (NIH data)26
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1.4 Protein kinases
Protein kinases are a group of enzymes involved in phosphorylation of other
substrates. Members of the kinome family constitute about 2% of all the human
genes28,29. Kinases regulate many cellular pathways including those involved in signal
transduction regulating growth and division of cells and therefore their deregulation
frequently is associated with tumor formation. Kinase subfamilies implicated in cancer
include the receptor tyrosine (RTK), cytoplasmic tyrosine (CTK), serine threonine (STK)
and lipid kinases (LK)27. RTKs phosphorylate tyrosine residues on substrate proteins and
generally function in transmembrane signaling. Various members of the RTK family
have been shown to be mutated in cancer and include the EGF, IGF and PDGF receptors
among others. Members of the CTKs regulate extracellular signaling e.g. the JAK-STAT
pathway and include c-SRC, Abl and JAK-2 kinases. PI3K kinases are lipid kinases
which modulate cell growth, proliferation, and intracellular trafficking, and
phosphorylate phosphatidylinositol31, 32. ST kinases phosphorylate serine and threonine
residues in various substrates that are required for controlling cell proliferation and
survival in the presence of abnormal ploidy. Some examples of such enzymes include the
cyclin dependent kinases (CDKs) that regulate cell cycle check points, the aurora kinases
which are required for chromosome separation and the polo like kinases involved in
numerous roles in mitosis and cytokinesis. CDKs play a significant role in cancer
mechanisms including amplification or overexpression occurring in sarcoma, glioma, and
melanoma. Mutations in CDK2 are not frequently observed however overexpression of
its activator cyclin E and the inactivation of p21 and p27 inhibitory proteins can lead to
excessive CDK2 activity in tumors. Although CDKs are directly and indirectly involved
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the majority of tumors, CDK inhibitory drugs have yet to be fully approved by the FDA
as anticancer therapeutics due to issues related to cross reactivity33.
1.5 Cyclin dependent kinases
Cyclin dependent kinases (CDKs) are heterodimeric complexes of a CDK
catalytic subunit and a cyclin acting as a positive regulatory subunit. The different
CDK/cyclin complexes known to date have key roles in regulating both cell cycle check
points and transcription events33,34. Most CDKs are activated by associating with a
particular cyclin and further through phosphorylation of the catalytic subunit on a
threonine residue adjacent to the active site. Prior to activation, the ATP binding site of
CDKs is hidden by the T-loop. Binding of cyclin leads to a conformational change
including movement of T-loop from the active site entrance. These structural changes
also arrange the ATP binding residues in the correct confirmation to allow catalysis at the
active site and which is completed through phosphorylation by CDK7 (CDK activating
kinase, CAK) on the T-loop threonine. The fully activated CDK/cyclin complexes are
then able to phosphorylate threonine and serine residues on CDK substrates35,36. For the
cell cycle CDKs it is known that key substrates require recruitment prior to
phosphorylation. This occurs through a shallow and mainly hydrophobic binding site
known as the cyclin binding groove (CBG). The CBG is also involved in regulation of
CDK catalytic activity by endogenous cell cycle inhibitory proteins which act as CDK
inhibitors (CDKIs)37. The CDKIs are classified in two families known as the INK4 and
Cip/Kip proteins that bind to catalytic sub unit or the whole CDK/cyclin complex
respectively. Members of INK4 family include p15, p16, p18 and p19 which inhibit

8

CDK4 and CDK6 whereas the Cip/Kip includes p21, p27 and p57 that can inhibit each of
the cell cycle CDK complexes38,39.
There are at least 13 CDKs and 11 cyclins that have been identified so far

40,41

.

CDKs are mainly classified into two groups based on their roles in the cell cycle as (i)
check point regulators and (ii) transcriptional regulators. The complexes of CDK4/cyclin
D1, CDK6/cyclin D1 and CDK2/cyclin E regulate G1/S transition by phosphorylating the
retinoblastoma protein (Rb). Further action of CDK2/cyclin A modulates the progression
of S phase and CDK1/cyclin B controls the G2/M transition and entry into mitosis.
CDK7/cyclin H, CDK9/cyclin T and CDK8/cyclin C function in regulating transcription
through phosphorylation of RNA polymerase II thereby facilitating initiation and
elongation of RNA transcripts333,42. A summary of the roles of CDK/cyclin complexes is
depicted in figure 1.3.

Figure 1.3 Role of CDK/cyclin complexes in cell cycle progression and transcription
1.6 Deregulation of cyclin D-CDK4/6-p16INK4-Rb pathway in cancer
The retinoblastoma protein Rb is a key regulator of the G1 to S phase transition.
Its function in transcriptional repression is inactivated by sequential phosphorylation by
CDK4/cyclin D, CDK6/cyclin D and CDK2/cyclin E. CDK4/6/cyclin D assists in
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progression through G1 by phosphorylation of the Rb-E2F complex. INK4 family protein
p16INK4 associates with CDK4/6 to regulate G1 progression by the release of cyclin D.
CDK4/cyclin D and CDK6/cyclin D also binds to the CDK2 inhibitors p21CIP1 or p27KIP1,
p57KIP2 sequestering these from CDK2. Mitogenic signals stimulate the synthesis of the D
cyclins and release of CDK4 and CDK6 from p16 INK4. Cyclin D associates with CDK4/6
which subsequently forms an assembly with Cip/Kip proteins. CDK4/cyclin D relieves
the assembly of Cip/Kip with CDK2/cyclin E, thus activating it and leading to further
phosphorylation of the Rb-E2F1 complex. Full activation of E2F results in gene
expression and production of proteins required for progression through S phase. During
this process, cyclin E gene is produced, binds to CDK2 by antagonizing Cip/Kip
inhibitory proteins and creating a positive feedback loop. Late in S phase, CDK2/cyclin
A maintains Rb in its inactive state and also phosphorylates E2F, releasing it from the
DNA after gene transcription for S-phase progression is complete (figure 1.4). The Rb
and Cip/Kip proteins play significant roles in maintain cells in a quiescent state33,34.
In general the cyclinD-CDK4/6-p16INK4/Rb pathway is disrupted in many forms
of cancer. Cyclin D is particular is overexpressed in many tumors including breast cancer
(due to gene rearrangement), multiple myeloma (due to translocation) and mutation of
cyclin D is found in esophageal cancer. Gene amplification of cyclin D is observed in
mantle cell lymphoma. Loss of the tumor suppressor p16INK4 occurs in many cancers due
to gene deletion, point mutation or transcriptional silencing ultimately resulting in
increased activity of CDK4/cyclin D. Due to the overexpression of cyclin D or the loss of
p16INK4, excessive CDK4 kinase activity results, further leading to up-regulated
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CDK2/cyclin E and in turn generating higher activity levels of the E2F transcription
factor43.

Figure 1.4 Role of cyclin D-CDK4/6-p16INK4-Rb in cell cycle
1.7 Selective apoptosis of cancer cells by the inhibition of CDK2/cyclin A through
E2F1 pathway
The Rb protein when in its hypo phosphorylated state acts as a transcriptional
repressor (i.e. bound to E2F) and is converted to a transcriptional activator when
phosphorylated resulting in its dissociation from E2F. E2F is then released to bind to the
DP1 protein and form a dimeric complex. The E2F1-DP1 heterodimer initiates gene
transcription through its DNA binding transcription factor activity. After replication is
complete, the activity of E2F1 must be neutralized prior to exit from S phase.
CDK2/cyclin A is responsible for this function through interaction with the N-terminus of
E2F and ultimately phosphorylates both E2F and DP1 to release the complex from DNA.
Since many tumors have high base line levels of E2F1 due to a deregulated Rb pathway,
inhibition of CDK2/cyclin A activity can lead to accumulation of E2F1 and persistent
11

activity. The result of this is to surpass the threshold required for the induction of
apoptosis in a p53 independent fashion. Inhibition of CDK2/cyclin A in the context of
normal cells has a much lower effect due to the lower levels of E2F1 activity and the
cells proceed with S phase (figure 1.5). Hence inhibition of CDK2/cyclin A should
promote selective apoptosis of cancer cells and as a result should be considered as an
important target for cancer34.

Figure 1.5 Role of CDK2/cyclin A in cancer cell apoptosis through E2F1 pathway
1.8 Strategies for the inhibition of CDK/Cyclin complex
The general strategies for the inhibition of CDK/Cyclin complexes include direct
and indirect modulation such as (i) ATP competitive and (ii) non-ATP competitive
inhibition respectively44. Direct modulators mainly antagonize ATP binding whereas
indirect mechanisms act in other ways. These include blocking substrate recruitment
through the cyclin binding groove, inhibition of kinase activation by interfering with
formation of the complex with the cyclin, and also stabilizing an inactive conformation of
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the complex45. The ATP binding pocket and cyclin binding groove are shown in figure
1.6.

Figure 1.6 CDK2/cyclin A complex showing CBG
and ATP binding site46
The majority of identified protein kinase inhibitors and FDA approved drugs are
based on these come under the category of direct modulators that block the binding of
ATP binding. The ATP binding site is highly conserved among the family of 519 kinases
and therefore limits the selectivity of these molecules. The non-specificity of ATP
competitive inhibitors can lead to cross reactivity with other members of the kinome
potentially resulting in off target side effects and toxicities44. The first generation of CDK
inhibitors included flavopiridol and roscovotine and exhibited limited activity and
unacceptable toxicities in clinical trials. These molecules were not specific for the desired
CDK2 target and were found to be capable of inhibiting several CDK/cyclin complexes
in addition to other kinome members. One side effect of Flavopiridol is hyperacute tumor
lysis syndrome and damage to the photoreceptor layer in eyes. Roscovitine has been used
in the treatment of NSCLC in phase I-II stage of clinical trials, where the reported side
effects are nausea, vomiting, elevations in serum creatinine levels and hypokalemia.
Other CDK inhibitors developed subsequent to these first generation inhibitors include
13

R547, AT7519, and AZD5438. Most of these compounds have good preclinical activity
but also are non-specific and are pan CDK inhibitors. This results in effects through
inhibition of transcription is a likely reason for the observed toxicities. A list of CDK
inhibitors that have been clinically investigated are shown in figure 1.7. The drug PD0322991(Palbociclib) has been given breakthrough status is in phase III clinical trials for
post-menopausal estrogen receptor positive breast cancer. It is the most selective CDK
inhibitor so far since it acts only on CDK4 and CDK6 thus inhibiting Rb 25,33,42,47.

Figure 1.7 CDK inhibitors in clinical trials
Non-ATP competitive CDK inhibitors developed to date include substrate derived
peptides (p53 and Rb derived peptides). The tumor suppressor p53 derived peptides
target the docking site of p53 tetramerization domain on CDK2 surface. A 20 mer peptide
14

derived from this site is known as CIP and inhibits phosphorylation. A GEF-CIP fusion
protein induces cell death in A375 melanoma cell lines by reducing p53 activity along
with suppression of p21. As discussed in section 1.6 and 1.7, the Rb protein is very
important for regulation of the G1/S transition and S phase. A 39 residue peptide in cell
permeable form derived from Rb (Spa310) has been shown to induce apoptosis via
G0/G1 arrest by the inhibition of CDK2 activity. Inhibitors of the interaction between
CDK and the cyclin have been recently discovered. C4, an inhibitor of the CDK2 cyclin
A interaction is a 22mer peptide derived from the α5 helix of cyclin A. This peptide
adopts a α-helical structure and mimics hydrophobic interactions between CDK2 and
cyclin A leading to an inactive conformation of CDK2/cyclin A complex. This peptide is
specific for the inhibition of CDK2 activity when introduced into MDA-MB-231 breast
cancer cell lines as a TAT fusion peptide. NBl1 is a hexapeptide which targets a cleft
present in the monomeric cyclin A, affecting the interactions of CDK2/cyclin A and also
the stability of the complex. This peptide inhibits most of the cell cycle CDK complexes
including CDK2/cyclin A, CDK2/cyclin E, CDK6/cyclin D and CDK1/cyclin E. Cellular
studies of an NBl1-TAT fusion peptide on cell lines including HCT116, HT29, T98G,
and A2780 showed that it also inhibits CDK2/cyclin A. Fluorescence polarization studies
showed that this peptide also inhibits CDK1/cyclin B1, CDK6/cyclin D3 however does
not affect other serine/threonine kinases such as glycogen synthase kinase and mitogenactivates kinase45. As can be seen, the majority of molecules in the category of non-ATP
competitive inhibitors is peptide based and are in the stage of early pre-clinical
development.
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In general, peptides are not suitable for drug development due to their non-drug
like characteristics including lack of cell permeability and susceptibility to proteolytic
degradation48. In this project an alternative approach for non-ATP competitive inhibition
has been pursued by targeting the cyclin binding groove (CBG). The CBG is primarily a
hydrophobic groove that is distant from ATP binding site and is present in cyclins A, D
and E46. It has been shown that a consensus sequence derived from CDK substrates and
inhibitory proteins interacts with the CBG and inhibits the cell cycle CDKs i.e. those that
associate with cyclins A, D and E. The overall goal of this project is to convert an
optimized CBM peptide to a non-peptidic inhibitor using the REPLACE drug design
strategy49.
1.9 Cyclin binding motif
Substrates of the cell cycle CDKs include the E2F and Rb proteins and these in
addition to the tumor suppressor inhibitory proteins (e.g. p21, p27, p57 and p53) contain
a conserved sequence (CBM) essential for the regulation of CDK activity and for
substrate recruitment. This motif is comprised of the ZRXL sequence (figure 1.8) in
which “Z” and “R” are basic residues. The residue “Z” is most frequently Lys and “X” is
a strictly conserved Arg residue (figure 1.8). Previous studies have shown that
CDK4/cyclin D and CDK2/cyclin E phosphorylation can be inhibited by the 20 mer
peptide (residues 141-160) derived from the C-terminus of p21. The same sequence of
peptides did not inhibit the phosphorylation of histone H1, hence has no effect on the
activity of CDK1/cyclin B further illustrating that early cell cycle CDKs can be
selectively blocked in this manner.
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Figure 1.8 CBM sequences present in tumor suppressors and substrates
that interact with CDK2/cyclin A, CDK2/cyclin E and CDK4/cyclin D
The sequence of p21WAF (DFYHSKRRLIF) determined to be the most active in
cyclin binding and CDK inhibition was found to be from residues 149 to 160. A
structure-activity relationship (SAR) study was carried out by exchanging each of the
residues within this sequence for alanine and therefore probing the contribution of each
side chain. It was found that the replacement of Ser153 resulted in potency gains in both
CDK4/cyclin D (IC50-10µM) and CDK2/cyclin E (IC50-0.004±0.005µM) (figure 1.9)50.
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Figure 1.9 Alanine scan of p21WAF1 (149-160) sequence
Further studies on the consensus cyclin binding motif (ZRXL) indicated that the
flanking residues (Ala on the N-teminus and Phe on C-terminus) make hydrophobic
interactions shown to be important for binding. Octapeptides including those from p21 Cterminus (HAKRRLIF), E2F1(PVKRRLDL) and p107 (SAKRRLFG), were tested for
kinase inhibition against CDK2/cyclin A, CDK2/cyclin E and CDK4/cyclin D and for
competitive binding with cyclin A. Of the peptides tested, HAKRRLIF was found to be
the most potent with an IC50 value of 0.028µM which is comparable to full length human
recombinant p21WAF1 (IC50 = 0.011µM) in competitive binding assay of CDK2/cyclin
A. Hence the CBM was optimized to the octapeptide, HAKRRLIF and which was further
minimized to a pentapeptide RRLIF (IC50-1.4µM in CDK2/cyclin A). The
crystallographic structure of CDK2/cyclin A/p27KIP1 shows how the CBM (SACRNLFG)
interacts with the CBG. Similarly the modeled structure of CDK2/cyclin A/p21WAF1 was
18

generated and in which HAKRRLIF interacts with the CBG46,50. It has been shown that
CBM peptides derived from E2F linked to the transfection sequence of HIV-TAT induces
a cytotoxic effect on tumor cells including U2OS and MDA-MB-435, cell types which
possess deregulated cyclin D-CDK4/6-p16INK4-Rb. At the same time, CBM peptides
exert little effect on non-transformed cells including HaCaT and rat 1A fibroblasts. A
further study investigated a 20mer peptide from the C-terminus of p21WAF1 conjugated to
a 16 residue sequence from the homeodomain of Antennapedia protein (penetratin) and
E2F derived peptides linked to Tat. These permeable peptides were tested in cancer lines
and flow cytometry suggested that cell death was due to nuclear condensation and sub
diploid DNA suggestive of apoptosis51,52.
1.10 Cyclin binding groove
The CBG is primarily a hydrophobic groove, distinct and distant from ATP
binding pocket, found only in cell cycle CDKs, through which cyclins recruit substrates
and inhibitory proteins. Targeting CBG leads to selective inhibition of CDK2/cyclin A
and CDK4/cyclin D over other members of the CDK family. The structure of the CBG is
somewhat different between cyclin A and cyclin D however in general consists of three
sub sites interacting with binding determinants from the octapeptide HAKRRLIF (figure
1.10). These sub sites include a primary hydrophobic pocket and a smaller secondary one
separated by a ridge of negatively charged residues49.
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Figure 1.10 Structure of CBG
HAKRRLIF binds at the CBG in such a way that the N-terminal tetrapeptide
interacts with the secondary pocket and acidic residues while the C-terminal region
contacts the primary pocket (figure 1.11). The types of interactions occurring between
HAKRRLIF and CBG include ion-pairing, hydrogen bonding and hydrophobic effects
through van der Waals interactions. The basic residues of HAKRRLIF undergo ionpairing interactions with the acidic residues of the CBG and include Glu220, Glu224 and
Asp283. The backbone amides of His1, Ala2, Lys3 and Arg4, form hydrogen bond (Hbonds) with Glu224, Trp217, Gln254 and Ile 281 respectively. The methyl side chain of
Ala2 fills the secondary pocket while the side chains of Leu6 and Phe8 occupy the
primary lipophilic pocket. These interactions are listed in detail in figure 1.11 and table
1.1.

Figure 1.11 Binding and interactions of HAKRRLIF in CBG
20

Table 1.1 List of interactions of HAKRRLIF with CBG

Type of interaction

N-terminal and central region

C-terminal region

Ion-pairing

Basic amino acids (H,K,R,R) with acidic
residues(Glu224, Glu220 and Asp283)

NA

H-bonding

Amide backbones of HAKRR (Glu224,
Trp217, Ile281, Gln254)

NA

van der Waals
hydrophobic effect

Ala methyl side chain with the secondary
hydrophobic pocket

Leu, Phe side chain with
the primary pocket

1.11 Comparison of CBG in cyclin A and cyclin D
Previous studies were conducted in the McInnes laboratory in order to investigate
the structural differences between the CBG of cyclins A and D1. The major differences in
the residues of the cyclin groove include the exchange of Ile132, Val60 and Thr62 for
Tyr286, Leu214 and Asp216 in cyclin A respectively. The superposition of cyclin A and
D1 structures reveals that these variations are accompanied by movement of a helix-loop
segment from residues 119 to 136 resulting in conformational differences between the
cyclins (figure 1.12). This conformational variation results in cyclin D having a shallower
but extended primary pocket. Furthermore, a narrow secondary pocket and fewer acidic
residues occur in cyclin D relative to cyclin A (figure 1.13). These variations could
potentially be exploited in the design of selective inhibitors of CDK4/cyclin D if these
were desired53.
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Figure 1.12 Comparison of CBG residues of cyclin A and cyclin D
Left- Overlay of crystal structures of cyclin D1 (orange carbon atoms; PDB code
2W96) and cyclin A2 (PDB code 1OKV) The Leu and Phe residues of the CBM
interacting with the primary hydrophobic pocket are shown. E220 and D216
comprise the acidic region, and the secondary hydrophobic pocket is to the left of
W217.
Right - Ribbon representation of the overlay highlighting the differences in the
cyclin box helices. Cyclin D1 is shown in yellow and the CGI peptide in blue. The
region displaying the largest structural differences after superimposing the
backbone atoms is labeled (residues 116_136 of cyclin D1)

Figure1.13 Comparison of CBG of cyclin A and cyclin D
Comparison of the solvent accessible surface of the cyclin grooves of A2 (left) and
D1 (right). The following regions displaying structural differences in cyclin binding
determinants are labeled: (left) The more acidic region of cyclin A compared to
cyclin D1, which results in differential interactions with Arg4 (peptide sequence
HAKRRLIF).
Right-The primary hydrophobic extension of cyclin D1 (top right); the shallower
cyclin D1 primary hydrophobic pocket (the Leu214_Val60 interchange, bottom
right); and the narrower cyclin D1 secondary hydrophobic pocket (bottom left).
Each of these structural features explains the differential requirements for cyclin
groove inhibitor binding.
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1.12 Rationale and hypothesis
Data supports the hypothesis that inhibition of cell cycle CDKs (CDK2 and
CDK4) by CBM peptides will lead to selective apoptosis of cancer cells. The structure of
the CBG in complex with CBM peptides (i.e. HAKRRLIF and RRLIF) have been
utilized in the development of non-ATP competitive CDK inhibitors. Furthermore the
REPLACE (REplacement with Partial Ligand Alternatives through Computational
Enrichment) strategy has been applied in order to convert optimized peptides into nonpeptidic and more pharmaceutically appropriate molecules. Truncation of key peptide
determinants and substitution of these with PLAs (Partial Ligand Alternatives) in the
context of the truncated p21WAF peptide, RRLIF has been undertaken in order to
construct more drug-like FLIPs (Fragment ligated inhibitory peptides). The resulting
FLIP molecules should retain the potency and interactions of the parent peptide however
with improved physicochemical properties more akin to drug-likeness. Based on this
rationale the following hypothesis and major goals of this project were proposed:
“REPLACE is a viable strategy to generate more drug-like inhibitors that selectively
inhibit cell cycle CDK/cyclin complexes and induce apoptosis in cancer cells”
In order to confirm the hypothesis and achieve the project goals, PLAs were
identified by computational and synthetic methods. The N-terminus of the RRLIF was
replaced fragment like small molecules to generate FLIPs based on derivatives of phenyl
heterocyclic scaffolds (chapter 2), heterocyclic fragments substituted with basic groups
(chapter 3), phenylacetic acid systems (chapter 3) and benzoic acid derived moieties
(chapter 5) in order to mimic key interactions of the peptide. In addition to N-cap
optimization, the hydrophobic C-terminal motif was replaced with residues designed to
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impart enhanced proteolytic stability and cell permeability (chapter 4). The competitive
binding efficiency of generated FLIPs was determined by a fluorescence polarization
assay developed in the McInnes laboratory and lead compounds were tested for their antiproliferative activity in U2OS and DU145 cell lines52,54.
In summary, the REPLACE strategy has been successfully utilized in the
development of FLIPs with improved drug like properties and results demonstrate
significant progress towards the overall goal of generating next generation and cell cycle
CDK inhibitors targeting the CBG and leading to selective apoptosis of cancer cells.
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CHAPTER 2
OPTIMIZATION OF CDK/CYCLIN GROOVE INHIBITORS THROUGH
REPLACE MEDIATED FRAGMENT ASSEMBLY

2.1 Introduction
REPLACE

(REplacement

with

Partial

Ligand

Alternatives

through

Computational Enrichment) is a fragment based approach developed for the design of
inhibitors targeting protein-protein interactions49.

In simple terms REPLACE is an

iterative strategy useful for the conversion of a peptide inhibitor into a more drug-like
molecule in order to make protein-protein interaction targets more broadly accessible.
REPLACE combines techniques at the interface of chemistry and biology including both
computational and both solution and solid phase synthetic chemistry to generate nonpeptidic compounds which are then evaluated in binding and cellular assays is shown in
figure 2.1. Peptides in general do not make good drugs due to their lack of membrane
permeability, and metabolic instability48. In this study the iterative conversion of a
peptidic cyclin groove inhibitor has been undertaken by replacing key N and C-terminal
binding determinants with more drug-like fragments. After a generation of FLIPs which
are N and/or C-terminally capped, these will be much less susceptible to proteolysis.
Reduction in polar surface area and molecular weight of an inhibitor should lead to
greater

cell

permeability

thereby
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improving

drug

likeness.

Figure 2.1 REPLACE methods
In REPLACE we utilize the structure activity relationship (SAR) combined with
interactions of HAKRRLIF in its receptor in the Discovery studio 3.0 to design capping
groups. The pentapeptide RRLIF is used as stating point to design FLIPs in which the Nterminal Arg is truncated. A library of commercially available molecules or molecules
designed in our lab is used for docking in the hollow region created by truncation of Arg.
Partial ligand alternatives (PLAs) or N-caps are selected such that these molecules would
retain most of the interactions of truncated binding determinants. Such a library is docked
(computationally placed in the binding site) using molecular modeling software (e.g.
LigandFit55 within Discovery studio 3.0) after which the docked poses are prioritized
based on the scoring function which is an assessment of their ability to bind. Top scoring
virtual hits are then obtained from commercial sources or synthesized so as to be
evaluated as capping groups. To do this they are ligated to the truncated peptide sequence
by solid phase synthesis in order to generate FLIP molecules56. These are tested in an in
vitro assay (e.g. FP57 assay to determine their competitive binding efficiency) to
determine if the activity of the parent peptide has been recapitulated however in a more
drug-like molecule. If so, FLIPs can be further evaluated in order to determine if any
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cellular activity has been achieved. An overview of the REPLACE strategy is illustrated
in scheme 2.1.

Scheme 2.1 Schematic representation of REPLACE strategy
The REPLACE strategy has been utilized to convert the peptidic inhibitor RRLIF
into a more drug like non-ATP competitive CDK inhibitor acting through the cyclin
groove. The initial objective of this project is to identify low molecular weight noncharged fragment alternatives for N-terminal arginine residue. Since arginine is the most
basic amino acid, it makes strong electrostatic interactions with the acidic region of CBG
but also potentially limits cell permeability. In order to improve drug likeness, several
uncharged fragment molecules based on phenyl heterocyclic carboxylic acids were
investigated. These were designed based on a previously reported N-capping group, 1(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (35DCPT) ligated to
RLIF. The crystal structure of this N-cap confirmed that the 35DCPT takes up the same
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position occupied by the N-terminal tetrapeptide of the p21 parent peptide (HAKRRLIF).

Figure 2.2 Binding mode of 3,5-DCPTRLIF in CBG
Binding of 3,5-DCPTRLIF is shown with hydrogen bonding interactions (depicted
in green dotted lines) with N-atom of Trp217 and Gln254
The 3,5-dichlorophenyl ring makes hydrophobic contacts through van der Waals
interactions with the secondary hydrophobic pocket replacing those of the peptide Ala2
methyl side chain. Further, the N-2 atom of the triazole ring and the amide carbonyl of
the capping group accept hydrogen bonds with the side chains of Trp217 and amide
bonds of Gln254 respectively (figure 2.2). The 35DCPT N-capped peptide (FLIP)
successfully recapitulated the activity of the intact pentapeptide providing proof of
concept for the REPLACE strategy49. In this study, the triazole core structure was
substituted with other heterocyclic isosteres (including pyrazole, furan, pyrrole, imidazole
and thiazole) to investigate the effect of alternate heteroatoms on binding. In addition to
this the phenyl ring was derivatized with methyl, methoxy and halogen substituents to
probe with the binding affinity of the secondary pocket. A structure activity relationship
(SAR) was carried out for this diverse set of heterocyclic core structures with
substitutions on phenyl ring was studied to establish the optimal requirement of
functional groups for binding. Along with improving binding affinity, optimization of the
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Ncapping group was investigated to improve the physicochemical properties (clogP,
polar surface area) and metabolic stability that determine drug likeness of the inhibitors.
2.2 Results
2.2.1 Synthesis of N-caps
In order to probe the structure-activity relationship of the 35DCPT Ncap scaffold,
a number of variants of this substructure were synthesized. These included 5-methyl-1phenyl-1H-1,2,4-triazole-3-carboxylic acid

(phenyltriazole), 5-methyl-1-phenyl-1H-

pyrazole-3-carboxylic, acid (phenylpyrazole), 1-phenyl-1H-pyrrole-3-carboxylic acid
(phenylpyrrole),

2-phenyl-2H-imidazole-4-carboxylic

acid

(phenylimidazole),

5-

phenylfuran-2-carboxylic acid (phenylfuran), and 2-phenylthiazole-4-carboxylic acid
(phenylthiazole). Each of these was modified by including a variety of substitutions on
the phenyl ring as shown in table 3.1.
Scheme 2.2 Preparation of phenyltriazole N-capping groups

The phenyltriazole carboxylic acid derivatives were synthesized by reacting the
diazonium salt of an appropriately substituted aniline with ethyl 2-chloroacetoacetate and
subsequent cyclization to the 1,2,4-triazole using acetaldehyde oxime, triethylamine in
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toluene. The resulting ester was subjected to base hydrolysis to generate the final capping
group product of about 80% yield (scheme 2.2)58,59. The phenylpyrazole capping groups
were prepared by the reaction of substituted phenyl hydrazines with ethylacetopyruvate
in triethylamine/ acetonitrile to generate the cyclized product as an ester with a yield of
21%. Base hydrolysis was then employed to convert to the free carboxylate obtained in
quantitative yield (scheme 2.3)60. Initial attempts at this reaction used base catalysis
however led to the formation of two isomers (figure 2.3) in equal amounts (these could be
separated by flash chromatography). The structure of the desired isomer was confirmed
by one dimensional nuclear overhauser effect (1D-NOE) NMR experiments. In this
experiment, irradiation of the methyl group in pyrazole ring lead to the enhancement of
two ortho aromatic proton signals. Further variants of this reaction showed that acid
catalysis of the cyclization reaction protonated the hydrazine leading to suppression of
the formation of the undesired isomer. The phenyl ring of the pyrazole substructure was
derivatized as 3,5-dichloro, 3 and 4-chloro, 3-fluoro, 3 and 4-methoxy derivatives in
order to study the effect of these substitutions on the interactions with secondary pocket.
Scheme 2.3 Preparation of phenylpyrazole N-capping groups
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Figure 2.3 Ethyl 1-(substituted phenyl)-5-methyl-1H-pyrazole-3-carboxylate
To generate phenylfuran derivatives, appropriate aniline was diazotized with
sodium nitrite and hydrochloric acid. The intermediate diazonium salt was then reacted
with furoic acid through catalysis with copper chloride (scheme 2.4) 61. The yield of the
final product was about 28%. In this series the 3-chloro and 3,5-dichloro derivatives were
successfully synthesized. Phenylpyrrole capping groups were prepared by reaction of a
substituted

aniline

(4-chloro

and

3,5-dichloro)

with

3,5-

dimethoxytetrahydrofurancarboxaldehyde through refluxing in acetic acid to generate the
cyclized phenylpyrrole as an aldehyde precursor with 94% yield. To obtain the final
capping group, this was oxidized to carboxylic acid (65% yield) using silver nitrate and
sodium hydroxide (scheme 2.5)12 . All the N-caps were ligated to RLIF by solid phase
synthesis and tested in FP assay.
Scheme 2.4 Preparation of phenylfuran N-capping groups

Scheme 2.5 Preparation of phenyl pyrrole N-capping groups
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2.2.2 Structure activity relationship of phenyl heterocyclic isosteres as N-caps
As comparators for the Ncapped peptides that were generated through application
of REPLACE, the potency of both the parent peptide (HAKRRLIF and RRLIF) were
evaluated in the FP competitive binding assay. It was found the HAKRRLIF (IC50 values
of 0.13 µM; CDK2/cyclin A, 0.22 µM; CDK4/cyclin D) shows better inhibitory potential
compared to RRLIF (1.4 µM; CDK2/cyclin A and 16.1 µM; CDK4/cyclin D).
HAKRRLIF is therefore about 10 fold more potent compared to RRLIF in the cyclin A
and 70 fold in cyclin D context. RRLIF has a higher affinity for cyclin A compared to
cyclin D. As mentioned above, the crystal structure of 35DCPT Ncapped peptides have
been previously solved. These structures reveal that this capping group only partially
mimics the interactions of N-terminal residues. The FP assay results of all heterocyclic
core structures with different phenyl substituents were compared and the isosteres
exhibited significant differences in potency as shown in table 3.163.
The SAR of FLIPs containing phenyl heterocyclic carboxylic acids was carried
out for understanding the importance of heteroatoms (N and O) with binding at CBG and
also the substituents on phenyl ring for van der Waals interactions with second pocket. In
the SAR of phenyl heterocyclic scaffolds, the most potent core structure incorporated into
a FLIP was found to be the starting phenyltriazole derivative followed by phenylpyrazole
and phenylfuran containing FLIPS. FLIPs having the phenylpyrrole, phenylthiazole and
phenylimidazole scaffolds displayed marginal or no activity. FLIPs 5773 (35DCPTRLIF) and 5774 (1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide-RLIF)
were shown to be the most potent compounds with IC50 values for CDK2/cyclin A of 4
μM and 11.5 μM respectively and in cyclin D was 27.3 µM and 12.0 µM respectively.

32

Thus, 5773 has better activity in the CDK2/cyclin A assay whereas the potency of 5774 is
reversed in that it has greater affinity towards CDK4/cyclin D. The activity of 5906 (1-(3chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide containing FLIP, IC50 5.7 µM)
was comparable to 5773 and 5907 (3-methylphenyl)-5-methyl-1H-1,2,4-triazole-3carboxamide-RLIF, IC50-13.8 µM) was comparable to 5774 in the cyclin A context in the
FP assay. The unsubstituted phenyltriazole FLIP, 5843 showed the lowest activity (cyclin
A-16.2 µM, cyclin D-49.2 µM) among the phenyltriazole series.
Table 2.1 Structure activity of phenyl heterocyclic N-terminal Partial Ligand
Alternatives

For the pyrazole isosteric FLIP series which have one less nitrogen heteroatom in
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the five membered ring, comparison of the 3,5-dichloro (5763, IC50-21.8 μM) and 4chloro (5765, IC50-21.8 μM) substituted derivatives with 5773 shows a relative loss of
activity by about 3-5 fold against CDK2/cyclin A. Similar to results obtained for the
phenyltriazole series, the 3,5-dichloro substituted analog (5763, IC50>100 µM) shows
lower potency compared to 4-chloro substituent (5765, IC50 -54.7µM) of pyrazole in the
CDK4/cyclin D assay. Although the size of a methyl group is similar to that of a chlorine
atom, the 3-substituted methylphenyltriazole derivative (5907) is about 3.5 fold less
potent compared to 5773 and 5906. The same trend was observed in the phenylpyrazole
series in that the 3,5-dichloro, 3-chloro and 3-fluoro derivatives show greater affinity for
CDK2/cyclin A2. The other FLIP showing detectable activity in this series is 3fluorophenylimidazole-RLIF (5852), the activity of which is comparable to
corresponding phenylpyrazole (5771) in both CDK2/cyclin A2 and CDK4/cyclin D1.
From these results it is evident that the presence of nitrogen atom in the heterocycle (for
H-bonding with Trp217) is required for good activity.
The inhibitory activity of a FLIP molecule capped with 3-fluorophenylpyrazole
(5771) was determined to be 29.6 μM for CDK2/cyclinA and 65.9 μM in CDK4/cyclin
D. Substitution of the 4-position on the phenyl ring provides improved binding relative to
the 3-position for CDK4/cyclin D as evidenced by the results for the phenyltriazole and
phenylpyrazole capped peptides. Binding of the unsubstituted phenylpyrazole containing
FLIP (5762, 40.3 μM for CDK2/cyclin A2; 54.2 μM for CDK4/cyclin D1) was similar to
the 4-chloro derivative. The increased steric bulk of the methoxy groups relative to
chorine and fluorine contributes to the potency drop for both 3- (5766) and 4-methoxy
(5767) phenylpyrazole derivatives.
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2.2.3 Docking of phenyl heterocyclic isosteres as N-capping groups
A docking analysis was carried out for all the isosteric phenyl heterocyclic series
to correlate with the binding potencies of FLIPs obtained from the FP assay.
Computational studies of these Ncaps were performed using the parameters obtained in
the validation of the use of the LigandFit program (docking validation and parameters are
explained in chapter 4) for high- throughput docking of ligands into the cyclin groove of
cyclin A (2UUE). The potential Ncapping groups shown in table 3.2 were docked and
subsequently analyzed and prioritized based on superimposability with the crystal
structure of 35DCPT, hydrogen bonding (with the side chains of Trp217 and Gln254),
and also PLP1 and consensus scoring. Consensus scoring is a combination of all the
seven scoring functions in LigandFit and it gives more accurate estimate of the various
interactions between the receptor and ligand.
Table 2.2 Docking results of phenyl heterocyclic N-terminal
Partial Ligand Alternatives
Core
structure
Triazole

Highest PLP1
score
57.29

Consensus
score
5-7

H-bond length with
Trp217(Å)
1.38 to 2.34

Pyrazole

55.28

5-7

1.24 to 2.43

Furan

53.04

4-7

>2.5

Imidazole

50.20

3-6

>2.5

Thiazole

47.3

1-4

>2.5

Pyrrole

47.1

0-3

NA

Phenyltriazole (PLP1-57.29) derivatives were found to have the highest PLP1
score and this was followed by phenylpyrazoles (PLP1-55.28), phenylfurans (PLP135

53.04), phenylimidazoles (PLP1-50.20), phenylthiazoles (47.3) and phenylpyrroles
(PLP1-47.1). For the most part, the consensus score was predictive for capping groups
with substitutions at 3-position and 3,5-position. High consensus score values (between 5
and 7) were obtained for poses that have 3-chloro or 3,5-dichloro substituents on the
phenyltriazole and phenylpyrazole and which were the most potent in the CDK2/cyclin A
context. The exception to this was methoxy derivatives of the phenylpyrazole FLIP series
where both high PLP1 score (>58) and consensus score (7) values were obtained for
incorrect poses and which did not interact well with the secondary pocket. Despite the
high scores, the incorrect binding mode is consistent with lack of activity of 5966 and
5967.
2.3 Discussion and conclusion
In this study protein-protein interactions at CBG are being targeted through
application of the REPLACE strategy49. REPLACE is a novel strategy for converting
peptidic molecules into more drug like molecules by sequential replacement of residues
of peptidic inhibitors with small molecule capping groups. FLIPs are peptidic molecules
where key determinants have been substituted with fragments that potentially have
increased drug likeness compared to the parent peptides and retain important interactions
of the truncated residues. Hence the goal in this section was to focus on the structure
activity relationship through optimizing interactions with the secondary pocket and
mimicking hydrogen bonding contacts observed with the peptide and in a previous study
where preliminary heterocyclic N-caps were identified.
A library of phenyl heterocyclic N-capping group derivatives was designed in
order to replace the N-terminal arginine residue of RRLIF and to potentially exploit
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additional interactions of the N-terminal tetrapeptide of HAKRRLIF. These include ionpairing interactions with acidic residues of the cyclin groove, hydrophobic interactions of
Ala2 with secondary pocket and backbone hydrogen bonds with various side chains of
the CBG. The N-caps were based on phenyltriazolecarboxylic acid derivatives identified
using REPLACE which were then used to construct FLIP molecules. X-ray
crystallographic analysis of 35DCPT ligated to RLIpfF-NH2 and in complex with
CDK2/cyclin A(PDB ID 2UUE) revealed that the 1,2,4-triazole core occupies the
position of Arg4 backbone on the ridge that separates both the hydrophobic pockets
while the dichlorophenyl group occupies the hydrophobic secondary pocket and provides
affinity through van der Waals interactions. The N-2 atom of the 1,2,4,-triazole ring and
the amide carbonyl oxygen act as hydrogen bond acceptors for the indole N-atom of
Trp217 and amide N-atom of Gln254 respectively.
For the library design, information from another recent study examining the
structural differences of the cyclin groove between cyclin A and cyclin D was exploited
(explained in more detail in chapter 1, section 1.11)53. Peptide analog SAR was used to
delineate the key variations in the major and minor hydrophobic pockets and in the acidic
regions between the two cyclins. Using the SAR revealed in these studies, a library of
isosteric heterocyclic N-caps were designed in order to retain similar interaction of 3,5DCPT and also to probe the contributions of this fragment replacement to cyclin groove
binding. An extensive SAR study was carried out by generating isosteres in which the
triazole core was replaced with other heterocyclic systems including pyrazole, furan,
pyrrole, imidazole and thiazole rings. Furthermore the SAR of the phenyl ring attached at
N1 of the triazole was explored through introduction of a variety of substitutions at
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positions 3, 4 and 5. The SAR of heterocyclic isosteres was carried out to provide insight
into the contributions of H bonding with indole N-atom of Trp217. The incorporation of
different heteroatoms in the appropriate position where an H bond is contributed by the
N2 of the triazole ring was undertaken through synthesis of the corresponding isostere
(nitrogen: pyrazole, thiazole and imidazole also oxygen: furan). Substitution of the
phenyl ring of the phenyl heterocycle with halogens (Cl, F), methyl or methoxy groups
was undertaken to identify groups that provide better interactions and complementarity
with the secondary pocket.
A common feature of all the molecules in the synthesized library is the presence
of carboxylate group which when ligated to the truncated peptide forms an amide bond
mimicking the H- bonding to the side chain amide N-atom of Gln254 as observed in the
peptide crystal structures. A docking study was carried out to determine if the N-caps in
this library were capable of making H bonding with Gln254 (figure 2.4) and with Trp217
as proposed. The results showed that this indeed was the case however variable lengths
and strengths of H-bonds would be expected.

Figure 2.4 Overlay of docked structures of N-caps
The interaction filters (Trp217 & Gln243) are indicated as green spheres and
hydrogen bonding are indicated in green dotted lines on the surface of cyclin A
(PBD ID2UUE)
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The results obtained from binding of the FLIPs to CDK2/cyclin A revealed that the
heterocyclic core is a critical determinant for potency. Since both the two ring structures
expected to have the strongest H-bond (triazole and pyrazole) were the most potent, the
conclusion was drawn that the H-bond is essential for the activity of this isosteric FLIP
series. Comparison of the N-caps having a 3,5 dichloro substitution strongly indicated the
importance of having an atom capable of acting as an H-bond acceptor to the NH group
of indole ring in Trp217. In the phenylfuran containing FLIPs, the N-atom is replaced
with an oxygen atom. Since oxygen is more electronegative (3.44, Pauling’s scale) than
the nitrogen (3.04, Pauling’s scale) 64 and the oxygen lone pairs of electrons participates
in the furan aromatic system, a much weaker H-bond interaction would be expected
compared to the triazole and pyrazole. Although the five membered ring of triazole and
pyrazole is also aromatic and the lone pairs participate in the aromaticity there are
however three and two lone pairs present respectively and at least any one pair of
electrons are more available for H bonding. These factors provide a strong reasoning for
the inactivity of the phenylfuran analogs and increased relative activity of the
phenyltriazole and phenylpyrazole containing FLIPs. Since only one phenyl imidazole
FLIP was generated, this could not be directly compared with the phenyltriazole series.
The 3-fluoro derivative was available however and could be compared with 3fluorophenylpyrazole. The comparable activity of these two FLIPs indicates that similar
H-bonding contributions are made to the phenylpyrazole FLIP.

The phenylpyrrole

isosteres do not exhibit good activity because the pyrrole ring does not have H-bond
acceptor to interact with the indole group of Trp217 and that the two H atoms may even
clash with each other. The docking results obtained support these results in terms of
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PLP1 score and hydrogen bond length. In case of phenyltriazole and phenylpyrazole
derivatives the hydrogen bond length between N-2 nitrogen atom and Trp217 varies
between 1.24 to 2.43Å whereas the hydrogen bond length between the weak hydrogen
bond acceptors in the phenylfuran and Trp217 is greater than 2.7Å.
Comparison of the binding activity results suggests that the phenyltriazole
containing FLIPs are considerably more potent that the phenylpyrazole containing ones
by 3 to 5 fold. These results suggest that the N-2 nitrogen atom is not the only binding
determinant in the heterocyclic ring and that the triazole N-4 atom plays an additional
role in binding. This observation was initially difficult to explain in structural terms since
no interactions between N-4 and the cyclin groove are observed in the crystal structures.
A modeling study was carried out in which a water molecule was placed between N-4
atom of the triazole (5773) and carboxylate side chain of Asp283 (cyclin A) or Asp129
(cyclin D). This water molecule can thus form a bridging hydrogen bond between N-4
atom of triazole and carboxylate group of the acidic residue (figure 3.3) thereby
suggesting a reason for the potency increase of the phenyltriazole series. Since the
phenylpyrazole derivatives cannot make such an interaction this potentially explains the
lower activity potential of this series. As a whole the SAR of phenyl heterocyclic Ncaps
demonstrates the importance of hydrogen bonding with the cyclin groove and
furthermore highlights the structural differences contributing to diversity in activity
profile.
The contributions of the substitutions on the phenyl ring to their interaction with
the secondary hydrophobic pocket were studied from the SAR of the phenyltriazole and
phenylpyrazole containing FLIPs. The activity profile of appropriate phenyl substituents
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could be correlated in both triazole and pyrazole based FLIPs. The phenyl group makes
hydrophobic contacts through van der Waals interaction with the secondary pocket and
appropriate substitution in phenyl ring provides better interaction. As mentioned earlier
3,5-dichloro derivative was the most potent compound (comparable potency with 3chloro derivative) followed by 4-chloro and 3-methyl derivatives in CDK2/cyclin A.
Substitution at the 3-position offers better activity for inhibition of CDK2/cyclin A. Of all
the substituents incorporated into the phenyl ring in these two isosteric series, chlorine
was found to be the most effective in binding to cyclin A and cyclin D in their respective
CDK complexes. The FP results also showed that the position of the substituents on the
phenyl ring determines specificity towards a particular cyclin. A 3-chloro substituted
phenyl ring (5906, 5907, 5764 and 5771) and 3, 5-dichloro substitution (5773, 5763) in
both the triazole and pyrazole context have

better activity in binding to cyclin A

compared to cyclin D. The 4-chloro substituted analogs however (5774 and 5765) have a
reverse potency order with respect to binding to the two cyclins. This observation can be
explained by the structural differences of secondary hydrophobic pocket between cyclin
A and cyclin D. In cyclin A this pocket in shallower and larger whereas it is smaller and
deeper in cyclin D. Hence larger volume of this sub site in cyclin A can accommodate 3
and 3,5 dichloro substituents with a better complementarity. As a result of the smaller
hydrophobic sub site in cyclin D, the 3 and 3,5-disubstituted phenyl group is displaced
relative to cyclin A and is further out of the secondary pocket. The 4-chloro substituent
binds deeper in the secondary pocket of cyclin D, allowing better van der Waals
interactions of the phenyl and furthermore allowing interaction with Glu66 and Glu70.
An overlay of modeled structure of 5773 in complex with CDK4/cyclin D1 and
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CDK2/cyclin A2 shown in figure 2.5 explains the binding modes of 3,5-disubstuted
phenyl ring in the second pocket of cyclin A and cyclin D63.

Figure 2.5 Modeled structure of 5773 in cyclin A & cyclin D
Showing bridging hydrogen bond between the ligand and the receptor
Modeled structure of SCCP 5773 in complex with CDK4/cyclin D1 (tan carbon
atoms) overlaid with the crystal structure of the same N-cap bound to CDK2/cyclin
A2 (yellow carbon atoms). A Connolly surface representation of cyclin A is shown
along with the putative water molecule contributing bridging hydrogen bonds.

The difference in the potency between 3-chloro and 3-fluoro substituents could be
observed with the phenylpyrzaole containing FLIP series is indicated by increased
complementarity of the larger chloro substituent with the secondary pocket.

In

comparison with the fluoro substituent, the chloro also allows closer contact of the phenyl
ring in the pocket (figure 2.6). Decreased potency of the 3-methyl substitution could be
due to less favorable interactions of the slightly larger group with the secondary pocket in
comparison with 3-chloro substituent. The methoxy groups in turn are too large due to
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the extra connecting atom (oxygen) and it is displaced outside of the minor hydrophobic
pocket due to the resulting steric clash also leading to loss of hydrogen bonding with
Trp217 in 4-methoxyphenylpyrazole derivative (figure 2.7).

Figure 2.6 Comparison of complementarity of 3-Chloro and
3-Fluoro substituents on phenyl ring of pyrazole
Complementarity of 3-chlorophenyl pyrazole (left) and 3-fluorophenyl pyrazole
(right) derivatives in the second pocket are shown as CPK structures on the surface
of cyclin A

Figure 2.7 Comparison of binding modes of chloro substituents and methoxy
substituents on the phenyl ring of pyrazole
Binding mode and complementarity of 3-chlorophenyl pyrazole, 3,5-dichlorophenyl
pyrazole (left) and 3-methoxy phenyl pyrazole and 4-methoxy phenyl pyrazole
(right) derivatives in the second pocket are shown on the surface of cyclin A.

In conclusion, the phenyltriazole Ncapping series was found to be the best
heterocyclic isostere and substitution at the 3 and 5 positions resulted in the most potent
FLIP molecule (5773) through the most favorable interactions and providing the best
complementarity with the secondary pocket. The position of chloro substituent of the
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phenyl ring determined specificity towards a particular cyclin with the 3-chloro and the
3,5-dichloro binding better to CDK2/cyclin A and the 4-chloro substitution resulting in
high affinity for CDK4/cyclin D. In this study one of the most important N-terminal
residues Arg of RRLIF was successfully replaced with phenyl heterocyclic based small
molecules. Through this SAR studies on phenyl heterocyclic capping groups, the
important interactions of N-capping groups that are key for binding have been explored.
H bonding with Trp217 and Gln254 are crucial for binding and the size of substituents in
the phenyl ring also contributes to complementarity and proper positioning of N-capping
groups on top of secondary pocket. In addition, the drug likeness of the most potent
molecule 5773 has been considerably improved compared to RRLIF. Physical properties
such as clogP and total polar surface area (tPSA) helps in determining drug likeness and
efficiency of the molecules to cross cell membranes. The clogP and polar surface area of
5773 is (+2.42 and 243) is better than RRLIF (-2.86, 303.52). The standard values for
clog P are between -0.4 to 5.6 and tPSA is less than 140 Å based on Lipinski’s rule of 5
for orally available drugs65,66. The FLIP molecule 5773 could be further improved for
drug likeness with modifications on C-terminus with non-natural amino acids such as (βLeu for Leu and Ile, NMePhe or 3thienylAla for Phe), as is discussed in detail in chapter
5. These observations related to the optimization of functional groups for binding and
physicochemical properties of 5773 were utilized in the design of improved N-capping
groups and converting the peptide RRLIF into more drug like molecule.
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2.4 Experimental section
2.4.1 Synthesis
2.4.1.1 Materials and method
All solvents and reagents were used as obtained. 1H NMR and 13C NMR spectra
were recorded with a Varian Mercury 300 and 400 Spectrometer, respectively. Mass
spectra were measured with Micromass QTOF: Tandem quadruple-time of flight mass
spectrometer electrospray ionization (ESI) and VG 70S: Double-focusing magnetic
sector mass spectrometer (EI). Analytical purities of evaluated compounds were >95%
unless stated otherwise. The following analytic method (unless stated otherwise) was
used on a Waters Alliance 2695 HPLC with a 2996 diode-array detector and equipped a
C18 (2) 100 A, 250 x 4.6mm, 5µ column (Phenomenox Luna). A gradient from 100%
water (0.1% trifluoroacetic acid) to 60% acetonitrile (0.1% trifluoroacetic acid) was run
over 30 mins and held for 4 mins. The chromatograms were extracted at 226 and 254 nm.
2.4.1.2 Synthesis of N-caps
The N-caps 1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid, 1(4-methylphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid, 2-(3,5-dichlorophenyl)1H-imidazole-5-carboxylic acid, 2-(3-chlorophenyl)-1H-imidazole-5-carboxylic acid
were obtained commercially and the compound 2-(4-chlorophenyl)thiazole-5-carboxylic
acid was synthesized in our lab. The NMR and MS spectra chromatograms for
representative N-capping groups are shown in appendix. The analytical characterization
data for all the FLIPs are shown in appendix table 1.
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Preparation of phenyltriazole N-capping groups57,58 (5843, 5773, 5774, 5906, 5907)
Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate (1a)
To a solution of 3,5-Dichloroaniline (1.62g, 10mmol) in 10 ml methanol, 10 ml of
6 N Hydrochloric acid was added while maintaining the temperature at 0°C. Sodium
nitrate (1.38g, 20mmol) was then slowly added as a solid. The reaction mixture was
stirred for 15 mins at 0°C after which sodium acetate was added as a solid to adjust the
reaction to pH 5. Subsequent to this, a solution of ethyl 2-chloroacetoacetate (1.64,
10mmol) in methanol was slowly added while maintaining the temperature at 0°C, after
which the reaction mixture was allowed to warm to ambient temperature and stirred for
12 h. The reaction was monitored by TLC using 25% ethyl acetate in hexanes, for
completion. Methanol was then removed under reduced pressure, diethyl ether was added
and the organic layer was separated and washed with saturated sodium bicarbonate and
water prior to drying over sodium sulfate. The organic layer was concentrated and the
product crystalized from ethanol to give an orange solid 2.29g (77.7%).
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.2 (s, 3H), 7.0 (s, 1H), 4.32-4.39 (q, J=3.52,

3H) 1.35-1.4 (t, J=3.41Hz, 3H). EI+ 294
Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate (1b)
1

H NMR (chloroform-D, 300 MHz) δ (ppm) 7.27-7.25(m, 1H), 7.22(d, J-8.28Hz, 1H),

7.05(s, 1H), 7.02(d, J=10.56Hz, 1H), 6.99(d, J=7.92Hz, 1H), 4.39(q, 21.54Hz, 2H),
1.40(t, J=6.99Hz, 3H) EI+260
Ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (2a)
The step 1 product, Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate
(1) (2.29g, 7.7mmol), and acetaldehyde oxime (0.473g, 7.7mmol) were dissolved in
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toluene and heated to reflux for 2h after which triethylamine (0.81g, 7.7mmol) was
added. The reaction was monitored by TLC using 25% ethyl acetate in hexanes. After
completion, the reaction mixture was then concentrated and partitioned between ethyl
acetate and water. The layers were separated and the aqueous layer was washed with
ethyl acetate. The combined organic layers were washed with water and brine, dried with
sodium sulfate, filtered, and then concentrated. The residue was crystallized from
diethylether/hexanes to give the product as fine, tan needles weighing 1.97g (84.5%).
1

H NMR (chloroform-D, 300 MHz) δ (ppm) 7.45 (s, 2H), 7.49 (s, 2H) 4.46-4.53 (q,

J=3.36Hz, 2H) 2.62 (s, 3H), 1.41-1.46 (t, J=3.35Hz, 3H) ES+ 300
Ethyl 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (2b)
1

H NMR (chloroform-D, 300 MHz) δ (ppm) 7.54(s,1H), 7.48-7.42(m, 3H), 4.50(q

J=6.93Hz, 2H), 2.58(s, 3H), 1.44(t, J=7.14Hz, 3H) EI+265
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (3a)
The

step

2

product,

Ethyl

1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-

carboxylate (2) (1.9g, 6.33mmol) was refluxed in sodium hydroxide (2.02g, 50.64mmol),
19ml of ethanol and 19ml of water for 2h and the reaction was monitored by TLC (35%
ethyl acetate in hexanes). After the completion of reaction, the reaction mixture was
cooled, the alcohol was evaporated and diluted with water. The reaction mixture was
acidified with 1N hydrochloric acid and stirred to precipitate the product.
1

H NMR (chloroform-D, 400 MHz) δ (ppm) 7.86 (t, J=1.04Hz) 7.8 (d, J= 1.12Hz3H)

2.54 (s, 3H)
13

C NMR (Dimethyl sulfoxide-D6, 400 MHz) δ (ppm) 160.6, 154.5, 154.11, 138.5,

135.1, 134.7, 129.0, 123.8
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HRMS EI+ observed 270.9914, calculated 270.9915, 0.4ppm
1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (3b)
1H NMR (Dimethylsulfoxide, 400 MHz) δ (ppm) 7.80(s,1H), 7.64 (s, 2H), 2.51(s, 3H)
13

C NMR (Dimethyl sulfoxide, 400 MHz) δ (ppm) 160.80, 154.21, 154.00, 137.87,

133.69, 131.20, 129.29, 124.73, 123.55, 12.81
EI+237
Preparation of phenylpyrazole N-capping groups59 (5762-5767, 5771)
Ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4a)
1 g (4.68mmol) of 3,5-dichlorophenyl hydrazine was dissolved in 25 ml of acetonitrile in
a 100 ml round bottom flask, triethylamine (0.47g, 6.9mmol) and ethyl aceto pyruvate
(0.74g, 4.68mmol) were added to the reaction mixture under stirring and left to continue
overnight. The reaction was monitored by TLC (25% ethyl acetate in hexanes) for
completion. After the reaction was complete, the reaction mixture was diluted with
dichloromethane and washed with water. The organic layer was separated, dried over
sodium sulfate and concentrated. The crude mixture was then purified by flash
chromatography (Biotage SP4) using a SNAP 100g column with a gradient run starting
from 6% ethylacetate: 94% hexanes to 50% ethyl acetate and 50% hexanes over 15
column volumes to yield a white solid 0.39g (21% yield).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.431 (s, 3H), 6.744 (s, 1H), 4.49-4.44 (t,

J=7.0Hz, 2H), 2.39 (s, 3H), 1.39-1.42 (t, J=2.54Hz, 3H), EI+298
Ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.37(q, J=8.61Hz, 4H), 6.81(s,1H), 4.23(q,

J=7.14Hz, 2H), 2.34(s,3H), 1.26(t, J=7.29Hz, 3H) EI+265
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Ethyl 1-(3-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4c)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.52(t, J=8.48Hz, 1H), 7.22(t, J=7.08, 3H),

6.88(s,1H), 4.42(q, J=7.02Hz, 2H), 3.86(s,3H), 1.40(t, J=7.29Hz, 3H) ES-263
Ethyl 1-(3-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4d)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.49(t, J=8.40Hz, 1H), 7.21(t, J=7.01, 3H),

6.78(s,1H), 4.38(q, J=7.02Hz, 2H), 3.76(s,3H), 1.34(t, J=7.18Hz, 3H) EI+249
Ethyl 1-(3-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate (4e)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.36(t, J=7.92Hz, 1H), 6.99(t, J=4.32, 3H),

6.95(s,1H), 4.41(q, J=6.96Hz, 2H), 3.86(s,3H), 2.32(s, 3H), 1.39(t, J=7.17Hz, 3H)
EI+261
Ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate (4f)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.45(d, J=8.79Hz, 2H), 7.07(d, J=8.79, 2H),

4.26(q, J=7.19Hz, 2H), 3.81(s,3H), 2.49(s, 3H), 1.27(t, J=7.19Hz, 3H) EI+ 261
ethyl 5-methyl-1-phenyl-1H-pyrazole-3-carboxylate (4g)
1

H NMR (chloroform-D3, 300MHz) δ (ppm)7.41(s, 5H), 6.79(s, 1H), 4.19(s, 2H), 2.35(s,

3H), 1.22(s, 3H) EI+231
1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5a)
The ester obtained from step1, ethyl 1-(3,5-dichlorophenyl)-5-methyl-1Hpyrazole-3-carboxylate (4) (0.39g, 1.3mmol) was dissolved in 10 ml methanol. The ester
solution was treated with a 10 ml solvent mixture of tetrahydrofuran, 20% potassium
hydroxide and methanol (1:1:1). The solution was stirred at room temperature overnight
and after completion, as evidenced by TLC (25% ethylacetate in hexanes), methanol was
evaporated and the reaction solution was partitioned between ethylacetate and water.
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After washing with ethyl acetate, the aqueous layer was collected and acidified to pH 2
using 1N hydrochloric acid. The acidified aqueous layer was then partitioned between
dichloromethane and additional water. The organic layer was dried over sodium sulfate
and concentrated to get solid product 0.23g (100%).
1

H NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 7.78-7.79 (t, J=0.937Hz,) 7.8 (d,

J=1.14, 1H), 6.74 (s, 1H), 2.50 (s, 3H)
13

C NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 162.9, 144.5, 141.4, 140.8, 134.5,

128.0, 123.5, 11.9
HRMS EI+ Observed 269.9959, calculated 269.9963, 1.5ppm
1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.45(q, J=9.30Hz, 4H), 6.79(s, 1H),

2.36(s,3H) ES- 235
1-(3-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5c)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.42(t, J=8.52Hz, 1H), 6.98(t, J=7.19Hz,

3H), 6.54(s,1H), 3.81(s, 3H), 2.32(s,3H) EI+ 237
1-(3-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5d)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.48(t, J=8.71Hz, 1H), 7.02(t, J=7.45Hz,

3H), 6.74(s,1H), 3.92(s, 3H), 2.46(s,3H) EI+ 221
1-(3-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5e)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.38(t, J=8.55Hz, 1H), 7.00(t, J=7.17Hz,

3H), 6.77(s, 1H), 3.84(s, 3H), 2.36(s,3H) EI+ 233
1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5f)
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1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.43(d, J=8.76Hz, 2H), 7.04(d, J=8.76Hz,

2H), 3.86(s, 3H), 2.38(s, 3H) EI+ 233
5-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid (5g)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.57 (s,1H), 7.44(s, 2H), 7.38(s, 1H),

6.80(s, 1H), 2.38(s,3H) ES- 201
Preparation of phenylfuran N-capping groups 60 (5768, 5769)
Synthesis of 5-(3,5-dichlorophenyl)furan-2-carboxylic acid (6a)
A mixture of 3,5-dichloro aniline (0.84g, 5mmol), hydrochloric acid (15%, 3ml )
and water (4.5ml), was heated until a clear solution was obtained. This solution was then
cooled to 0oC, diazotized with aqueous sodium nitrite (30%, 1.2ml) and filtered. To the
filtered solution, water (2.5ml) and furoic acid (0.56g, 5mmol) were added. An aqueous
solution of cupric chloride (0.125g in 10 ml water) was added dropwise and stirred for 4h
at room temperature and kept aside for 16h. The resulting solid was filtered off,
suspended in water and purified by flash chromatography (Biotage SP4) using a SNAP
100g column with a gradient 0% to 40% ethylacetate for 5 column volumes, the
concentration of ethyl acetate at 40% was kept constant for 2 column volumes and then
increased to 100% in 5 column volume. The purified product obtained weighed 0.36g
(28%)
1

H NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 7.85 (d, 2H), 7.65 (t, 2H), 7.36 (d,

J=3.88Hz, 1H), 7.40 (d, 3.96, 1H)
13

C NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 159.0, 152.9, 145.0, 134.9, 132.2,

128.0, 122.7, 119.7, 110.5
HRMS EI+ Observed 255.9698, calculated 255.9694, 1.6ppm
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Synthesis of 5-(3,5-dichlorophenyl)furan-2-carboxylic acid (6b)
1

H NMR (dimethyl sulfoxide-D6, 300MHz) δ (ppm) 7.80(d, J=8.64Hz, 2H), 7.53(d,

J=12.36Hz, 2H), 7.30(d, J=4.53Hz, 1H), 7.17(d, J=3.69Hz, 1H) ES-221
Preparation of phenylpyrrole N-capping groups 61 (5775, 5776)
1-(4-chlorophenyl)-1H-pyrrole-3-carbaldehyde (7a)
4-chloroaniline (0.51g, 4 mmol), 2,5-dimethoxytetrahydrofuran-3-carbaldehyde
(0.76g, 4.8 mmol), acetic acid (16ml) were stirred in a round bottom flask until a red
colored solution was observed. The reaction mixture was then refluxed at 120 oC for 15
mins and a dark reddish brown solution was obtained. The reaction was monitored by
TLC (25% ethyl acetate: 75% hexanes) and worked up when complete. The reaction
mixture was cooled, extracted with ethyl acetate and the organic layer was washed with
saturated sodium bicarbonate, dried over sodium sulfate and concentrated to get 0.77g
(94%)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 9.85 (s, 1H), 7.62-7.63 (t, J=1.8Hz, 1H),

7.44-7.47 (d, J=9Hz, 2H), 7.34-7.37 (d,J=9.3Hz, 2H) 7.05 (t, J=0.9Hz, 1H), 6.57-6.58 (q,
J=1.5Hz, 1H) EI+204
1-(3,5-dichlorophenyl)-1H-pyrrole-3-carbaldehyde (7b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 9.86(s,1H), 7.64(s, 3H), 7.34(s, 1H),

7.06(s,1H), 6.82(s,1H) ES+ 240
1-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid (8a)
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1-(4-chlorophenyl)-1H-pyrrole-3-carbaldehyde(7) (0.76g, 3.58mmol) obtained from step
1, silver nitrate (1216.26mg, 7.16mmol), 6 N sodiumhydroxide (15ml) and methanol
(5.8ml) were refluxed for 5h and the reaction was monitored by TLC for completion. The
reaction mixture was filtered through celite and the aqueous layer was acidified to get a
white precipitate. The precipitate was filtered off, dissolved in ethyl acetate, and dried
over sodium sulfate to get the product 0.6g (65%)
1

H NMR (dimethyl sulfoxide-d6, 400 MHz) δ (ppm) 7.95 (t, J=0.93, 1H), 7.71-7.73 (d,

J=4.6Hz, 2H), 7.53-7.56 (d, J= 4.7Hz, 2H), 7.43-7.44 (t, J= 1.33Hz1H), 6.61-6.62 (q,
J=0.88Hz, 1H)
13

C NMR (dimethyl sulfoxide-d6, 400 MHz) δ (ppm) 165.0, 137.9, 130.5, 129.5, 123.9,

121.7, 120.7, 118.6, 111.5 HRMS
EI+ observed 221.0242, calculated 221.0244, 0.9ppm
1-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid (8b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.64(s,1H), 7.34(s,3H), 7.06(s,1H),

6.82(s,1H) ES+ 256
2.4.2 Fluorescence Polarization Binding Assay
CDK4D1 FP assay: This assay was performed using black 384-well plates using a
previously described procedure2 with the following modifications. To each well were
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-ArgArg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted
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using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM
dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with
shaking for 45 mins at room temperature. Fluorescence polarization was read on DTX880
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was
calculated for each concentration tested using the equation showing below. IC50 values
were determined by logarithmic regression by correlating relative mps and testing
concentrations.
mP(compound)-mP(DMSO, protein, tracer)

Relative mp = mP( DMSO, protein)-mP(DMSO, protein, tracer)
CDK2A2 FP assay: This assay was performed using black 384-well plates. To
each well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-ArgLeu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for
45 mins at room temperature. Fluorescence polarization was read on DTX880 multimode
detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm excitation/emission
filters and a dichroic mirror suitable for fluorescein. Relative mp was calculated for each
concentration tested using the equation showing below. IC50 values were determined by
logarithmic regression by correlating relative mps and testing concentrations.
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2.4.3 Docking55
All the N-capping groups were docked in the cyclin A/CDK2 crystal structure
(PDB

ID

2UUE)

using

1-(3,5-

dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-

carbaldehyde as control ligand. The parameters of the LigandFit (Discovery Studio 3.0,
Accelrys) were PLP1 energy grid, minimization sphere “on”, number of poses 10. All the
docked poses analyzed with PLP1 scoring function, hydrogen bonding and were
subjected to visual analysis for complementarity with second pocket.
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CHAPTER 3
FRAGMENT BASED DISCOVERY OF ARGININE ISOSTERES THROUGH
REPLACE: TOWARDS NON-ATP COMPETITIVE CDK INHIBITORS

3.1 Introduction
In the chapter 2, the design, SAR and optimization of fragment alternatives based
on phenyl heterocyclic carboxylic acids was described. These were designed from a
phenyltriazole Ncap that was discovered during proof of concept for the REPLACE
strategy49. Despite the search for replacements for the critical Arg4 residue, this capping
group only retained the interactions of the Ala2 methyl side chain and hydrogen bonding
interactions with Trp217 and Gln25449. The ion-pairing contacts of Arg4 were not
observed in this for any of the subsequent phenyl heterocyclic isosteres. As next step, the
design of N-capping groups retaining hydrophobic contacts with the secondary pocket
and H-bonding interactions observed in the previous series but adding basic functionality
were explored to identify surrogates for arginine and more completely mimic the contacts
of the native peptide. The REPLACE strategy was used to identify FLIPs synthesized
from derivatives of phenyl acetic, furoic and picolinic acids as N-capping groups. These
fragment alternatives were identified through molecular docking studies. The LigandFit55
method was used after validation that it was predictive for similar known fragment
ligands that were docked into the binding site for Arg4 after its deletion from the
structural complex. Virtual fragment hits were obtained and used to generate Fragment
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Ligated Inhibitory Peptides (FLIPs)56 and tested in the previously mentioned assay to
study their competitive binding efficiency57.
3.2 Results
3.2.1 Validation of LigandFit docking method
The first step for any in silico screening method is to assess its predictive
capability. LigandFit55 is an accurate, fast and shape based method which can identify
and generate poses of ligands that are complementary to the active site of the protein of
interest. The procedure involves two main steps: (i) cavity detection for the identification
of active site and (ii) docking of ligands at the active site. In the case of an unknown
binding site, LigandFit utilizes a cavity detection algorithm for detecting a potential
ligand interacting site and in case of a known active site through the crystal structure of a
protein-ligand complex, the ligand structure is used to define the active site points. A
shape based comparison filter combined with a Monte Carlo conformational search is
employed for generating ligand poses that have shape complementarity to the active site.
Furthermore, a grid based method is employed to generate more realistic protein-ligand
interactions for poses minimized based on the active site55.
As mentioned above, parameters used in any docking protocol should be
optimized prior to docking of unknown ligands to ensure that these will be predictive. To
do this a ligand with known orientation in the cyclin groove is redocked to assess if
correct binding modes are reproduced by the algorithm. To accomplish this, docking was
carried out in CBG of CDK2/cyclin A (PBD ID:2UUE) by varying the parameters of the
docking protocol using the ligands (1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3carbonyl

(35DCPT)

and

1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl)
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(4CPT) as positive controls and 5-chloro-2-phenyl-1,8a-dihydroimidazo[1,2-a]pyridine3-carbaldehyde as a negative control. These molecules were used as controls based on
previous studies in which 35DCPT and 4CPT were shown to occupy the position of Arg4
at CBG in their respective crystal structures (PBD ID: 2UUE, 2V22). FLIPs N-capped
with 35DCPT and 4CPT bind to CBG and inhibit CDK2/cyclin A whereas the negative
control containing FLIP had very poor inhibitory activity49. The structures of positive and
negative control are shown in figure 3.1. Important parameters of the LigandFit protocol
affecting the generated binding mode were optimized and include the type of energy grid
and minimization algorithm and also the number of poses generated and scoring function
used to differentiate good from bad poses.

Figure 3.1 Structures of positive and negative controls
The energy grid is the force field for calculating ligand-receptor interaction and
three types are available within LigandFit: the Dreiding force field with Gasteiger
charges, the CFF (Consistent Force Field) and PLP1 (Piecewise linear potential). The
first step in the validation study was to evaluate each of these energy grids and then select
the one that generates the highest number of accurate poses. After finding a suitable
energy grid, the use of a minimization algorithm was studied by turning it on or off
during LigandFit docking. It can be used to generate poses with relaxed conformations
and also to remove steric overlap that occurs during docking and results in bad poses. The
next step in the validation exercise is to determine which overall force field is optimal.
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CHARM and CFF are two examples of those available to generate atom types and to
assign partial charges to the atoms of the simulation and ultimately to estimate the
binding affinity as sum of the strength of intermolecular van der Waals and electrostatic
interaction between atoms of the ligand and receptor. Docking time is a concern when
evaluating thousands of compounds and thus it is very important to set an optimal value
for the number of poses generated for each ligand docked determines length of the
calculation. For this validation, the number of poses generated was varied between 5, 10
and 20 to determine the optimal number required in order to reduce the docking time.
The last step in the docking validation is to determine which scoring function is able to
correctly assess experimental binding modes for a known ligand. Scoring functions are
used to rapidly estimate the binding affinity of a docked ligand pose based on the
geometry of the conformation and its non-covalent interaction with the target receptor.
Ligscore1_Dreiding, Ligscore2_Dreiding, PLP1, PLP2, PMF, DOCKSCORE and Jain
scoring functions were evaluated.
The LigandFit parameters were optimized based on the number and accuracy of
poses for the known ligands docked into the cyclin groove i.e., maximum number of
correct poses of the positive control ligands and minimum or no poses of negative control
ligand in top scoring poses. A correct pose is one that binds in the receptor in a very
similar orientation to the true ligand and thus superimposes well with true ligand binding
mode and interactions with the defined interaction filters. A close pose is one where the
positive control ligand binds in similar orientation to the correct pose and has RMSD
(root mean square distance) of less than 2.0 Å compared to the true ligand binding mode.
Optimized parameters obtained in the validation exercise will then be selected for
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docking of the library of unknown fragments.
The binding modes of the 35DCPT Ncap have been previously characterized by
X-ray crystallography and were used for the generation of site points. The volume
occupied by the ligand at the binding site determines the site points. In this study, site
points cover the interaction of the phenyl ring (attached to N-1 atom of triazole) in the
secondary hydrophobic cleft of the CBG and those of the H-bonds of the triazole N-2
atom with indole nitrogen of Trp217 and carbonyl oxyen with the amide side chain of
Gln254. Along with these interactions, the correct orientation of the carbonyl group was
studied because this is required for the formation of an amide bond to the peptide in FLIP
synthesis. As the crystal structure is a tetrameric complex of two CDK2/cyclin A
heterodimers, both cyclin subunits were evaluated in the validation by docking the
positive and negative control ligands into the CBG (PBD ID 2UUE).
Table 3.1 Determination of the optimal cyclin subunit (2UUE)
Energy Grid
Dreiding
CFF
PLP1
Sub units
Subunit B Subunit D Subunit B Subunit D Subunit B
No. of correct poses
2
4
6
of 3,5-DCPT
No. of correct poses
8
4-DCPT
No. of closer poses
(<2.0Å) of 3,53
4
4
DCPT
No. of closer poses
15
8
6
(<2.0Å) of 4-DCPT
-ve controls in top
18
15
25
Best scoring
functions

LigScore2
_Dreiding

-

PLP1,
PLP2

-

PLP1,
PLP2

Subunit D
11
Ligscore1_
dreiding,
Ligscore2_
dreiding, PLP1

Docking results for B subunit showed that 10 and 14 correct/close poses
respectively were obtained for 35DCPT and 4CPT respectively whereas for the D
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subunit, 11 close poses of 4-CPT and no correct poses for 3,5-DCPT resulted from the
calculations. There were no poses of the negative control ligand in the top 25 poses for
either subunit. As a result, the B subunit was considered for further parameter
optimization (Table 3.1). For each energy grid evaluated, the number of correct/close
poses in top 25 based on ranking of the scoring function (Ligscore1_Dreiding,
Ligscore2_Dreiding, PLP1, PLP2, Jain, PMF and DOCKSCORE) was determined. The
energy grids, Dreiding, CFF and PLP1 generated 2, 4 and 6 correct poses respectively for
35DCPT. In top 25 scoring poses, there were 18 and 15 poses of negative ligands
observed for Dreiding and CFF respectively but there were no negative ligand poses
found for PLP1. After confirming that the PLP1 energy grid was the most effective, it
was used for further validation runs where scoring functions were analyzed individually.
The best scoring function was found to be PLP1 which generated 6 correct and/or close
poses of 35DCPT and 4CPT in the top 25 ranked poses. Results for the docking
parameter optimization are shown in Table 3.2.
Table 3.2 Optimization of LigandFit docking parameters for the cyclin A groove
Energy Grid

Dreiding

CFF

PLP1

No. of correct poses 3,5DCPT

2

4

6

No. of correct poses 4DCPT

-

-

8

No. of -negative controls in
top 25

-PLP1(4), -PLP2(4),
Jain (4), PMF(4),
DOCK SCORE(6)

-PMF (7), DOCK
SCORE (6)

No –ve control poses
in all the scoring
functions

Best scoring functions

LigScore2_Dreiding

PLP1, PLP2

PLP1, PLP2

3,5-DCPT(rank of top 25
correct/closer poses for the
best scoring function)

4,5 (for all the scoring PLP1(9-12,25),
functions)
PLP2(13-16,25)

4-DCPT (rank of top 25
correct/closer poses for the
best scoring function)

-

PLP1(1-8),
PLP2(17-24)
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PLP1(7-14,25),
PLP2(11-18)

PLP1(1-6) PLP2(2025)

Having minimization sphere “on” minimizes the ligands to their lowest energy
conformations after docking. Hence 10 was considered an optimal number for number of
poses generated because it generated sufficient number of poses for interpreting the
results while saving the docking time. The conclusion of this docking validation study is
that the optimized parameters were found involve the use of the PLP1 energy grid the
minimization sphere, and the generation of 10 poses. The docking carried out for the
known ligands showed that the experimental binding modes of ligands can successfully
be reproduced and therefore the method should be predictive.
3.2.2. Docking of the virtual capping group library.
To more completely exploit the interactions of high affinity peptidic cyclin
groove inhibitors, a library of compounds based on the crystal structure ligand (1-(3,5dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxaldehyde 35DCPT) and using SAR
of the parent peptide (HAKRRLIF) was designed. The criteria used in the library design
included (i) molecular weight less than 400, (ii) presence of a carboxylic acid group for
the formation of amide bond with the peptide sequence, (iii) incorporation of alkyl/aryl
substitutions for van der Waals interactions with the secondary pocket, (iv) basic
functionality for ion-pairing interaction with acidic residues and (iv) synthetic feasibility/
commercial availability. This library was built using the following cores strucures: 5membered heterocyclic ring substituted with a carboxylate, phenyl acetic acids and 6membered heterocyclic ring substituted with a carboxylate.
1. 5-membered heterocyclic rings: These include 1,2,4- triazole, pyrazole, furan,
pyrrole, and thiophene

rings. The latter were linked to another 5-membered

heterocyclic structure (imidazole, pyrazole and thiophene). In addition to these, the
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furoic acids were substituted with diethylaminomethyl and piperazinylmethyl groups.
Some examples are shown in figure 3.2. These basic groups were included to exploit
ion-pairing interactions with the acidic residues (Glu220, Glu224 and Asp283; cyclin
A numbering) made by Lys3 and Arg4 (HAKRRLIF). The heteroatoms in the 5membered ring were included to interact with H bond donors in the cyclin groove
(e.g. the indole nitrogen of Trp217).

Figure 3.2 Examples of structures 5-membered
heterocyclic structures docked
2. Phenyl acetic acids: These were substituted with alkoxy groups at the 3 position and
were expected to interact with the secondary pocket occupied by the Ala2 methyl side
chain in the peptide.
3. Picolinic acids: These were substituted with alkyl groups at the 3 position for
interacting with the secondary pocket and with basic groups at the 4 position for ionpairing interactions (piperazinylmethyl, guanidomethyl and dimethylaminomethyl
groups).
Each potential Ncap was docked as an aldehyde into the cyclin groove of
CDK2/Cyclin A (PBD ID 2UUE) using the validated LigandFit docking method in order
to predict the correct orientation. Presence of carboxylic acid group would be hindrance
and interfere with interaction filter. Hence the molecules were docked as aldehydes.
Docked molecules were prioritized based on high PLP1 score, shape complementarity
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and consensus scoring. Consensus scoring is a way of assessing poses that score well in
multiple scoring functions (in this case, the seven scoring functions used) with the aim of
obtaining a more accurate estimate of the various interactions between the receptor and
the ligand. The PLP1 scoring and the shape complementarity of top scoring poses were
comparable with the true ligands 3,5-DCPT and 4-CPT. The structures and PLP1 scoring
values of virtual hits are shown in table 3.3.
Table 3.3 Hit molecules with their PLP1 scoring
Structure

PLP 1

Structure

PLP 1

54.28

48.83

42.61

53.12

52.1

49.18

48.4

45.32

45.35

46.7

43.84

45.92

3.2.3. Structure activity relationship of N-capping groups
In Chapter 3, phenylheterocyclic carboxamido FLIPs, were described and the
structure-activity was explored for interactions with the secondary pocket and H-bonding
residues of the cyclin groove (e.g. Trp217 and Gln254)63. Residues of the N-terminal
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tetrapeptide of HAKRRLIF make ion-pairing interactions with acidic side chains
surrounding the secondary pocket. Arg4 of HAKRRLIF occupies the ridge of the cyclin
groove that separates both the major and minor lipophilic pockets and makes ion-pairing
interactions with Glu220 and Glu224 thus providing a significant portion of the affinity
for the peptide. Here, groups capable of ion-pairing interactions were incorporated onto
various scaffolds. Some of these scaffolds were designed to be capable of H-bonding and
hydrophobic interactions. The heterocyclic carboxylic acids substituted with basic
functionality were designed to make ion-pairing interactions with the acidic residues
(Glu220 and Glu224) and H-bonding contacts with cyclin groove side chain atoms
(Trp217 and Gln254). 5 and 6 membered nitrogen and oxygen heterocycles were
hypothesized to facilitate H-bonding interactions observed in the 35DCPT capping group
(to the indole nitrogen of Trp217). The amide group present in all the compounds makes
hydrogen bonding with Gln254. Phenylacetic and picolinic acid derivatives were
substituted with alkyl/alkoxy groups to further explore SAR of the minor hydrophobic
pocket.
After scoring the docked ligands, potential capping groups were further
prioritized based on commercial availability and/or ease of synthesis and subsequent to
this incorporated into FLIPs (appended onto the RLIF sequence). Of all of the FLIPs
synthesized and derived from furoic acids (table 4.4), only 5581 (CDK2/cyclin A- 43.4
µM, CDK4/cyclin D-41.9µM) and 5589 (CDK2/cyclin A- 50.3 µM, CDK4/cyclin D-43.2
µM) possessed significant activity and exhibited similar potency in binding to both
CDK2/cyclin A and CDK4/cyclin D. All the other FLIPS from this series and those
derived from thiophene carboxylic acids showed weak activity (table 3.4).
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Table 3.4 SAR of 2-Furoic acid and Thiazole-4 carboxylic acid based FLIPs

SCCP ID

Core

R

CDK2/cyclin A IC50
(mM)

CDK4/cyclin D1
IC50 (mM)

5581

1

-

43.5±1.2

41.9±3.1

5585

1

-

>100

>100

5586

1

-

>100

>100

5589

1

-

50.3±1.3

43.2±5.0

5761

1

-

>100

>180

5582

-

2

56.2±1.2

>180

5584

-

2

>180

>180

An additional scaffold which was explored and verified computationally was the
picolinic acid based fragment. The 6 position was substituted with alkyl, alkyloxy and
piperazinylmethyl groups and these were incorporated as Ncaps into either the RLIF or
RLNpfF peptide. Thus, unsubstituted, 6-methoxy, 6-ethoxy derivatives were ligated to
RLNpFF while 6-methyl and 5-piperazinylmethyl analogs (5856) were appended to the
RLIF sequence. The compound having a piperazinyl methyl substitution at the 5 position,
5856 shows moderate activity in binding to CDK2/cyclin A (>100µM) and greater
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potency for inhibition of the cyclin groove of CDK4/cyclin D (21.9 µM) with roughly
equal activity compared to RRLIF (CDK4/cyclin D- 16.4 µM). The results are shown in
table 3.5.
Table 3.5 SAR of Picolinic acids based FLIPs

CDK2/cyclin A IC 50
(mM)

CDK4/cyclin D1 IC 50
(mM)

-

29.2±1.3

48.4±1.2

-

2

>100

85.7±1.9

OMe

1

-

36.4±1.2

>100

OEt

1

-

39.7±1.2

>100

-

2

>100

21.9±1.1

Core

SCCP ID

R2

525

H

1

5845

Me

524

523

5856

Phenylacetic acid derivatives were a third scaffold that was studied and analogs
were designed to explore the effect of the incorporation of methylene bridge between the
phenyl ring and the carboxyl group, on the lipophilic interactions with the secondary
pocket. Three analogs 3-ethoxy (5854), 3-propoxy (5853) and 3-isobutyloxy (5855)
phenylacetic acid were synthesized by alkylation of 3-hydroxyphenylacetic acid using the
appropriate alkyl bromide followed by base hydrolysis of the ester which occurs due to
concomitant alkylation of the carboxylate (scheme 4.1)67. These N-capping groups were
then ligated to RLIF with the exception of 530 where 3,4- diethoxyphenyl acetic acid was
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obtained commercially and appended to RLNpfF. This bis-substituted analog showed the
best activity in this phenylacetic acid derived series with IC50 values of 5.2 µM and 3 µM
in CDK2/cyclin A and CDK4/cyclin D respectively. All other compounds were
marginally or completely inactive. The activity of the phenylacetic acid based FLIPs are
shown in table 3.6.
Scheme 3.1 Synthesis of phenyl acetic acid derivatives

.
Table 3.6 SAR of Phenylacetic acid based FLIPs

SCCP ID

R1

R2

CDK2/cyclin A
IC50 (mM)

CDK4/cyclin D1
IC50 (mM)

5854

H

OEt

>100

>100

5853

H

n-OPr

>100

>50

5855

H

t-OBu

>100

>100

530

OEt

OEt

5.2±1.3

3.0±2.12
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3.3 Discussion and conclusion
Optimizing docking parameters is a mandatory step for every receptor-ligand
complex as interactions vary considerably with each target. For every target we need to
find the optimal set of parameters that will reproduce experimental binding modes and
thus will be customized to that particular target. Validation of the LigandFit method was
carried out to ensure that the method is able to reproduce experimental binding modes for
known ligands of the cyclin groove and therefore show that the docking results of
unknown compounds will be predictive. The PLP1 energy grid and scoring function were
selected as optimal parameters that were effective in reproducing the binding modes of
native ligands (35DCPT, 4CPT). Energy grid PLP1 was able to reproduce maximum
number of correct or closer poses compared to Dreiding and CFF. Scoring functions in
general are calculated based on assessment of a combination of electrostatic, van der
Waals and hydrogen bonding energies. Of all the seven scoring functions (Jain,
Ligscore1, Ligscore2, PLP1, PLP2, DOCKSCORE and PMF) studied PLP1 was found to
be the most successful as this includes hydrogen bonding terms and hydrophobic
interactions. In this study the binding efficiency at the cyclin groove – substrate proteinprotein interaction interface is being evaluated and thus is comprised of a variety of
interactions with H-bonding being a major contributor to affinity of CGI ligands. A
library of small molecules based on 5-furoic acid, thiazole-4-carboxylic acid, 5 and 6
substituted picolinic acids, and also 3 and 4 substituted phenylacetic acids were docked to
evaluate for their ability to completely interact with cyclin groove. Among the docked
molecules, 16 molecules were synthesized as FLIPs and tested in FP assay.
Among the Ncap series based on furoic acids, FLIPs having furoic acid with basic
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substituents (5-((diethylamino)methyl)furan-2-carboxylic acid - 5581 and 5-((4methylpiperazin-1-yl)methyl)furan-2-carboxylic acid - 5589) showed greater activity
towards both cyclin complexes than 5-((1H-imidazol-1-yl)methyl)furan-2-carboxylic acid
- 5585 and 5-((1H-pyrazol-1-yl)methyl)furan-2-carboxylic acid - 5586. The basic groups
in the Ncaps will be protonated and thus positively charged at physiological pH. This
activity observed for 5581 and 5589 is most likely because of the ion-pairing interaction
of the charged basic groups with acidic residues in the cyclin groove (Glu220 and
Glu224; cyclin A and Glu66; cyclin D). In addition to their ion-pairing interactions,
docked poses indicate that the ethyl groups of 5581 and the piperazine ring carbons of
5589 interact with the secondary pocket occupied by the Ala side chain of the parent
peptide and also mimicking the van der Waals interactions of the phenyl ring of the
35DCPT capping group. Among the thienyl FLIP analogs (5-(thiophen-2-yl)furan-2carboxylic acid - 5584) and (5-(thiophen-3-yl)furan-2-carboxylic acid -5582), 5582
possessed the greatest affinity for cyclin A in complex with CDK2 most likely because it
has a larger secondary pocket to accommodate the thiophene ring.
As previously discussed in chapter 3, the oxygen atom in the furan ring is a poor
hydrogen bond acceptor compared to nitrogen containing heterocycles (i.e. 1,2,4-triazoles
and pyrazoles) resulting in weak binding affinity of FLIPs containing this ring system 63.
This is a likely reason for the overall weak affinity of this series relative to the
phenyltriazole capping groups discussed in chapter 3. But 5581 and 5589 exhibit better
binding affinity towards CBG compared to other phenylfuroic acid derivatives as a result
to the presence of basic groups. Therefore, it is likely that appending the basic
substituents evaluated in furoic acid series onto the 1,2-4 triazole should result in
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significant improvements in binding. The interactions of selected results are shown in
figure 3.3. In addition, benzoic acid derived capping groups incorporating basic groups
were evaluated and are discussed in chapter 5.
Picolinic acids derivatives were designed to incorporate a heteroatom capable of
mimicking H- bonding interactions (Trp217, Gln254) observed in the 35DCPT capping
group and in the peptide context. This was confirmed by the respectable activity of the
unsubstituted picolinamide capped peptide (525). In addition to H-bonding, the methyl or
alkoxy group at the 6 position was hypothesized to provide hydrophobic complementarity
with the second pocket while the piperazinylmethyl group should offer both ion-pairing
and van der Waals interactions (5856). This did not prove to the case since the designed
FLIP was inactive in binding to the CDK2/cyclin A complex. The considerable binding
activity of 5856 for cyclin D/CDK4 is likely the result of closer positioning of the free
piperazine N-atom for ion-pairing with Glu66. Minimal activity of the 6-methoxy (524)
and 6-ethoxy (523) derivatives relative to the unsubstituted compound (525) indicate that
these substitutions are not appropriately positioned to interact with the pocket. Since the
picolinamide capping group is a six membered ring system, placing larger substituents in
the 6-position may lead to a steric clash leading to weaker interaction with Trp217.

71

5581 (PLP1- 52.1)
IC50 (CDK2/cyclin A- 43.5±1.2µM
CDK4/cyclin D-41.9±3.1µM)

5589 (PLP1-54.28)
IC50 (CDK2/cyclin A- 50.3±1.3µM,
CDK4/cyclin D-43.2±5.0µM)

5585 (PLP1- 42.61)
IC50 (CDK2/cyclin A> 100µM
CDK4/cyclin D>100µM

5856 (PLP1-35.03)
IC50 (CDK2/cyclin A- >100 µM
CDK4/cyclin D – 21.9 ±1.1 µM)

Figure 3.3 Interactions of 5581, 5585, 5589 and 5856 at the
Arg binding site of CBG
The binding of hit molecules at the Arg binding site of CBG is shown. The
interaction filters NH-atom of Trp217 and Gln254 are shown as green spheres;
hydrogen bonds with the interaction filters are shown as green dotted lines. The
closer acidic residues and interaction filters are shown in three letter codes. Ionpairing interactions with GLu220 and Glu224 are depicted in green lines
The loss of activity for the mono substituted phenylacetic acid derivatives could
be a result of the absence of the potential hydrogen bonding interaction with Trp217. The
increased potency of the diethoxy analog (530) is likely due to the presence of the
additional substituent at 4 position enabling better placement of the 3-ethoxy group in the
secondary pocket68. The activity of this type of substitution was explored in the context
of benzoic acid derivatives which do not have the methylene bridge and these results are
discussed in chapter 5.
Validation of the LigandFit docking method was useful for predicting binding
interactions of unknown compounds at the protein-protein interface. The results obtained
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from FLIP CGI compounds derived from furoic, thiazole, picolinic and phenylacetic acid
derivatives as N-capping groups suggests that these groups are good substituents for Nterminal Arg. The results correlated from docking analysis and binding assay of FLIPs
confirms validation of docking parameters. In addition to hydrogen bonding interactions,
basic groups substituted in furoic acid and picolinic acid provided insights on ion-pairing
interactions. Overall these FLIP molecules developed in this series contribute to
validation of REPLACE strategy for the development of drug like molecules and also
provides a platform for further investigation of ion-pairing interactions with acidic region
of CBG through the use of more optimal scaffolds.
3.4 Experimental section
3.4.1 Validation of LigandFit
The parameters of the LigandFit (Discovery Studio 3.0, Accelrys) docking
method were validated using ligands from cyclin A/CDK2 crystal structures. The
crystallographic

ligands

1-(3,5-

dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-

carbaldehyde (3,5-DCPT) (PDB ID:2UUE) and 1-(4- chlorophenyl)-5-methyl-1H-1,2,4triazole-3-carbaldehyde (4-CPT) (PDB ID:2V22) were used as positive controls and 5chloro-2-phenyl-1,8a-dihydroimidazo[1,2-a]pyridine-3-carbaldehyde was evaluated as a
negative control. The three ligands were docked successively into the cyclin grooves of
two structures (2V22, 2UUE) and 20 poses were generated for each. This was repeated
by variation of the LigandFit parameters including the forcefield used for the energy grid
(Dreiding, CFF and PLP1), use of minimization sphere (on or off) and different scoring
functions (Ligscore1_Dreiding, Ligscore2_Dreiding, PLP1, PLP2, PMF, DOCKSCORE)
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to determine which generated a calculated binding energy most predictive of the
experimental binding mode. For each parameter and scoring function, the number of
correct poses of the positive controls in the top 25 ranked binding modes (out 25 of 60
possible, 20 for each of the three ligands) was determined. A library of 20 potential
fragment alternatives was manually built using ChemDraw for Excel (Perkin Elmer) and
subsequently imported into DiscoveryStudio 3.0 (Accelrys). For docking of unknown
compounds, 10 poses were generated since this was sufficient to generate correct poses
for the control ligands.
3.4.2. Synthesis
3.4.2.1 Material and methods
All the starting materials, solvents and reagents were used as obtained without
further purification. Analytical thin layer chromatography was performed on silica gel
(GF-254 plates). 1H NMR and 13 C NMR spectra were recorded with a Varian Mercury
300 and 400 Spectrometer, respectively. Mass spectra were measured with a Micromass
QTOF (Tandem quadruple-1 time of flight mass spectrometer), electrospray ionization
(ESI) and VG 70S (Double-focusing magnetic sector mass spectrometer, EI). Analytical
purities of evaluated compounds were >95% unless stated otherwise. The following
analytical method (unless stated otherwise) was used on a Waters Alliance 2695 HPLC
with a 2996 diode-array detector and equipped with a C18 (2) 100 A, 250 x 4.6mm, 5μm
column (Phenomenox Luna). A gradient from 100% water (0.1% trifluoroacetic acid) to
60% acetonitrile (0.1% trifluoroacetic acid) was run over 30 mins and held for 4 mins.
The chromatograms were extracted at 226 and 254 nm.
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3.4.2.2 Synthesis of capping groups
Furoic acid, picolinic acid and 2-(3,4-dihydroxyphenyl)acetic acid N-terminal
capping groups were all obtained commercially (Chembridge, Matrix Scientific and
UKROrgSyth). 3-alkoxy phenyl acetic acid derivatives were synthesized using the
following procedure:
Step 1: Synthesis of ethyl 2-(3-ethoxyphenyl) acetate (9a) 67
3-hydroxyphenylacetic acid (0.76 g, 5 mmol), ethyl bromide (0.25 g, 23 mmol)
and potassiumcarbonate (0.13 g, 16.5 mmol) were refluxed in 5 ml of DMF for 12-18 hrs.
The reaction was monitored by TLC (Ethylacetate: Hexanes= 35:65), after the reaction
was complete, the reaction mixture was cooled to room temperature; water was added to
dissolve potassium carbonate. The aqueous layer was extracted with ethyl acetate and the
combined organic layers were washed with saturated sodium bicarbonate, brine, dried
over sodium sulfate and evaporated to yield reddish oil (0.31 g, yield-30.0%).
1

H NMR (Chloroform-D, 300MHz) δ (ppm) 7.13(t, J=7.32Hz, 1H), 6.75(t, J=8.73Hz,

3H), 4.06(q,24 J=7.80Hz, 2H), 3.93(q, J=6.75Hz, 2H), 3.50(d, J=7.26Hz, 2H), 1.31(t,
J=6.87Hz, 3H), 1.16(t,25 J=7.02Hz, 3H)
EI 208
propyl 2-(3-propoxyphenyl)acetate (9b)
Reddish oil (yield-28.2%) 1H NMR (Chloroform-D, 300MHz) δ (ppm) 7.25-7.19(m, 1H),
6.83(t,29 J=8.07Hz, 3H), 4.05(t, J=6.78Hz, 2H), 3.91(t, J=6.39Hz, 2H), 3.59(d,
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J=6.96Hz, 2H), 1.80(q, 30 J=7.35Hz, 2H), 1.64(q, J=6.00Hz, 2H), 1.03(t, J=7.32Hz, 3H),
0.91(t=7.33Hz, 3H)
EI 224
isobutyl 2-(3-isobutoxyphenyl)acetate (9c)
Reddish oil (yield-24.2%) 1H NMR (Chloroform-D, 300MHz) δ (ppm) 7.22(t, J=8.34Hz,
1H), 6.85-4 6.79(m, 3H), 3.89(d, J=6.48Hz, 2H), 3.71(d, J=6.93Hz, 2H), 3.60(s, 2H),
2.12-2.03(m, 1H), 1.97-5 1.88(m, 1H), 1.03(d, J=6.18Hz, 6H), 0.92(d, J=6.60Hz, 6H)
EI 264
Step 2: 2-(3-ethoxyphenyl) acetic acid (10a)3
The ethyl 2-(3-ethoxyphenyl) acetate (1.41g, 5mmol) obtained from step 1 was
treated with sodium hydroxide (2.8 g, 70 mmol) and a solution of 15 ml ethanol and 15
ml water. The reaction mixture was refluxed for two hours and the reaction was
monitored by TLC (Ethylacetate: Hexanes= 35:65). After the completion of reaction, the
reaction mixture was cooled; the alcohol was evaporated and diluted with water. The
reaction mixture was acidified with 1N hydrochloric acid and stirred to precipitate the
product as white solid (0.73 g, Yield-81.2%).
1

H NMR (chloroform-D, 500MHz) δ (ppm) 7.28-7.24(m, 1H), 6.88-6.83(m, 3H), 4.05(q,

J=6.80Hz, 2H), 3.63 (s, 2H), 1.42 (t, J=7.25Hz, 3H)
13

C NMR (chloroform-D, 125MHz) δ (ppm) 177.15, 159.14, 134.61, 129.60, 121.55,

115.65, 113.41, 63.41, 41.01, 14.80
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EI 180
2-(3-propoxyphenyl)acetic acid (10b)
White solid (yield-85.2%) 1H NMR (chloroform-D, 300MHz) δ (ppm) 7.21(d, J=7.44Hz,
2H), 6.83(t,22 J=7.86Hz, 2H), 3.90(t, J=6.03Hz, 2H), 3.61(s, 2H), 1.79(q, J=6.42Hz, 2H),
1.02(t, J=7.05Hz, 3H)
EI 194
2-(3-isobutoxyphenyl)acetic acid (10c)
White solid (yield-82.8%) 1H NMR (chloroform-D, 300MHz) δ (ppm) 7.22(d, J=8.19Hz,
1H), 6.83(t, 26 J=8.70Hz, 3H), 3.70(d, J=7.26Hz, 2H), 3.62(s, 2H), 2.11-2.00(m, 1H),
1.01(d, J=6.69Hz, 6H)
EI 208
Analytical data (NMR and MS) of representative N-caps are shown in appendix.
Characterization data for FLIPs are shown in appendix table 2.
3.4.3 Fluorescence polarization assay57
CDK4D1 FP assay: This assay was performed using black 384-well plates using a
previously described procedure with the following modifications. To each well were
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-ArgArg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM
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dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with
shaking for 45 mins at room temperature. Fluorescence polarization was read on DTX880
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was
calculated for each concentration tested using the equation showing below. IC50 values
were determined by logarithmic regression by correlating relative mps and testing
concentrations.
mP(compound)-mP(DMSO, protein, tracer)

Relative mp = mP( DMSO, protein)-mP(DMSO, protein, tracer)
CDK2A2 FP: assay This assay was performed using black 384-well plates. To each
well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-ArgLeu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for
45 minutes at room temperature. Fluorescence polarization was read on DTX880
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was
calculated for each concentration tested using the equation showing below. IC50 values
were determined by logarithmic regression by correlating relative mps and testing
concentrations.
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CHAPTER 4
STRUCTURE ACTIVITY RELATIONSHIP LEADING TO CONVERSION OF
CYCLIN BINDING GROOVE PEPTIDES TO DRUG LIKE CDK INHIBITORS
THROUGH REPLACE

4.1 Introduction
In this chapter, structure-activity relationships of peptidic cyclin groove inhibitors
derived from the p21WAF CDK inhibitory protein and the Rb like substrate, p107 are
described. This was carried out towards the overall aim of targeting substrate recruitment
through the cyclin binding groove (CBG) present in cell cycle CDK/cyclin complexes.
The Cyclin Binding Motif (CBM) has been studied in detail and shown to be comprised
of the consensus sequence, ZXRLYY’ where Z, X are basic residues (Lys, Arg), L is
leucine and Y, Y’ are non-polar residues with a requirement for Phe at one of these two
positions. Ala scanning of the p21WAF sequence from residues 149 to160 has been carried
out showing that the sequence, DFYHAKRRLIFS was a potent inhibitor of CDK4/cyclin
D and CDK2/cyclin E in kinase assays. Minimization studies showed that the peptide
octamer, HAKRRLIF was a highly potent inhibitor of CDK2/cyclin A when tested in
competitive binding assay and also that the activity was comparable to the intact human
recombinant p21WAF( IC50 = 0.028µM vs. 0.011µM). This octamer was further truncated
to RRLIF (IC50-1.4µM in CDK2/cyclin A) showing that respectable levels of potency
could be retained with a MW more akin to drug-likeness. Overall these results show that
potent and selective inhibition of cell cycle CDKs can be obtained in p21 derived
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peptides that are non-ATP competitive compounds. Similarly another octapeptide derived
from the retinoblastoma like protein p107, SAKRRLFG binds to the CBG and results in
potent inhibition of cell cycle CDKs (IC50 - 0.035µM in CDK2/cyclin A) 46. Because of
their lack of cell permeability and metabolic instability, peptides in general do not make
good drugs48. The first aim of this study is to investigate the SAR of the CBM in greater
depth in order to replace peptide residues that prevent it from crossing the cell membrane
and to incorporate substitutions to improve metabolic stability. The liabilities of the CBM
peptides include the basic residues (Lys, Arg) that limit cell permeability and the
susceptibility of the amide backbone to proteolytic degradation. Furthermore, the goal
was to iteratively convert the peptide RRLIF into drug like FLIP molecules utilizing
REPLACE strategy. Based on the SAR data, a variety of modifications were included to
replace Arg5 and to stabilize the C-terminal motif against degradation. These were then
then converted into more pharmaceutically appropriate compounds through addition of
the 35DCPT as the most effective Ncap identified to date.
4.2 Results
A detailed structure activity relationship was carried out for peptides derived from
p21WAF and p107 with several modifications of the key residues to determine how the key
determinants of binding could be replaced and based on the results allow conversion to
more drug like molecules. Three series of CGI peptides were selected for a detailed study
of their structure activity relationships. Two of these include the p21WAF derived
peptides HAKRRLIF and its truncated variant RRLIF. The third series is from the Rb
like protein substrate, p107 and has the sequence SAKRRLFG. Previous SAR
information revealed that the residues His1, Lys3, Arg4 and Arg5 make ion-pairing
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interactions with the acidic regions and are therefore important or critical for activity44.
Furthermore Ala3, Leu6 and Phe8 contact the two hydrophobic pocket regions through
van der Waals interactions and these are essential determinants for binding to the CBG.
Inclusion of the Ile spacer residue between Leu and Phe in the p21WAF peptide
(HAKRRLIF) improves potency relative to the p107 peptide (SAKRRLFG)
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. An

extensive SAR investigation was therefore carried out so as to find residue alternatives
that might reduce peptide length and consequently improve the drug likeness.

Figure 4.1 Structure of non-natural amino acids
For the octapeptides, HAKRRLIF and SAKRRLFG, modifications of the Cterminus were attempted. For RRLIF, Arg 4 was substituted with non-natural amino acids
or fragment capping groups designed to further probe its contributions and Arg5 was
replaced with isosteric residues. These modifications were carried out to study SAR
which then would help in investigating the effect of substituted residues in retaining the
inhibitory activity but with improved stability and drug likeness. The isosteric residues
incorporated are shown in figure 4.1. Modified peptides were synthesized by standard
solid phase chemistry56, and then tested for their ability to bind to the cyclin groove of
CDK2/cyclin A and CDK4/cyclin D1. Furthermore the experimental binding affinity was
correlated with the calculated interaction energies for peptides modeled in complex with
CDK2/cyclin A.
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4.2.1 Structure activity relationship of SAKRRLFG (p107) and HAKRRLIF
(p21WAF) based peptide analogs
Peptides derived from p107 and p21WAF have been shown to exhibit potent nonATP competitive inhibitory activities against CDK2/cyclin A and CDK4/cyclin D. The
key residues that contribute to binding and inhibitory activity need to be investigated to
extend the structure-activity relationships.

As discussed, the CBG has three major

subsites including an acidic region and a major (primary) and a minor (secondary)
hydrophobic pocket. Lys3 and Arg4 in the N-terminal tetrapeptide of the octapeptides
interact with acidic residues (Glu220, Glu224 and Asp284) and whereas Ala2 interacts
with the secondary hydrophobic pocket. Leu6 and Phe (7 or 8) in the C-terminal region of
the octomer bind to the primary lipophilic pocket49,70 . In this first instance, these Cterminal determinants were exchanged to determine their contributions with the major
hydrophobic pocket and also the consequences of the structural differences of cyclin A
and cyclin D on affinity of these inhibitors. The competitive binding efficiency
determined by FP assay of a number of octapeptide variants based on SAKRRLFG and
HAKRRLIF are shown in table 4.1.
C-terminal modifications of SAKRRLFG were designed to examine (i) effect of
C-terminal functional group (CONH2 or COOH), (ii) extension of the C-terminus to
probe interaction with the major hydrophobic pocket (iii) replacement of Arg5 and (iv)
modification of the motif interacting with the major hydrophobic pocket by deletion and
substitution of key residues. Modification of the C-terminal functional group was
assessed by synthesizing SAKRRLFG as its C-terminal amide (SAKRRLFG-NH2, 457).
Compared to the corresponding C-terminal acid peptide (5815), 457 showed similar
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binding to both CDK2/cyclin A (0.05 µM, 0.07 µM) and CDK4/cyclin D (0.66 µM, 0.88
µM). Extension of the peptide with methionine (SAKRRLFGM, 5564) shows
comparable results with 5815 (CDK2/cyclin A- 0.07 µM, CDK4/cyclin D-0.70 µM).
5814 with the 3TA Phe replacement shows a 3 fold decrease in potency in CDK2/cyclin
A (0.18 µM) and 2 fold decrease in CDK4/cyclin D (1.67 µM) compared to 5815.
Replacement of Leu with betahomoleucine (β-Leu) leads to 2-3 fold potency
improvement (5820, CDK2/cyclin A- 0.02 µM, CDK4/cyclin D- 0.29 µM) compared to
5815. CBM peptides of p21 with LIF sequence on C-terminus are more potent than p107
peptides that have LFG sequence. The isoleucine of HAKRRLIF (5816) acts as spacer
residue and thus adding the extra carbon in the β-Leu (compared to leucine) provides for
more optimal spacing to allow adaptation of the Phe to the pocket. In order to determine
the effect of the β-Leu residue in the 3TA context, both Leu and Phe were replaced with
these residues respectively (5813). These substitutions were found to be the most
effective in this series with a 20 fold enhancement in potency compared to 5814 in both
cyclin A and cyclin D context (CDK2/cyclin A- 0.01 µM, CDK4/cyclin D- 0.04 µM).
Previous studies have indicated that Arg5 is less important for activity than Arg4 and
which makes critical contributions to binding. . When Arg5 was substituted with Asn
(5557, 5558) the activity decreased 3-4 fold for binding to both cyclins (CDK2/cyclin A0.19 µM, CDK4/cyclin D- 4.15 µM). Similarly replacement of Arg5 with Ala (5559)
resulted in reduced potency. HAKRRLIF (444) exhibited comparable binding activity
(CDK2/cyclin A-0.02 µM) with a peptide in which Phe was replaced with
cyclohexylalanine(HAKRRLI(CHA), 5816).
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Table 4.1 Structure activity relationship of p21 and p107 derived peptide analogs

CDK2/cyclin A CDK4/cyclin D1
IC50 (µM)
IC50 (µM)
0.07±0.02
0.88±0.34

SCCP ID

Structure

457

SAKRRLFG-NH2

5815

SAKRRLFG-OH

0.05±0.02

0.66±0.21

5814

SAKRRL3TA G-OH

0.18±0.07

1.67±0.53

5564

SAKRRLFGM

0.07±0.04

0.70±0.30

5820

SAKRR{βLeu}FG-OH

0.02±0.00

0.29±0.07

5813

SAKRR{βLeu}3TAG-OH

0.01±0.00

0.04±0.07

5557

SAKRNLFGM

0.19±0.06

4.15±1.36

5558

SAKRNLFG-NH2

0.24±0.11

3.09±2.00

5559

SAKRALFGM

0.81±0.10

4.92±0.34

5816

HAKRRLI{CHA}

0.02±0.00

0.18±0.04

444

HAKRRLIF

0.02±0.01

0.12±0.05

4.2.2 Structure activity relationship of RRLIF (p21WAF) based peptide analogs
Previous SAR studies resulted in the identification of RRLIF as the minimal
cyclin groove binding sequence with CDK inhibitory activity. Hence RRLIF was used as
a starting point to convert the peptide to a more drug like molecule. A variety of peptide
analogs derived from RRLIF (IC50 = 1.01 μM and IC50 = 25.12 μM for CDK2/cyclin A
and CDK4/cyclin D respectively) were designed to introduce replacements for each of
these residues and to probe their contributions and potential for replacement with more
drug-like moieties. Results obtained from the SAR studies of RRLIF modifications are
shown in tables 5.2, 5.4 and 5.5 and discussed in the following sections.
4.2.2.1 Arg replacements
Substitutions of both the N-terminal arginines were carried out to examine the
sensitivity and binding requirement for each one. Previous studies have indicated that
Arg4 critical for activity while Arg5 is less so. Both arginine residues were replaced with
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citrulline as shown in 5812 (Cit-RLIF) and 5831(RCitLIF) to study the effect of noncharged isostere urea in place of highly basic group guanidine. Activity data shows IC 50
values of 5812 in CDK2/cyclin A as 43.17 μM and CDK4/cyclin D as 40.46 µM
indicating a potency drop of 42 and 1.6 fold respectively. For 5831, the IC50 values were
found to be 5.19 μM and 15.76 μM in CDK2/cyclin A and CDK4/cyclin respectively
which showed 5 fold less activity in CDK2/cyclin A and slightly improved potency in
CDK4/cyclin D. Substitution of Arg5 with isosteric residues including N,Ndimethyllysine

(Figure

4.1,

5925-

R(dimethyllys)LIF,

IC50

1.70

µM)

and

Nmethylarginine (Figure 4.1, 5918 R(NMeArg)LIF, 20.62 µM) results in potency
decreases in binding to CDK2/cyclin A. 5925 retains similar activity while

5918

undergoes a 20 fold decrease in binding activity. 5918 shows slight decrease in the
activity for CDK4/cyclin D (IC50 33.76 µM) while 5925 is about 2.7 fold more potent
than RRLIF (IC50 9.19µM) in this context.
Further subsitutions for Arg5 included the neutral residues Gly, Ala and Pro to
study the loss of ion-pairing interactions with the acidic region. Peptides incorporating
these replacements resulted in very weak or no binding to both CDK/Cyclin complexes
evaluated. Proline substitution (RPLIF 5832) was proven to be detrimental to the activity
with IC50 values of greater than 180 μM for both CDK2/cyclin A and CDK4/cyclin D.
Glycine substitution for this residue (RGLIF-5873- >180 μM for CDK2/cyclin A and
CDK4/cyclin D) resulted in a similar loss of binding. The activity of the alanine surrogate
(RALIF 5833) significantly decreased with respect to the native residue by 20 fold with
respect to CDK2/cyclin A (IC50 of 20.36 μM) but had no dramatic loss of binding to
RRLIF in CDK4/cyclin D (IC50 > 28.76 μM). A molecular modeling study was carried

86

out in order to examine the structural basis for the potency loss of these Arg replacement
analogs. After formation of the peptide cyclin complex by mutation of RRLIF (from the
crystal structure 1OKV) and subsequent energy minimization, interaction energies were
calculated for all of the Arg5 alternatives of RRLIF. The competitive binding efficiency
of each peptide was compared with the interaction energy for its complex modeled with
CDK2/cyclin A. A trend in the relationship between the interaction energy and the
competitive binding data was observed with R2 correlation coefficients of 0.85 and 0.87
for potential and electrostatic energy respectively (table 4.3, figure 4.2).
Table 4.2 N-terminal modifications with R substitutions

Nonnatural
amino
acids
Natural
amino
acids

Peptoid

SCCP ID

Structure

CDK2/cyclin A IC50
(µM)

CDK4/cyclin D1 IC50
(µM)

5811

RRLIF

1.01±0.17

25.12±2.97

5812

Cit-RLIF

43.17±8.77

40.46±1.07

5831

RCitLIF

5.19±1.56

15.76±1.94

5918

R(dimethyllys)LIF

20.62±2.57

33.76±10.72

5925

R(NMeArg)LIF

1.70±0.76

9.19±2.18

5832

RPLIF

>180

>100

5833

RALIF

20.36±7.57

28.76±12.86

5873

RGLIF

>180

>100

5877

R-X1-LIF

>180

>100

5879

R-X2-LIF

>180

>100

5878

NCAP1-X1-LIF

>180

>100

5895

NCAP2-X1-LIF

>180

>100

X1- DMAM peptoid, X2-DMAMAla, NCAP1-2-(3-methoxyphenyl)acetic acid,
NCAP2- 4-(piperidin-4-yloxy)benzoic acid
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Table 4.3 Interaction energy calculated for the peptide analogs

Peptide
sequence

LogIC50

Potential Energy
(kcal/mol)

Van der Waals
Energy(kcal/mol)

Electrostatic
Energy(kcal/mol)

RRLIF

0.004

-195.25

-47.03

-148.21

CitRLIF

1.635

-162.61

-47.97

-114.64

RCitLIF

0.715

-169.05

-48.02

-121.02

RALIF
RGLIF

1.309
2.255

-155.52
-155.03

-43.6
-43.49

-111.92
-111.54

R(NMeArg)LIF

0.23

-191.38

-47.15

-144.23

In t e r a c t i o n E n e r g y V s I C 5 0
2

-1 0 0

P o t e n t ia l e n e r g y R - 0 .8 5 5 2
2

E le c t r o s t a t ic e n e r g y R - 0 .8 7 4 5
-1 5 0

-2 0 0

-2 5 0
0 .0

0 .5

1 .0

1 .5

2 .0

L o g IC 5 0

Figure 4.2 Correlation of interaction energy with binding affinity
Further to these exchanges for the second arginine, peptoid substitutions were
utilized to attempt Arg5 replacement (Figure 4.3). Peptoids are peptidomimetics that have
side chains attached to the amide N-atom and these are resistant to proteolysis. Two
different peptoid residues were generated and incorporated. These included
dimethylaminomethyl glycine and dimethylaminomethyl alanine which were included as
Arg5 replacements in the RRLIF context (5877, 5879). 5878 and 5895 incorporated 3methoxyphenylacetamide

and

4-piperidiyloxybenzamide

as

Ncapping

group

replacements respectively for Arg4. Peptoid incorporation was not successful as shown
by the inactivity for CDK2/cyclin A (Table 4.2). The loss of activity for these analogs
suggests that shift of the side chains to the α-nitrogen from the α-carbon may not provide
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favorable contacts with CBGs.

Figure 4.3 Structure of FLIPs containing peptoids
4.2.2.2 C-terminal modifications of RRLIF
As previously described, Leu6 and Phe8 of the RRLIF sequence are critical
residues for binding through the hydrophobic effect and van der Waals interactions with
the primary pocket. Previously SAR modifications have not been extensively probed in
the pentapeptide context for binding to both CDK/cyclin complexes, were further
investigated. The C-terminus was modified by deletion of the isoleucine (RRLIF
sequence) or glycine (RRLFG sequence) residues and also through substitution with
rationally selected non-natural amino acids (table 5.4). Ile7 (RRLIF) is a spacer residue
that enables proper positioning of both Leu and Phe for optimal hydrophobic contacts.
Deletion of this residue (RRLF, 5874) leads to a 35 fold decrease in potency for
CDK2/cyclin A (IC50 35.651μM) and almost complete loss of activity for CDK4/cyclin
D. Adding glycine to this sequence generates the p107 pentapeptide (5871- RRLFG) and
results in a 2 fold improvement in binding to CDK2/cyclin A. Its IC50 of 18.88 μM is still
almost 20 fold higher compared to RRLIF however. Incorporation of the non-natural
residues, β-Leu and N-MePhe previously investigated in the octapeptide context showed
promising results with respect to activity improvements. Substitution of Leu with βLeu
resulted in recovery of binding activity that was lost with the removal of Ile spacer
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residue. RRβLF (5875) is only 2 fold less potent than RRLIF in the CDK2/cyclin A
context (5811, 2.81 µM) and has similar binding in the CDK4/cyclin D context (21.17
µM). Extension of this sequence with Gly resulted in improved activity only in binding to
CDK2/cyclin A (RRβLeuFG – 5876, 1.73 μM, CDK2/cyclin A; 20.24 μM CDK4/cyclin
D). Replacement of Phe with N-MePhe in both C-terminal acid and amide contexts
shows drop in the activity CDK4/cyclin D compared to RRLIF however has comparable
binding activity to CDK2/cyclin A. 5941, RR{βLeu}NMeF-NH2 and 5930,
RR{βLeu}NMeF had IC50 values of 1.74 µM and 5.82 µM in CDK2/cyclin A and 45.58
µM and 81.13

µM

in CDK4/cyclin D respectively. βLeu and N-MePhe were

incorporated in the same peptide for the purpose of improving drug-likeness by
enhancing metabolic stability. In addition, the C-terminal amide functionality of 5941
helps in reducing the total polar surface area (to 271.42 vs. 303.52 (RRLIF)).
Table 4.4 C-terminal modifications with LIF substitutions

ID

Sequence

CDK2A IC50 (µM)

CDK4D IC50 (µM)

5811

RRLIF

1.01 ± 0.17

25.12±2.97

5871

RRLFG

18.88±4.45

>100

5874

RRLF

35.65±10.51

>100

540
5875

RRLNpfFG
RR{βLeu}F

0.70±0.19
2.81±0.76

9.26±2.07
21.17±2.99

5876

RR{βLeu}FG

1.73±0.46

20.24±5.37

5930

RR{βLeu}{NMeF)

1.35±1.38

45.58±5.63

5941

RR{βLeu}{NMePhe}-NH2

5.82±3.12

81.13±3.78

5.2.2.3 Combination of optimal Ncapping groups with SAR information to improve
drug likeness of RRLIF derivatives.
In previous chapters, N-capping groups designed to exploit H-bonding (with
Trp217, Gln254), van der Waals (secondary pocket) and ion-pairing interactions (acidic
region) of CBG were described. An extensive SAR study of phenyl heterocyclic
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carboxylic acids and Arg alternatives based on furoic, picolinic, thiazole and phenylacetic
acid derivatives was undertaken/ These results indicated that 1-(3,5-dichlorophenyl)-5methyl-1H-1,2,4-triazole-3-carboxylic acid (35DCPT) was among the most effective and
drug-like N-caps. As a result, this fragment was combined with the substitutions
described above that removed some of the metabolic liabilities of RRLIF while retaining
its potency. Synthesized derivatives included 35DCPTCit {βLeu}NMeF (5962), 35DCPT
Arg{βLeu}NMeF(5963), 35DCPT Arg{βLeu}3TA (5964) whose structures and
activitites are shown in figure 4.5 and table 4.4 respectively. As a result of the citrulline
substitution, FLIP 5962 has no activity in CDK2/cyclin A and CDK2/cyclin D. The other
35DCPT capped peptides containing arginine, 5963 and 5964 have respectable activity
for CDK2/cyclin A with IC50s of 8.95 µM and 5.70 µM respectively. Although these
FLIPs have decreased compared to RRLIF, they possess greater drug likeness as
evidenced by calculation of their physicochemical properties including of clog P
(partition coefficient) and pTSA (total polar surface area).

Figure 4.4 FLIPs with modification on N-terminus and C-terminus
As a further step to improve drug likeness, Arg5 was substituted with alkylated
guanidine derivatives shown in a previous context to improve ion-pairing interactions
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while potentially imporving cell permeability properties. Arg5 was replaced in the 5964
scaffold with alkylated arginine isosteres including monomethyl (6030); monoethyl
(6028) and dimethyl (6029) derivatives and also the cyclic guanidine variant (6027)
(figure 5.4). The IC50 values are 4.50 µM (6030), 16.39 µM (6029), 3.69 µM (6028) and
46.75 µM (6027). Testing of this set revealed that monalkyl derivatives had decreased
binding compared to 5964 whereas the dimethyl and cyclic guanidine derivatives
displayed similar affinity.
Based on the calculation of key properties (clog P and tPSA), it was concluded
that these 35DCPT capped peptides had improved pharmaceutical like properties relative
to RRLIF while potentially increasing permeability and stabilization against proteolytic
degradation. These FLIPs were therefore evaluated for their ability induce antiproliferative effects in U2OS (osteosarcoma) and DU145 (prostate cancer) cell lines as
evidence for cell permeability and anti-tumor activity. In line with its decreased activity
in the binding assay, 5962 did not show any growth inhibitory activity when evaluated in
the MTT assay whereas the cyclin groove inhibitory FLIPS, 5963 and 5964 had
respectable cellular activity on U2OS cells (IC50 30.7 M, 18.3 M respectively) and
DU145 (IC50 36.5 M, 21.8 M respectively). Comparison of the anti-proliferative
activities of 5963 and 5964 was suggestive of consistency between the binding affinity
on CDK2/cyclin A and the cellular activity since a roughly 2 fold difference was
observed in both. The modified guanidine derivatives all exhibit weaker cellular activities
compared to 5964. Inhibition of cell cycle CDKs should lead to G1 arrest and therefore to
determine if these FLIPs act by this mechanism, cell cycle distribution analysis was
carried out by fluorescence activated cell sorting. The FLIP 5964 causes cell cycle arrest
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at G1 compared to DMSO control and it is mechanistically distinct from Flavopiridol
which leads to accumulation of cells in the G2/M phase (figure 4.5).
Table 4.5. FLIP Modifications to the N and C-terminii

FP assay IC50 (µM)

Physical properties

MTT assay IC50 (µM)

SCCP ID

Structure

clogP

tPSA*

U2OS

DU145

5811

RRLIF

1.4 ± 0.42

16.1±1.73

-1.64

303.52

NA

NA

5962

35DCPT-Cit{βLeu}{NMeF}-NH2

>100

>100

5.142

242.57

>100

>100

5963

35DCPT-R{βLeu}{NMeF}-NH2

8.95±4.15

78.25±11.09

4.947

249.35

30.7±2.7

36.5±2.6

CDK2/cyclin A CDK4/cyclin D1

5964

35DCPT-R{βLeu}{3TA}-NH2

5.70±3.55

>100

2.573

220.25

18.3±1.5

21.8±0.32

6027

35DCPT-G10-{βLeu}{3TA}-NH2

46.75±10.68

>100

3.32

208.76

>100

>100

6028

35DCPT-G11-{βLeu}{3TA}-NH2

3.69±0.23

>100

3.8

194.77

75.6±1.2

102±14

6029

35DCPT-G12-{βLeu}{3TA}-NH2

16.39±3.72

>100

3.85

208.76

108±4

130±27

6030

35DCPT-G19-{βLeu}{3TA}-NH2

4.50±0.74

>100

2.34

194.77

60.5±3.3

81.0±8

Figure 4.5 Cell cycle analysis by FACS
4. 3 Discussion and conclusion
As indicated previously, the CBG is comprised of two hydrophobic pockets and
an acidic region. Key interactions of CBM peptides include ion-pairing interactions with
acidic region, hydrogen bonding with backbone amides of the cyclin and van der Waals
interactions with hydrophobic regions. The critical residues of the CBM include Arg4,
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Arg5, Leu7 and Phe8 are conserved in the three parent peptides in this SAR study. The
main objective in this chapter was to further investigate critical residues of the CBM and
then determine ways to convert the CBM pentapeptides RRLIF to more drug like
molecule through further application of REPLACE.
Contacts between species containing opposite formal charges are the strongest
among non-bonded interactions. Since Arg4 and 5 of the CBM involve ion pairing
interactions with negatively charged residues in the cyclin groove, both are important for
binding of HAKRRLIF and its minimized counterpart. The decrease in potency observed
when these were substituted with isosteric residues can be therefore attributed to
decreased ion-pairing interactions in these analogs. Results obtained for citrulline
substitution indicated that ion pairing contacts of Arg4 are more significant than those of
Arg5, an observation consistent with the number of negatively charged residues of the
cyclin contacting them. Citrulline which has an uncharged urea group in place of
guanidine in Arg that leads to loss of ion-pairing interactions. Arg 4 makes multiple ionpairing interactions at CBG unlike Arg5 hence replacing Arg4 with its uncharged isostere
causes major activity loss. The difference in activity between cyclin A and cyclin D most
likely arises from the structural differences between the cyclins and the variation in the
CBM contacting residues in these two proteins. When bound to cyclin A, the Arg4
residue interacts with Asp283 through ion pairing. This residue occurs as Thr62 in cyclin
D and results in fewer ion-pairing interactions53. Replacement of Arg with citrulline
therefore is tolerated better in the cyclin D context. This is consistent with the results
obtained for replacement of Arg5 with N,N-dimethyllysine (5918) which undergoes a 20
fold reduction in potency for binding to CDK /cyclin A and a decrease of 1.3 fold for
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CDK4/cyclin D. Although 5918 has a basic residue available for ion paring interaction,
the hindered methylated tertiary amine may prevent interaction with the Asp283 side
chain. Methylation of the amide backbone nitrogen is a common strategy to stabilize
peptides and make them resistant to proteolysis71,72. Incorporation of N-Me Arg in place
of Arg5 lowers the potency less than 2 fold suggesting that N-methylation would be
beneficial to increase proteolytic stability while preserving binding activity. Uncharged
alternatives for the Arg5 were incorporated (Gly, Ala and Pro) and for the most part led
to poor binding due to loss of ion-pairing and H-bond interactions. The peptide
containing proline would undergo perturbation of its conformation (as observed in the
modeled structure of RPLIF) along with the loss of H-bonding interactions from the
backbone amide. Similarly RGLIF and RALIF suffer from loss of ion pairing. As a whole
calculated interaction energies from the modeled complexes correlate very well with the
IC50 values determined in FP assay. Consistent with the results obtained for
pentapeptides, potency levels observed for the octapeptide Arg5 replacements decreased
significantly.
Peptoids are peptide replacements based on N-substituted glycine residues i.e.
where the side chain is attached to the -N atom instead of α C-atom. Since these
compounds are tertiary amides and non-natural, they are resistant to proteolysis73. In the
peptoid series, Arg5 was substituted with dimethylaminomethyl glycine (DMAM) and
dimethylaminomethyl alanine (DMAMAla) peptoid residues. Loss of activity for the
peptoid series can be explained by these compounds adopting a different conformation
leading to loss of hydrogen bonding and van der Waals interactions.
In order to explore substitutions for the key residues (Leu, Phe) contacting the
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primary hydrophobic pocket and to imbue cyclin groove inhibitors with greater metabolic
stability and cell permeability while further minimizing the size, β-Leu and non-natural
residues were incorporated. Deletion of the Ile spacer residue (RRLF) leads a dramatic
loss of binding to CDK2/cyclin A. The majority of the potency loss could be recovered
by the addition of a methylene spacer in Leu of RRLF i.e, substituting β-Leu for Leu as
seen in RR β-LeuPhe-NH2 (5941) Incorporation of β-Leu has the advantage of improving
stability of the peptide and also reducing the peptide length. Along with this, β-Leu
provides similar van der Waals interaction from its side chain while the extra methylene
also acts as a spacer offering flexibility to the Phe sidechain for improved
complementarity with the primary hydrophobic pocket69,70. This was confirmed by
testing of the octapeptides 5920 and 5813, both were among the most potent in
competitive inhibition of CDK2/cyclin A and CDK4/cyclin D and further corroborated
by the binding potency for 5975 (RR{βLeu}F) and 5976 (RR{βLeu}FG) with
CDK2/cyclin A. Results from both penta and octapeptide analogs suggest that 3TA is an
effective replacement for Phe while also potentially improving drug likeness. Nmethylation of the Phe residue did not lead to potency loss and therefore suggests that its
inclusion into the peptide or FLIP would result in stabilization against proteolysis.
Incorporation of β-Leu and N-MePhe/3TA (in place of LIF) results in a smaller peptide
while retaining the majority of interactions. Apart from this, presence of the amide group
on the C-terminus improves the tPSA compared to RRLIF. The tPSA and clog P are
parameters that determine the exposed hydrophilic surface and overall hydrophobicity of
a molecule. These should be in a balance if used in a predictive sense for estimating if a
molecule will be useful as for drug development. According to Lipinski’s rule of 5 and
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other guidelines for drug likeness, the tPSA is typically less than 140 Å and clog P is
between -0.4 to 5.6 for orally available drugs65,66.
In previous chapters, the REPLACE strategy was described in the identification
and optimization of N-capping groups as suitable ligand alternatives for Arg4. The
molecule 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide was found to
be most potent N-capping group. As a result, FLIPs were synthesized combining this
capping group with the C-terminal modifications in an attempt to improve drug likeness
while retaining affinity of the original peptide. In order to provide insights into the cell
permeability and anti-tumor effects of these FLIPs, cellular viability studies were
undertaken. The results indicated that both cyclin groove inhibitors have antiproliferative
effects on DU145 and U2OS cancer cell lines52,54. As these cell lines have deregulated Rb
pathways, it is probable that the growth inhibitory effects of 5963 and 5964 are through
inhibition of cell cycle CDKs and specifically through E2F1. In the MTT cell viability
assay 74, the 3TA analog (5964) was observed to be 2 fold more potent compared to NMePhe analog (5963) which is in accordance with the binding assay. Modifications to the
guanidine side chain were attempted by addition of linear or cyclic alkyl groups.
Although some of these have similar cyclin groove binding ability, their weaker cellular
suggests that the modified guanidine group interferes with cellular permeability. This
could result from steric hindrance of the modified guanidine group precluding interaction
with negative charges of the lipid bilayer and therefore preventing permeability. Results
from the binding assay and cell cycle analysis strongly indicate that 5964 is a lead
compound in that it binds to and inhibits CDK2/cyclin A thereby inducing G1 cell cycle
arrest and anti-proliferative effects in tumor cells. These results are consistent with on
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target inhibition of the cell cycle CDKs and pave the way for more in depth studies with
these FLIPs. Development of FLIPs with cellular activity is an important milestone in
this project and contributes overall to the development of anti-tumor therapeutics using
REPLACE strategy. Future studies will focus on the mechanism of action of the lead
FLIP molecule 5964 in cancer cell lines and will be further optimized to improve its
cellular activity.
4.4 Materials and methods
4.4.1. Peptide & FLIP Synthesis56
All N-terminally capped FLIPs were synthesized and purified using standard
Fmoc chemistry by GenScript (Piscataway, NJ). HPLC and MS were used to confirm the
purity and structure of each peptide. Peptides were assembled by using standard solidphase synthesis methods. A sample procedure is given as follows: 5 equivalents of the Cterminal amino acid were coupled to Rink resin at the first place using 1 DIEA (0.082
mL) and HBTU (189.6 mg) in 2 mL of DMF for 1 h. The Fmoc of the C-terminal amino
acid was removed using 20% piperidine in 3 mL of DMF for 10 min before addition of 5
equiv of the next amino acid using DIEA (0.082 mL) and HBTU (189.6 mg) in 5 mL of
DMF. Wash cycles (5 x 10 mL of DMF + 5 x 10 mL of DCM) were applied to each step
in between coupling and deprotection of Fmoc. Upon completion of assembly, side chain
protecting groups were removed, and peptides were cleaved from Rink resin using 90:5:5
mixtures of TFA/H2O/TIPS. Crude peptides were purified using reverse-phase flash
chromatography and semi preparative reverse-phase HPLC methods. Pure compounds
were lyophilized and characterized using mass spectrometry and analytical HPLC (see
Supplementary Table 3).
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4.4.2 Energy minimization and Interaction energy calculation
Energy minimization was performed in Discovery studio 3.0 in the Cylin A (PBD
ID: 1OKV) at the cyclin binding groove. Prior to minimization, the heavy atoms of the
protein were set as constraints, CHARMm force field was applied to the receptor ligandcomplex. The minimization protocol was used for calculating the energy minimization.
The parameters used were Smart minimizer Algorithm with 2000 steps and 0.1 as RMS
gradient, GBSW (Generalized Born with a Simple Switching) implicit solvent model
using Dielectric constant as 1 and implicit solvent dielectric constant as 80. The other
parameters non-bonded radius and electrostatics were set as default.
The interaction energy between the protein and each ligand was calculated with
interaction energy protocol in Discovery studio 3.0. Default parameters were used for (i)
In-Situ Ligand Minimization, (ii) Ligand Conformational Entropy (iii) Non-bonded
radius (iv) Electrostatics (v) Advanced and (vi) Parallel processing. The implicit solvent
model was set to GBSW (Generalized Born with a Simple Switching) along with
dielectric constant as 1 and implicit solvent dielectric constant as 80.
4.4.3 Cell culture74
U2OS osteosarcoma cells and DU145 human prostate cancer cells were obtained
from ATCC (Manassas, VA). All cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM , Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS,
USA Scientific) and 100µg/ml of Streptomycin (strep)/ 100 U/ml of Penicillin (pen).
Cells were incubated at 37ºC with 5% CO2.
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4.4.4 Viability assay
Cells were seeded in 96-well plates at (2 × 103 cells/ml) and allowed to adhere
overnight in DMEM growth media containing 10% NU serum and 1% Pen/Strep. The
compounds 5962, 5963, and 5964 were dissolved in DMSO and added in a dose
dependent manner (1 µM to 100 µM). The diluted compounds were added to the cells in
triplicate and incubated for 72 hours at 37oC with 5% CO2. The cell viability was
determined

using

Bromide) assay4.

MTT (3-(4,5-Dimethylthiazol-2YI)-2,5-Diphenyl

tetrazolium

Absorbance readings were obtained using a DTX880 multimode

detector fitted with 595nm filter. Cell viability results were represented as the ratio of the
absorbance reading in treated vs. untreated cells. IC50 values were obtained using a
nonlinear regression line with 5.0 Graghpad Prism. Experiments performed in triplicates.
4.4.5 Cell Cycle Analysis
Cells were plated at 150,000/ml overnight in six well plates. CDK2 inhibitors
were added in a dose dependent fashion for 48 hrs. The cells were then fixed with 70%
Ethanol overnight at -20 degrees. The cells were centrifuged and ethanol was removed.
The cells were washed twice with 1X PBS following staining with DAPI(4’,6’ diamino2-phenylindole) and analyzed using BD LSR II (Becton Dickenson) with a blue filter.
Experiments were performed in triplicates.
4.4.6 Fluorescence Polarization Binding Assay
CDK4D1 FP assay: This assay was performed using black 384-well plates using
a previously described procedure57 with the following modifications. To each well were
added: 5 µl CDK4D1 (37 µg/ml purified recombinant human kinase complex from
Invitrogen), 5 µl compound solution, 5 µl 12 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg100

Arg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, BSA
1mg/ml, 20mM dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then
incubated with shaking for 45 mins at room temperature. Fluorescence polarization was
read on DTX880 multimode detector (Beckman Coulter, Brea, CA) fitted with 485
nm/535 nm excitation/emission filters and a dichroic mirror suitable for fluorescein.
Relative mp was calculated for each concentration tested using the equation showing
below. IC50 values were determined by logarithmic regression by correlating relative mps
and testing concentrations.
mP(compound)-mP(DMSO, protein, tracer)

Relative mp = mP( DMSO, protein)-mP(DMSO, protein, tracer)
CDK2A2 FP assay :This assay was performed using black 384-well plates. To
each well were added: 5 µl CDK2A2 (18 µg/ml purified recombinant human kinase
complex), 5 µl compound solution, 5 µl 12 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-ArgLeu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted using
assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, BSA 1mg/ml,
20mM dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then
incubated with shaking for 45 mins at room temperature. Fluorescence polarization was
read on DTX880 multimode detector (Beckman Coulter, Brea, CA) fitted with 485
nm/535 nm excitation/emission filters and a dichroic mirror suitable for fluorescein.
Relative mp was calculated for each concentration tested using the equation showing
below. IC50 values were determined by logarithmic regression by correlating relative mps
and testing concentrations.
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CHAPTER 5
OPTIMIZATION OF BENZOIC ACID DERIVED INHIBITORS OF THE
CYCLIN GROOVE OF CDK2 USING THE REPLACE STRATEGY

5.1 Introduction
As described, the pentamer RRLIF was found to be the minimal CBM sequence
with sufficient potency to inhibit CDK2/cyclin A and CDK4/cyclin D. Chapters 3 and 4
describe the identification and optimization of arginine isosteres as N-terminal capping
groups63,68 and further peptide SAR. Extensive information was obtained for these Ncaps
based mainly on substituted 5 membered heterocyclic rings. These fragment alternatives
were designed to mimic peptide interactions with the secondary pocket and with cyclin
residues interacting with the peptide backbone. The heteroatoms in these fragments
provided H-bond acceptors observed in the peptide context with Trp 217 of the cyclin
groove63. Interactions with the negatively charged residues (Glu220, Glu224, and Asp
283) observed in the peptide/cyclin complex were largely absent in the phenyltriazole
Ncaps. Further series of Ncaps incorporating basic functionality in furoic and picolinic
acid derivatives resulted in FLIPs with moderate activity therefore leaving considerable
scope for improvement68. A literature precedent for CBG inhibitors provided insight an
additional scaffold based on benzoic acids and which is capable of mimicking peptide
interactions with the acidic region. These benzoic acid capped peptides were substituted
on the Ncap with basic functionality and were found to possess potent activity against
CDK2/cyclin A75. Based on SAR results and preliminary activities described in chapters
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3 and 4 and the resulting scope for potency improvement, the benzoic acid derivative
precedent was further investigated. Potential N-capping groups based on this scaffold
were therefore designed to present groups with the capability of retaining interactions
with the secondary pocket while including functionality to make ion-pairing interactions
with acidic region. The REPLACE strategy therefore was further utilized in the design of
FLIPs which have increased potency through more complete interactions with the cyclin
groove49. In this series design, synthesis and optimization of benzoic acid derivative Ncaps (ligated to RLIF) was undertaken through application of REPLACE. As before, their
potential anti-cancer activity was assessed through use of the FP assay to measure
competitive binding to CDK2/cyclin A and CDK4/cyclin D57. Optimization studies of Ncapping groups were conducted based on SAR results and docking analysis. Promising
compounds were then further tested for anti-proliferative activity on cancer cells through
cell culture experiments74.
5.2 Results
5.2.1 Synthesis of N-caps
The synthesis of benzoic acid derivatives with substitutions at 3-position and/or 4position was undertaken (figure 5.1). Based on computational studies, it was
hypothesized that substituents at the 3-position would make complementary interactions
with the secondary hydrophobic pocket. In addition, functional groups incorporated at the
4-position were designed based on their predicted ion-pairing thus mimicking the
contacts of the critical arginine. To examine SAR of the 3 position in the benzoic acid
capping group, a number of alkoxy derivatives were generated by reaction of 3-hydroxy
benzoic acid with the appropriate alkyl halide. Alkylation of the hydroxyl also results in
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concomitant alkylation of the acid and therefore the corresponding ester was base
hydrolyzed to generate the 3-ethoxy and 3-propoxy benzoic acids as desired products (21
a-b) (scheme 5.1)76.

Figure 5.1 Core structures of benzoic acid derivatives
Scheme 5.1 Synthesis of 3-alkoxy benzoic acid derivatives76

Two commercially available N-caps included 4-(piperazin-1-yl) and 3-(piperidin4-yloxy)benzoic acids were obtained as their free amines. In order to append these to the
peptide as capping groups, the amino groups were first Boc protected using a standard
method. The desired protected N caps were obtained in approximately 50% yield (22)77.
The Boc protection reaction is shown in scheme 5.2.
Scheme 5.2 Synthesis of Boc protected 4-piperazinyl benzoic acid77

Further analogs in the piperidinyloxybenzoic acid series were synthesized by
Mitsunobu reaction78. These include the 4-piperidinyloxy (26a), 3-methoxy-4piperidinyloxy (26b) and 3,5-bis piperidinyloxy derivatives (26c). These compounds
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were synthesized to study their ion-pairing interactions of the piperidinyl N-atom with
acidic regions and van der Waals interactions of substituents at 3-position with second
pocket. The Mitsunobu reaction and subsequent ester hydrolysis are outlined in scheme
5.3.
Scheme 5.3 Synthesis of 4-piperidinyl oxy benzoic acid derivatives78

The majority of the N-caps based on the benzoic acid scaffold were designed to
incorporate a piperazinemethyl group as a substituent at the 4-position. Synthesis of 4(piperazin-1-ylmethyl)benzoic acid and its derivatives were carried out by reductive
amination reactions in which an aldehyde is converted to amine through reduction of an
imine intermediate79. This reaction was carried out with 4-formyl benzoic acid precursors
and the required amine with sodium triacetoxyborohydride as reducing agent (scheme 5.4
to 5.9). The synthesis of the 4-(piperazin-1-ylmethyl) analogs, 27a and 27b were
accomplished using 4-formyl benzoic acid precursors. It was observed that the 3hydroxyl substitution helped the reaction to go to completion overnight whereas the
reaction in 4-formyl benzoic acid required 24 hours to complete (27a-b). The
intermediate

compound

4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-
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hydroxybenzoic acid (27a) was then used as starting material for the synthesis of the
derivatives alkylated on the 3-hydroxyl (28a and 28b) (scheme 5.4).
Scheme 5.4 Synthesis of 3-alkoxy-4-piperazinylmethyl benzoic acid derivatives79,76

When
compounds containing a substituted piperazine (i.e. 4-((4-(1-methylpiperidin-4yl)piperazin-1-yl)methyl) or (R or S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1yl)methyl)) were appended using reductive amination, difficulties occurred in recovery
of the resulting product during

aqueous work up. Hence the starting material was

benzylated with (bromomethyl)benzene using sodium hydride80. Using the benzylated
precursor, the reductive amination product was easily recovered from the organic layer.
To obtain the final product, the benzyl group was removed by hydrogenation81 (scheme
5.5) however was not successful in every case (i.e. with 33a and 33b), and therefore base
hydrolysis was used (scheme 5.5). By way of a similar procedure to the one used for
compounds

32

and

yl)(methyl)amino)methyl)benzoic

33,
acid

4-(((1-(tert-butoxycarbonyl)piperidin-3and

4-(((1-(tert-butoxycarbonyl)piperidin-4-

yl)(methyl)amino)methyl)benzoic acid (35a and 35b) were synthesized by reductive
amination of 4-formyl methyl benzoate with the requisite amine followed by base
hydrolysis79.

For

the

synthesis
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of

4-(((tert-butoxycarbonyl)(1-(tert-

butoxycarbonyl)piperidin-4-yl)amino)methyl)benzoic acid (37), Boc protection of the
amine was required (scheme 5.6)77.
Scheme 5.5 Synthesis of modified piperazinyl benzoic acid derivatives79,80

Scheme 5.6 Synthesis of piperidinyl amino methyl benzoic acid derivatives

Scheme 5.7 Synthesis of 4- substituted piperazinylmethyl benzoic acid derivatives79
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Three such derivatives were synthesized from 3-hydroxy-4-formyl benzoic acid by direct
reductive amination79. The recovery and purification of these compounds were successful
and hence the additional derivatives 39a and 39b were synthesized and purified (scheme
5.7). Substituents were included on the piperazine ring to imcreasee the hydrophobicity
of the capping groups.
Similar to the N-caps mentioned above, alkyl substituents were incorporated into
(S) methyl piperazine analogs to improve binding affinity as well increase the
hydrophobicity. Synthesis of (S)-4-((4-alkyl-2-methylpiperazin-1-yl)methyl)benzoic acid
was carried out by reductive amination of 4-formylmethyl benzoate with tert-butyl (S)-3methylpiperazine-1-carboxylate as described previously79. Alkylation of the free
piperazine nitrogen was acheieved by reductive amination with the requisite aliphatic
aldehyde using similar conditions76. As before base hydrolysis of the ester liberated the
required Ncap product (scheme 5.8).
Scheme 5.8 Synthesis of (S)-4-((4-alkyl-2-methylpiperazin-1-yl)methyl)benzoic acid

Piperidin-4-ylidenemethyl benzoic acid derivatives were synthesized in the first
instance by a Wittig reaction of methyl 4-((diethoxyphosphoryl)methyl)benzoate with
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amino piperidone to generate 45a and b (Boc protected and methylated respectively).
The resulting ylidene was then base hydrolyzed to obtain the corresponding free benzoic
acid, 46a and 46b. The utility of this reaction and the potential SAR information could be
further extended by high pressure hydrogenation of the ylidine to reduce the double bond
and obtain methyl 4-((1-Bocpiperidin-4-yl)methyl)benzoate (47) which after hydrolysis
generated capping group 48 82(scheme 5.9).
Scheme 5.9 Synthesis of piperidinyl methyl benzoic acid derivatives82

5.2.2 SAR of benzoic acid capped peptides
5.2.2.1 SAR of 3-susbtituted benzoic acid derivatives
As described in chapter 4, the phenylacetic acid capped FLIP, 530 (3,5diethoxyphenylacetic acid) possessed good affinity for both CDK2/cyclin complexes.
Modeling of this analog suggests that the ethoxy group in the 3-position occupies the
minor hydrophobic pocket providing a structural basis for its reasonable activity68. In
order to probe such modifications in the similar benzoic acid derived capping groups, a
series of 3-substituted derivatives were docked using the validated LigandFit protocol55.
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Table 5.1 SAR of 3-substitued benzoic acid derivatives for van der Waals
interactions

The results indicated that the inclusion of alkyl or alkoxy groups at the 3-position
provides good complementarity with the secondary pocket as predicted and that the
amide carbonyl can form an H-bond with the amide side chain of Gln254. Based on these
docking results FLIPs were generated in which RLIF/RLNpfF was N-capped with the
described derivatives (Table 5.1). All the FLIPs generated in this series were inactive
except 5858 which showed moderate inhibition of CDK4/cyclin D.
5.2.2.2 SAR of 4-Substituted benzoic acid derivatives
Previous investigations (chapter 4), on furoic acid analogs revealed that presence
of basic groups resulted in moderate binding activities of CDK2/cyclin A inhibitors
targeting the CBG. Furthermore the previously reported CGI compounds incorporated
benzoic acids as Ncaps that were substituted with basic functionality68. Based on this
precedent and the Ncaps described in chapter 4, the design and synthesis of a unique
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series of benzoic acid derived fragment alternatives was undertaken. These encompassed
derivatives reported in this previous study and new variants which were computationally
designed. Substituents appended onto the 4-position included piperazinyl (5850),
piperazin-1ylmethyl (5566, 5919, 5923, 5920) and guanidomethyl (541). Some of these
Ncap derivatives included the 3-(piperidin-4yloxy) group (5851) and 3-hydroxy (5920).
One of the previously reported derivatives incorporated a 4-guanidinomethyl substituent
(541) and was synthesized for comparison. Each of these N-caps were ligated to RLIF
except 5566 and 541 which were N-capped to RLNpfF. The SAR results of these
compounds are shown in table 5.2.
In this series the most potent compounds are those ligated to RLNpfF which are 2
fold more potent compared to RRLIF (0.7 µM vs 1.01 µM in CDK2/cyclin A, 2.17 µM
vs 25.12 µM in CDK4/cyclin D).

The FLIP molecule 541 is the most effective

compound (CDK2/cyclin A 0.69 µM and CDK4/cyclin D - 15.32 µM) and where the Ncapping group is a benzoic acid substituted with guanidinomethyl group at the 4-position.
Incorporation of 4-(piperazine-1ylmethyl)benzoic acid as an N-cap (5566) resulted in
comparable activity to the 35DCPT triazole Ncaps described in chapter 3 with a binding
IC50 to CDK2/cyclin A of 5.3 µM and to CDK4/cyclin D of 12.87 µM. The 4-(piperidin1yloxy)benzamide (5851-31.34µM) and the 4-(piperazine-1yl)benzamide (585035.16µM) FLIPs showed nearly equal potencies in binding to cyclin A in its CDK2
complex. The piperidinyloxy FLIP 5851 (8.52µM) is 4 fold more potent than its
piperazinyl counterpart (5850- 23.82 µM) in binding to CDK4/cyclin D. Varying the
peptide sequence in the 4-piperazinylmethyl benzamide context was undertaken. ALIF
(5923) is inactive and RLIF (5919) is slightly 2 fold less potent than RLNpfF (5566) in
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cyclin A. Comparison of 5919 and 5566 again confirmed that the difference in activity is
because of the more potent peptide sequence RLNpfF.
Table 5.2 SAR of 3/4 mono and 3,5-disubstituted benzoic acid
derivatives for ion-pairing interactions

SCCP ID

R1

5851

CDK2/Cyclin A CDK4/D1
IC50 (µM)
IC50 (µM)

R2

PeptideSequence

H

RLIF

31.34±15.71

8.52±4.43

5850

H

RLIF

35.16±10.17

23.82

5566

H

RLNpfF

5.30±0.99

12.87±1.67

541

H

RLNpfF

0.69±0.34

15.32±5.09

5919

H

RLIF

12.89±2.99

11.70±5.92

5923

H

ALIF

>100

51.49±21.34

5920

OH

RLIF

4.56±0.74

10.41±0.61

5.2.3 SAR of benzoic acid FLIPs capable of ion-pairing and van der Waals
interactions
In order to further extend the SAR of these 4-(piperazine-1yl)benzoic acid
derivatives and to exploit the unoccupied secondary pocket in this context, alkyl
substitution of the 3-position was undertaken. The addition of and role of the 3subsitution was examined through testing of 5896 (3-methoxy, 4-piperidinyloxybenzoic
acid) and comparison with its mono 4-substituted counterpart 5851. The potency of the
bis substituted benzamide FLIP increased significantly in binding to CDK2/cyclin A (22
µM vs 31 µM in cyclin A) but was essentially equipotent towards CDK4/cyclin D (9 µM
vs 8 µM). Addition of a 3-hydroxyl to this series (5920) results in a 2 fold potency
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enhancement compared to 5919 for CDK2/cyclin A (IC50 - 4.56 µM) however does not
significantly improve activity towards CDK4/cyclin D (CDK4/cyclin D, IC 50 -10.41 µM).
Incorporation of a 3-ethoxy substituent into the FLIP (5922) resulted in similar activity
compared to 5920 in cyclin A and 2 fold better activities in cyclin D. Methylation of the
free piperizinyl N-atom (5921) resulted in slightly diminished potency compared to 5920.
Further benzoic acid derived capping group modifications were investigated in the
RβLNMeF context described in chapter 5 so as to improve compound stability and cell
permeability. In this series (table 5.3), the 4- (piperidin-4yl)oxybenzoic acid derivative
(5965) is less active in the binding assay compared to the same N-cap ligated to RLIF
(5851) in CDK2/cyclin A(40 µM (5965) vs 31 µM (5851)). Comparable results are seen
for 5966 (RbLNMeF-NH2) vs 5920 (RLIF) in both cyclins where the N-cap is 3-hydroxy4-(piperazin-1-ylmethyl)benzamide. The RβLNMeF counterpart (5968) to the 3-ethoxy,
4-(piperazin-1yl)benzamide Ncap (5968) has diminished potency for

both cyclin A

(22.61µM) and D (18.64 µM). Among FLIPs containing modified versions of the
piperazine

ring

system,

5967

(4-((4-(1-methylpiperidin-4-yl)piperazin-1-

yl)methyl)benzamide is the most potent followed by 5970 ((S)-4-((2-methylpiperazin-1yl)methyl) benzamide) and 5969 ((R)-4-((2-methylpiperazin-1-yl)methyl) benzamide).
These compounds are unique in this series as they have respectable potency, lower
activity towards CDK4/cyclin D and incorporate more drug-like features. The results are
shown in table 5.3.
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Table 5.3 SAR of benzoic acid FLIPs capable of ion-pairing and
van der Waals interactions

SCCP ID

R1

R2

5922

PeptideSequence

CDK2/Cyclin A CDK4/D1
IC50 (µM)
IC50 (µM)

RLIF

5.95±2.53

5.14±1.47

5921

H

RLIF

7.92±1.39

11.31±1.48

5896

OCH3

RLIF

22.42±9.66

9.36±6.56

RbLNMeF-NH2

40.38±17.76

30.99±1.18

RbLNMeF-NH2

7.42±1.69

11.76±1.01

RbLNMeF-NH2

22.61±1.89

18.64±9.72

5965
5966

H
OH

5968
5967

H

RbLNMeF-NH2

8.32±0.36

48.89±40.36

5969

H

RbLNMeF-NH2

22.28±5.22

45.45±0.47

5970

H

RbLNMeF-NH2

13.39±4.35

>100

Due to the introduction of the non-natural C-terminus and more drug-like Ncaps,
several FLIPs from this series (Table 5.4) were tested for anti-proliferative activity in
U2OS and DU145 cells52,54. So as to assess their drug-like character and to predict which
modifications might lead to optimization of pharmaceutical properties, their clog P and
tPSA were calculated. The resulting parameters were then compared with 5963 (35DCPT
RβLNMeF) and 5964 (35DCPT- RβL3-TA) which were both shown to have respectable
growth inhibitory activity. For the most part the benzoic acid derived FLIPs were inactive
with the exception of 5970 which exhibited very weak anti-proliferative activity. The Ncaps in 5969 and 5970 had total low polar surface area (tPSA) of 3.35 (<140 for orally
available drug molecules) and a positive value of clog P (2.71) 65,66 (table 6.4). Due to its
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weak cellular activity, it was hypothesized that modifications that increase
hydrophobicity would potentially improve cellular permeability and potency. Therefore
derivatives of 4-piperidin-1ylmethylbenzoic acid were designed based on addition of
alkyl groups to increase the lipophilicity. The clogP values were used as a guideline to
assess effective modifications. The clog P values for the 35DCPT N-capped FLIP (5964)
were used as a target value for further modification of N-caps.
Table 5.4 Cellular activity and PSA and clogP of selected
benzoic acid derivatives
Ncap

ID

CDK2/Cyclin
A(µM)

U2OS(µM)

PSA

clog P

5963

6.49±0.27

30.7±2.7

27.96

2.9

5964

7.91±5.08

18.3±1.5

27.96

2.9

5965

31.08±14.4

>100

25.84

2.13

5966

9.22±6.15

>100

40.08

1.47

5967

10.45±3.58

>100

12.12

3.13

5968

22.48±1.33

>100

29.08

2.64

5969

18.42±4.59

>100

19.85

2.71

5970

4.85

67.3

19.85

2.71

Additional benzoic acid derivatives were designed based on clog P and PSA using
the corresponding values of 35DCPT as a reference. The 4-substituents incorporated
were piperazinylmethyl or piperidinyl derivatives, were ligated to RβL3-TA and tested in
the binding assay and for anti-tumor activity on DU145 cancer cell lines. These
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compounds showed good to moderate activity against CDK2/cyclin A but none of them
were active in the cellular assay. The results are shown in table 5.5.
Table 5.5 Benzoic acid derivatives tested in cancer cells.

R2

PeptideSequence

CDK2/Cyclin A CDK4/D1
Du145
IC50 (µM)
IC50 (µM) IC50 (μM)

SCCP ID

R1

6033

H

R-bL-3TA

17.44±13.39

74.28±4.45

>100

6034

H

R-bL-3TA

6.78±2.72

45.60±13.69

>100

6031

H

R-bL-3TA

9.16±8.74

>100

>100

6032

H

R-bL-3TA

26.02±7.13

69.91±7.07

>100

Several other N-caps were designed based improved binding results and calculated
physicochemical properties (clogP and PSA) in order to optimize drug-likeness (table
5.6). FLIPs containing the capping groups NC-8, 9 and 10 were designed on the basis that
improved hydrophobicity will result in greater cell permeability and anti-tumor activity.
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Table 5.6 Benzoic acid derivatives designed to improve cell permeability.

ID

N-cap

PSA

clogP

NC-1

21.05

2.29

NC-2

21.05

2.29

NC-3

33.22

2.95

NC-4

40.08

1.99

NC-5

27.91

2.03

NC-6

32.35

2.41

NC-7

32.35

2.41

NC-8

7.68

2.41

NC-9

7.68

4.32

NC-10

16.61

3.33

5.3 Discussion and conclusions
Several N-capping groups scaffolds have been identified however non are optimal
in terms of mimicking the majority of the interactions of N-terminal tetrapeptide of
HAKRRLIF. Even 35DCPT, the most effective N-cap only practically interacts with this
region and hence there is a need for improvement. A previously published study
described benzoic acid capped peptides with a chlorophenylcyclohexylamine replacement
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for the phenylalanine. These derivatives included basic substituents which when
incorporated into cyclin groove inhibitors resulted into potent compounds when tested in
CDK2/cyclin A ELISA using retinoblastoma protein as substrate for competitive
binding75 (Figure 5.2). This suggested that the benzoic acid scaffold would be an
effective one for the presentation of the required functionality to interact more completely
with the cyclin groove by including contacts with the secondary pocket while also
making ion-pairing interactions with the acidic residues. As described in chapter 3,
previous

studies

demonstrated

that

FLIP

molecules

containing

3,4

diethoxyphenylacetamido group as N-cap (530) were good inhibitors of CDK2/cyclin A
(6.5µM) and CDK4/cyclin D (25.5µM). Incorporation of basic substituents including
piperazinyl and alkyl amines onto heterocyclic scaffolds (5-((4-methylpiperazin-1yl)methyl)furan-2-carboxamide-RLIF,

5589,

5-((diethylamino)methyl)furan-2-

carboxamide-RLIF - 5581) resulted in moderate activity in both CDK2/cyclin A and
CDK4/cyclin D68. Supportive docking results suggest that ion-pairing interactions with
the negatively charged residues contributed to binding. Based on this result and literature
reviews, benzoic acid derivatives were explored as N-capping groups. It was
hypothesized that through effective substitutions on the 3,4 positions of benzoic acid core
structure, ion-pairing, hydrogen bonding and van der Waals interactions might be
retained.

Figure 5.2 CDK2/cyclin A inhibitors developed by Genentech Inc.
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In the first steps to exploiting the potential of the benzoic acid scaffold, 3-alkoxy
derivatives were designed so as to build on the success of 3,5-diethoxyphenylacetic acid
as an Ncapping group. Although docking studies were undertaken with 3- alkyloxy or
aryl oxy substituted benzoic acids (Overlays of 3-substituted benzoic acid derivatives are
shown in figure 5.3), none of these FLIPs had significant activity in the FP binding assay
with the exception of 3-ethoxybenzamido substituted FLIP which had marginal affinity
for CDK4/cyclin D. The observed inactivity of this FLIP series could be because of
weaker van der Waals interactions resulting from too much flexibility of the groups
without the ion-pairing interactions to stabilize binding. For sufficient activity, N-capped
peptides require more extensive interactions that are made by the potent CGI peptides
including ion-pairing and H-bond contacts. In order to improve the affinity of these
Ncapped peptides, and due to the synthetic versatility of the benzoic acid scaffold,
additional substituents were appended at the 4 position to include groups capable of ionpairing with the cyclin groove.

Figure 5.3 Overlays of 3-susbtituted
benzoic acid derivatives
Overlay of docked poses of 3-susbtituted benzoic acid shows van der Waals
interaction at the secondary pocket and hydrogen bonding with Gln 254.
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In the first instance, single 4-substituted benzoic acids were generated for
incorporation as capping groups. Inclusion of basic groups (guanidomethyl (541),
piperazin1-yl (5850), piperidin-4yloxy (5851) and 4-methylpiperazin-1ylmethyl (5919)
shown in table 6.1 resulted in significant improvement in the activity compared to the 3alkyl analogs. The guanidinomethyl substitution which has been previously reported, was
generated as a RLNpfF FLIP and was the highest potency cyclin groove inhibitor in this
series (0.69µM). The effectiveness of this compound is due to its very strong electrostatic
interaction of the positively charged guanidine with the acidic region (Glu220, Glu224).
Both the piperidin-4yloxymethyl (5851) and piperazinyl (5850) are similarly potent in
binding to cyclin A in complex with CDK2 however 5851 exhibits higher activity for
CDK4/cyclin D. The better activity in cyclin D could due to the proximity of piperidinyl
group with Glu70 and GLu66. RRLNpfF is a better CBG inhibitor compared to RRLIF
by 2 fold increased potency. The p-fluoro substituent on the phenylalanine ring enables
increased hydrophobic contacts in the primary pocket69. The increased binding of the
RLNpfF peptide was confirmed by the comparison of 5566 and 5919 since both of these
FLIPs have (4-piperazin-1ylmethyl)benzoic acid as N-cap. When ligated to RLNpfF
(5566) has 2.5 fold better potency in cyclin A compared to the one ligated to RLIF
(5919). Incorporation of a methoxy or a hydroxyl substituent at 3 position in 5896 and
5920 improves cyclin A activity compared to the mono substituted counterparts (5851,
5919) (figure 5.4). Alkoxy or hydroxyl substitution provides additional hydrophobic
complementarity with secondary pocket in addition to H-bonding interactions of the OH
with Trp217. The activity profiles of these two compounds confirms the hypothesis that
having a basic group at 4 position and an alkyl group at 3 position improves the activity
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of benzamide FLIPs through ion-pairing and van der Waals interactions. Based on
improvement in the activity profiles of 3,4-disubstituted benzoic acid N-caps, 5896 and
5920, next generation fragment alternatives included modifications on the piperazine
moieties for additional hydrophobic interactions. These compounds were designed with
alkoxy or hydroxyl substituents at 3-position and piperazine with additional alkyl groups
at the 4 position of benzoic acid as shown in scheme 5.10.

Glu224

Gln254

Figure 5.4 Docked pose of 5920 in CDK2/cyclin A
Examination of the binding mode of 5920 reveals that N4 of the piperazine1ylmethylbenzoic acid Ncap forms ion-pairing interactions with Glu224, the
carbonyl contributes to an H-bond with Gln 254 and 3-hyrdoxyl can H-bond to
Trp217.
Scheme 5.10 Design and optimization of benzoic acid derivatives for interaction with
the secondary hydrophobic pocket.
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Docking studies were carried out on a series of benzoic acid derivatives with 3alkoxy-4-(piperazine-1ylmethyl) groups. The docked poses were prioritized based on
their PLP1 score and further based on expected complementarity with the key acidic
residues of the CBG (Glu220, Glu224), and with the secondary pocket. For the most part,
results obtained in testing the synthesized FLIP compounds were in accordance the
highly ranked docked poses. The design hypothesis was confirmed in that 3,4disubstituted benzamido FLIPS and those with a modified piperazine ring possess
improved activity compared to previous series. The presence of an ethoxy group at 3position provides increased van der Waals contacts however the complementarity of the
propoxy substitution is more optimal as was observed through increased binding
observed with 5922 and 5968. As described in chapter 4, FLIPs 5963 (35DCPTRβLNMeFNH2) and 5964 (35DCPT- RβL3TA) provided proof of concept for cell
permeability and therefore this sequence was employed in the context of benzoic acid
Ncap modification to compare activities with 35DCPT and examine cell permeability.
Modifications to the piperazine ring (5967, 5969 and 5970) results in decreased binding
to CDK4/cyclin D and shows selectivity for CDK2/cyclin A. Since these contain
modified piperazine groups that have increased size, they can be more easily
accommodated in the cyclin A groove relative to cyclin D which has a narrower
secondary pocket. Although 5969 and 5970 are stereoisomers there is a significant
difference in their activity. This can be explained through structural analysis where it was
observed that the piperazine-2-methyl group of 5969 points out of the minor pocket
however in 5970, the methyl group interacts efficiently with the secondary pocket
resulting in the increased binding affinity for this analog (figure 5.5).
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Figure 5.5 Binding modes of 5969 and 5970.
Docked poses of 5969 and 5970 showing the orientation of 3-methyl substituent of
piperazine. In 5969 it is pointing above the second pocket and in 55970 it is
contacting with the second pocket
As the FLIP molecules in this series were considered to potentially have more
drug-likeness and stability they were tested for anti-tumor activity in a MTT assay. For
the most part this series were inactive in both U2OS and DU145 cell lines with the
exception of 5970 which showed marginal activity. To determine the lack of cellular
activity compared to 5964, the physicochemical properties that determine drug likeness
(including hydrophobicity and polar surface area) were calculated for these compounds to
compare with the 35DCPT capping group. An additional series of benzoic acid
derivatives were designed based on the FP results and physicochemical properties of
35DCPT. Further experiments will examine the effects of increased hydrophobicity on
cellular anti-proliferative activity.
The main objective of the work described in this chapter was to more completely
mimic of the interactions of CGI peptides through optimization of benzoic acid based Ncaps. From the SAR results obtained, this objective has been achieved with appropriately
modified FLIPs in which the ion-pairing, hydrophobic and hydrogen bonding interactions
were retained. Based on the physicochemical properties of 35DCPT, several analogs
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were designed to have similar hydrophobicity and PSA characteristics. Although the
initial analogs were in active in cellular studies, further analogs were proposed to address
this issue and improve drug-like characteristics. In summary, the extensive SAR data
obtained for optimized benzoic acid Ncapped peptides further validates REPLACE
strategy and suggests how these FLIPS can be further modified and improved for the
development non-ATP competitive CDK inhibitors.
5.4 Experimental section
5.4.1 Materials and methods
All solvents and reagents were used as obtained. 1H NMR and 13C NMR spectra
were recorded with a Varian Mercury 300 and 400 Spectrometer, respectively. Mass
spectra were measured with Micromass QTOF: Tandem quadruple-time of flight mass
spectrometer electrospray ionization (ESI) and VG 70S: Double-focusing magnetic
sector mass spectrometer (EI). Analytical purities of evaluated compounds were >95%
unless stated otherwise. The following analytic method (unless stated otherwise) was
used on a Waters Alliance 2695 HPLC with a 2996 diode-array detector and equipped a
C18 (2) 100 A, 250 x 4.6mm, 5µ column (Phenomenox Luna). A gradient from 100%
water (0.1% trifluoroacetic acid) to 60% acetonitrile (0.1% trifluoroacetic acid) was run
over 30 mins and held for 4 mins. The chromatograms were extracted at 226 and 254 nm.
Synthesis of 3-alkoxy benzoic acid derivatives76
Step 1: Synthesis of ethyl 3-ethoxybenzoate (20a)
3-hydroxy benzoic acid (0.69g, 5mmol), ethoxy bromide (0.25g, 23mmol) and
potassium carbonate (0.13g, 16.5mmol) were refluxed in 5ml of DMF for 12-18hrs. The
reaction was monitored by TLC (Ethylacetate: Hexanes= 35:65), after the reaction was
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complete, the reaction mixture was cooled to room temperature; water was added to
dissolve potassium carbonate. The aqueous layer was extracted with ethyl acetate and the
combined organic layers were washed with saturated sodium bicarbonate, brine, dried
over sodium sulfate and evaporated to get reddish oil (0.29g, 30%).
ethyl 2-(3-ethoxyphenyl)acetate: 1H NMR (dimethyl sulfoxide-D6, 300MHz) δ (ppm)
7.18(s,1H), 7.13 (t. J=7.71Hz, 1H), 6.75-6.78 (d, J=8.88Hz, 2H), 6.70-6.73 (d, J=8.67Hz,
2H), 1.31 (t, J=7.11Hz, 3H), 1.16 (t, J=7.29Hz, 3H) GC MS- 208
Step 2: Synthesis of 3-ethoxybenzoic acid (21a)
The ethyl 3-ethoxybenzoate (0.97g, 5mmol) obtained from step 1 was treated with
sodium hydroxide (2.8g, 70mmol) and a solution of 15ml ethanol and 15ml water. The
reaction mixture was refluxed for two hours and the reaction was monitored by TLC
(35% ethyl acetate in hexanes). After the completion of reaction, the reaction mixture
was cooled, the alcohol was evaporated and diluted with water. The reaction mixture was
acidified with 1N hydrochloric acid and stirred to precipitate the product as white solid
(0.67g, 81.2%)
2-(3-ethoxyphenyl)acetic acid :1H NMR (chloroform-D3, 500MHz) δ (ppm) 7.256 (t,
J=7.75Hz, 1H) 6.8753 (d, J=7.65Hz, 1H), 6.8507(s, 1H), 6.8319 (d, J=2.2Hz, 1H), 4.0636
(q, J=7.0Hz, 2H), 3.636 (s, 1H), 1,4296 (d, J=55.57Hz, 3H)
13

C NMR (chloroform-D3, 500MHz) δ (ppm) 177.15, 159.14, 134.61, 129.6, 121.55,

115.65, 113.41, 63.41, 41.01, 31.16, 14.80 GC MS-108
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Synthesis of 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid and 4-(4(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (22)77
To a solution of 3-(piperidin-4-yloxy) benzoic acid (0.12g, 0.5 mmol) and
potassium carbonate (0.13g, 1mmol) in 1mL of water di-tert-butyl dicarbonate (0.11g,
0.5 mmol) was added as a solution in 0.6ml tetrahydrofuran, dropwise at 0 °C. After the
addition was completed, the reaction mixture was allowed to come to room temperature
and stirred for 4 h. THF was removed in vacuum and the aqueous phase was washed with
ether. The aqueous phase was separated and adjusted to pH 2 with 1 N hydrochloric acid,
and extracted with ethyl acetate. The combined organic extracts were concentrated to get
3-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (0.15 g, 49.5%) as a white
solid.
1H NMR (chloroform-D3, 400MHz) δ (ppm) 7.70 (d, J=7.17Hz, 1H), 7.61(s,1H), 7.37(t,
J=8.34Hz, 1H), 7.15 (d, J=8.64, 1H), 4.55 (s,1H), 3.70(q, 2H), 3.36(q, 2H), 1.93(q, 2H).
1.77(q, 2H), 1.46 (s,9H)
13

C NMR (chloroform-D3, 400MHz) δ (ppm) 170.89, 157.29, 154.89, 130.65, 129.74,

122.94, 122.26, 116.69, 79.75, 72.45, 28.45
ES+344
Synthesis of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (23)77
To a solution of sodium salt of 4-(piperazin-1-yl)benzoic acid (0.36g, 1.5 mmol)
and potassium carbonate (0.20g, 1.5mmol) in 3mL of water di-tert-butyl dicarbonate
(0.32g, 1.5 mmol) was added as a solution in 1.8ml tetrahydrofuran, dropwise at 0 °C.
After the addition was completed, the reaction mixture was allowed to come to room
temperature and stirred for 4 h. THF was removed in vacuum and the aqueous phase was
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washed with ether. The aqueous phase was separated and adjusted to pH 2 with 1 N
hydrochloric acid, and extracted with ethyl acetate. The combined organic extracts were
concentrated to get 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (0.13 g, 45%)
as a white solid.
1H NMR (chloroform-D3, 400MHz) δ (ppm) 7.98(d, J=8.10Hz, 2H), 6.87(d, J=8.67Hz,
2H), 3.58(s, 4H), 3.33 (s,4H), 1.48 (2,9H)
13

C NMR (chloroform-D3, 400MHz) δ (ppm) 170.86, 154.68, 154.44, 132.03, 118.92,

113.78, 80.21, 47.35, 28.42
ES+307
Synthesis of 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid78
Step 1. Synthesis of 3-methoxybenzoic acid methyl ester (24)76
To a solution of vanilic acid (0.67g, 4mmol) in 9ml of anhydrous methanol
0.25ml of Conc. Sulfuric acid (3.0 mL) was added and the mixture was refluxed
overnight. The reaction mixture was cooled to room temperature, the solvent was
evaporated and the residue was dissolved in ethyl acetate. The organic layer was washed
with 5% sodium bicarbonate, water and brine. Then it was dried over sodium sulfate,
filtered, and concentrated to get a white solid (0.49 g, 68.2%)
Step 2: Synthesis of tert-butyl 4-(4-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate
(25a)78
4-Hydroxymethylbenzoate (0.30g, 2mmol) and triphenylphosphine (2.62g,
10mmol) were dissolved in 30 mL of dry THF at 0 °C. To the stirred mixture a solution
of N-(tertbutyloxycarbonyl)piperidin-4-ol (1.15g, 10mmol) and DIAD(2.02g, 10mmol)
20 mL of dry THF was added drop wise over a period of 2 h,. The reaction mixture was
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stirred for 5 days at room temperature and monitored by TLC (Ethylacetate: Hexanes35:65) to see the consumption of starting material. After the reaction was completed, the
reaction mixture was diluted with 50 mL of ethyl acetate. The organic phase was washed
with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and
concentrated to give a semisolid. This material was suspended in 100-200 mL of
hexane/ethyl acetate (9:1), stirred, and filtered to remove triphenylphosphine oxide.
Evaporation of the filtrate under reduced pressure yielded oil that was purified by Flash
column (hexane/ethyl acetate 6.5:3.5) to give oil that solidified on standing (0.23g, 70%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.97(d, J=8.7Hz, 2H), 6.9 (d, J=8.7Hz, 2H),

4.55(m, 1H), 3.88(s,3H), 3.68(m,2H), 3.36(m,2H), 1.92(m,2H), 1.77(m,2H), 1.46(s,9H)
EI+335
di-tert-butyl

4,4'-((5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))bis(piperidine-1-

carboxylate) (25c)
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.16(s, 2H), 6.78(s, 1H), 4.59(s, 2H), 4.09(q,

J= 7.35Hz, 2H), 3.88(s, 3H), 3.69(s, 3H), 3.36(s, 3H), 1.92(s, 2H), 1.66(s, 2H), 1.46(s,
18H) ES+535
Step 3: Synthesis of 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (26a)
1

H NMR (chloroform-D3, 500MHz) δ (ppm) 8.03 (d, J=8.73Hz, 2H), 6.93(d, J=9.0Hz,

2H), 5.58(m,1H), 3.69(m, 2H), 3.73(m,2H), 1.93(m,2H), 1.85(m,2H), 1.47(s,9H)
EI+321
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4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (26b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.71 (d, J=8.4Hz, 1H). 7.6(s, 1H), 6.93 (d,

J=8.49Hz, 1H), 4.56(m,1H), 3.78(m,2H), 3.292(m,2H), 1.95(m,2H), 1.81(m,2H),
1.46(s,9H)
EI+365
13

C NMR (chloroform-D3, 400MHz) δ (ppm) 171.22, 154.84, 151.48, 150.06, 124.21,

122.28,114.45, 113.37, 79.77, 73.90, 56.09, 28.45
EI+351
3,5-bis((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (26c)
1H NMR (methanol-d4, 300 MHz) δ (ppm) 7.16(s, 2H), 6.65(s, 1H), 4.63-4.51(m, 2H),
4.09(d, J=12.3Hz, 1H), 3.77-3.65(m, 4H), 3.39-3.32(m, 3H), 2.79(s, 1H), 1.91(s, 3H),
1.73-1.57(m, 4H), 1.46(s, 18H) ES+521
Synthesis

of

4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-hydroxybenzoic

acid23(27a)79
To a solution of 4-Formyl-3-hydroxy benzoic (0.16g, 1mmol) and 1-BocPiperazine (0.18g, 1mmol) in 25ml of dichloromethane was added sodium triacetoxy
borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred overnight at RT and the
reaction was monitored by TLC (ethylacetate:hexanes-35:65). After the reaction was
completed the reaction mixture was quenched with 2N sodium hydroxide and the reaction
mixture was stirred for 10mins. The reaction mixture was diluted with dichloromethane
and 2N sodium hydroxide. The layers were separated; the aqueous layer was acidified to
pH4 to precipitate the product. The product was filtered off to get a white solid (0.33g,
80.2%).
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1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.69 (d, J=7.17Hz, 1H), 7,64(s,1H), 7.31(d,

J=7.74Hz, 1H), 4.34(s,2H), 4.25(d, J=15.33, 2H), 3.67(d, J=10.95Hz), 3.43(m,2H),
2.98(m,2H), 1.48(s,9H)
ES+ 337
tert-butyl 4-(2-ethoxy-4-(ethoxycarbonyl)benzyl)piperazine-1-carboxylate (28a)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.61(d, J=7.47Hz, 1H), 7.5 (s,1H), 7.45(d,

J=8.13Hz, 1H), 4.36(q, J=6.27, 2H), 4.09(q, J=7.68Hz, 2H), 3.63(s,2H), 3.45(s,3H),
2.65(s,2H), 2.46(s, 3H), 1.44(s,9H), 1.42-1.35(m,6H)
EI+392
tert-butyl 4-(2-propoxy-4-(propoxycarbonyl)benzyl)piperazine-1-carboxylate (28b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.63(d, J=5.31Hz, 1H), 7.52(s,2H), 4.27(t,

J=5.91Hz, 2H), 4.0(t, J=6.87Hz, 2H), 3.75(s, 4H), 3.52(s, 4H), 2.55(s,4H), 1.87-1.75(m,
4H), 1.44(s,9H), 1.04(q, J=7.74Hz, 6H)
EI+420
4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoic acid (29a)
1

H NMR (Dimethyl sulphoxide- D6, 300MHz) δ (ppm) 7.67(s, 2H), 7.62(s, 1H), 4.4(s,

2H), 4.22(q, J=6.39Hz), 4.07(s,2H), 3.41(s,2H), 3.16(s,4H), 1.46(s,9H), 1.30-1.22(m,3H),
EI+365
4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-propoxybenzoic acid (29b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.57(s, 2H), 7.53(s,1H), 4.01(t, J=6.69Hz,

2H), 3.89(s,2H), 3.65(s,4H), 2.81(s,4H), 1.84(q, J=8.01Hz, 2H), 1.44(s, 9H), 1.05(t,
J=7.32Hz, 3H),
ES+379
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Synthesis of 4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoic acid/(R)
and (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid
Step 1: Synthesis of benzyl 4-formylbenzoate76 (30)
To a sample of 4-Formyl benzoic acid (0.75g, 5mmol) dry dimethyl formamide
(15 mL) was slowly added with stirring 60 wt % NaH in mineral oil (0.14g, 6mmol). The
reaction solution was stirred for 45 min, benzyl bromide (0.10g, 6 mmol) was added
dropwise, and the reaction solution was stirred for an additional 5 h and monitored by
TLC (ethylacetate:hexanes-35:65 with few drops of acetic acid). After the completion of
the reaction, and the reaction solution was poured into 1N HCl (27mL) and extracted
with ethyl acetate. The combined organic extracts were washed with saturated sodium
bicarbonate and brine, dried over sodium sulfate, and concentrated to get a crude a yellow
oil which was purified by flash chromatography (Biotage SP4) using a SNAP 100g
column with a gradient run starting from 6% ethylacetate: 94% hexanes to 35% ethyl
acetate and 65% hexanes over 15 column volumes to yield a white solid (0.62g, 51.6%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 10.1(2,1H), 8.23(d, J=8.04Hz), 2H), 9.95(d,

J=7.922Hz, 2H), 7.47-7.311(m, 5H), 5.39(s,2H)
EI+240
Step 2: Synthesis of benzyl 4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoate
(31c)79
To a solution of benzyl 4-Formyl benzoate (0.24g, 1mmol) and 1-(1methylpiperidin-4-yl)piperazine (0.18g, 1mmol) in 25ml of dichloromethane was added
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65).
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After the reaction was completed the reaction mixture was quenched with 2N sodium
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the
organic layer was evaporated to get the crude product. The crude material was then
purified by flash chromatography (Biotage SP4) using a SNAP 25g column with a
gradient run starting from 6% ethylacetate: 94% hexanes to 25% ethyl acetate and 75%
hexanes over 10 column volumes to yield a white solid (0.34g, 85.3%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.01(d, J=7.80Hz, 2H), 7.45-7.33(m, 7H),

5.35(s,2H),

3.53(s,2H),

2.89(s,3H),

2.57(s,3H),

2.47(s,3H),

2.24(s,3H),

1.91(t,

J=10.98Hz, 2H), 1.78(d, J=12.78, 2H), 1.64-1.50(m, 4H)
ES+408
(R)-tert-butyl 4-(4-((benzyloxy)carbonyl)benzyl)-3-methylpiperazine-1-carboxylate (31a)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.02(d, J=7.77Hz, 2H), 7.48-7.29(m, 7H),

5.35(s,2H), 4.01(d, J=14.28Hz,1H), 3.74(s, 1H), 3.62(d, 15.09Hz, 1H), 3.24(d,
J=12.95Hz, 1H), 3.07(t, J=11.10Hz, 1H), 2.87(s,1H), 2.59(d, 12.72Hz, 1H), 2.43(s, 1H),
2.09(d, J=12.7Hz, 1H), 1.44(s,9H), 1.10(d, J=6.3Hz, 3H)
ES+425
(S)-tert-butyl 4-(4-((benzyloxy)carbonyl)benzyl)-3-methylpiperazine-1-carboxylate (31b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.07-8.00(m, 2H), 7.45-7.33(m, 7H),

5.35(s,2H), 3.99(d, J=13.53Hz, 1H), 3.61(d, J=13.53Hz, 1H), 3.23(d, J=13.53Hz, 1H),
3.07(d, J=12.78Hz, 1H), 2.92(d, J=8.25Hz, 1H), 2.75(d, J=9.03Hz, 1H), 2.59(d,
J=12.03Hz, 1H), 2.49-2.30(m,1H), 1.76(s,1H), 1.44(s,9H), 1.09(d, 6.09Hz, 3H)
ES+425
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Step

3a:

Synthesis

of

Synthesis

of

4-((4-(1-methylpiperidin-4-yl)piperazin-1-

yl)methyl)benzoic acid (32)80
The product obtained from step 1 (0.24g, 0.5mmol) was treated with Palladium
over activated carbon (24mg, 10%) in the presence of methanol. The reaction mixture
was stirred while hydrogen gas was passed from a balloon. The reaction was continued
for 12 hours and monitored by TLC (ethylacetate:hexanes-35:65). After the reaction was
completed, methanol was evaporated and the reaction mixture was dissolved in water.
The palladium catalyst was filtered off using 0.45u filter. The aqueous layer was
evaporated to get the desired product as white solid (0.15g, 99%).
1

H NMR (methanol-d4, 400 MHz) δ (ppm) 8.18(s,2H), 7.72(s,2H), 3.97(s,2H),

3.76(s,2H), 2.23(t, J=13.68Hz, 2H), 3.09(s,3H), 2.98(d, J=19..3Hz, 9H), 2.45(d,
J=16.01Hz, 2H, 2.08-1.92(m, 2H)
13

C NMR (methanol-d4, 400 MHz) δ (ppm) 130.18, 129.0, 61.75, 58.74, 53.94, 52.06,

48.20, 43.21, 25.89
ES+318
Step

3b:

Synthesis

of

(R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-

yl)methyl)benzoic (33 a)76
The SM (0.44g, 1.1mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol
were refluxed at 100oC for 2 hours. The reaction was monitored by TLC
(ethylacetate:hexanes-35:65). After the completion of reaction, the aqueous solution was
evaporated completely. The residue was dissolved in methanol, white solid that was not
soluble in methanol was filtered off. The methanol was evaporated to get a reddish brown
solid (0.27g, 73.5%).
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(R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid (33a)
1

H NMR (methanol-d4, 400 MHz) δ (ppm) 7.61(d, J=8.32Hz, 2H), 7.13(d, J=7.52Hz,

2H) 3.92(d, J=17.6Hz, 2H), 3.25-3.12(m, 4H), 3.10-2.98(m, 1H), 2.94-2.80(m, 2H),
1.29(s, 9H), 1.14(d, J=6.44Hz, 3H)
13

C NMR (dimethylsulfoxide-D6, 500MHz) δ (ppm) 170.84, 168.96, 142.41, 134.18,

129.56, 79.7, 60.24, 57.48, 54.74, 28.51,
ES+335
(S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid (33b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.96(d, J=8.04Hz, 2H), 7.43(d, J=8.04Hz,

2H), 4.077(d, J=13.5Hz, 2H), 3.80-3.53(m,2H), 3.12(t, J=22.74Hz, 2H), 2.9(s, 1H), 2.732.62(m, 1H), 2.50(s,1H), 2.15(t, J=10.11Hz, 1H), 1.44(s,9H), 1.16(d, J=6.57, 3H)
13

C NMR (dimethylsulfoxide-D6, 500MHz) δ (ppm) 172.78, 169.26, 154.23, 142.99,

141.21, 136.43, 129.47, 128.48, 128.38, 127.06, 126.87, 79.14, 63.33, 57.54, 54.70, 28.67
ES+335
Synthesis of 4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)methyl)benzoic
acid

(16a)

and

4-(((tert-butoxycarbonyl)(1-(tert-butoxycarbonyl)piperidin-4-

yl)amino)methyl)benzoic acid (37)
Step1: tert-butyl 4-((4-(methoxycarbonyl)benzyl)(methyl)amino)piperidine-1-carboxylate
(34a)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98(d, J=8.19Hz, 2H), 7.39(d, J=7.92Hz,

2H), 4.16(s,2H), 3.9(s,3H), 3.67(s,2H), 2.71-2.56(m,3H), 2.21(s,3H), 1,81(d, J=12.39Hz,
2H), 1.56-1.50(m,2H), 1.44(s,9H) ES+363
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tert-butyl 4-((4-(methoxycarbonyl)benzyl)amino)piperidine-1-carboxylate (34c)
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.99(d, J=7.86Hz, 2H), 7.40(d, J=8.43Hz,

2H), 4.03(s,2H), 3.90(s,5H), 3.59(s,2H), 2.80(s,1H), 2.03(s,1H), 1.86(d, J=12.15Hz, 2H),
1.44s, 9H) ES+349
Step 2: Synthesis of 4-(((1-(tert-butoxycarbonyl)piperidin-4yl)(methyl)amino)methyl)benzoic acid (35a)76
The SM (0.24g, 0.648 mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol
were refluxed at 100oC for 2 hours. The reaction was monitored by TLC
(ethylacetate:hexanes-35:65). After the completion of reaction, the aqueous solution was
evaporated completely to get a white solid (0.1g, 80%). The crude mixture was purified
by semi-prep HPLC22.
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.99(d, J=7.68Hz, 2H), 7.47(d, J=8.19Hz,

2H), 4.22(d, J=13.34Hz, 2H), 4.08(s, 2H), 3.13(t, J=10.68Hz, 1H), 2.78(t, J=14.01, 2H),
2.50(s, 3H), 2.02(d, J=14.01Hz, 2H), 1.63(q, J=12.0Hz, 2H), 1.45(s, 9H) ES+349
Step 2a: Synthesis of tert-butyl 4-((tert-butoxycarbonyl)(4(methoxycarbonyl)benzyl)amino)piperidine-1-carboxylate (36)77
The starting material (0.34g, 1.16mmol), and potassium carbonate (0.13g,
1.16mmol) were dissolved in water and methanol to get a clear solution. The reaction
mixture was stirred in an ice bath. The di-tert-butyl dicarbonate (0.50g, 2.32mmol) was
dissolved in THF and added drop wise into the reaction mixture. The reaction mixture
was allowed to come to room temperature and then it was stirred overnight. The
consumption of the starting material was monitored by TLC (100% Ethylacetate). After
the reaction was completed, the solvents were evaporated and the crude mixture was

136

separated by flash chromatography using a gradient of 12-100% Ethylacetate in 5 column
volumes. The product was obtained as a white solid (0.4g, 77%) 20.
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.97(d, J=7.92Hz, 2H), 7.35(d, J=8.67Hz,

2H) 4.47(s, 2H), 4.09(d, J=11.85Hz, 2H), 3.34(s,3H), 2.74(s,2H), 1.61(s,4H), 1.41(s,
18H) ES+449
Step

3:

Synthesis

of

4-(((tert-butoxycarbonyl)(1-(tert-butoxycarbonyl)piperidin-4-

yl)amino)methyl)benzoic acid (37)76
The SM (0.44g, 1mmol), 3ml of 1N NaOH, 3ml of water and 3ml of alcohol were
refluxed at 100oC for 2 hours. The reaction was monitored by TLC (ethylacetate:hexanes35:65). After the completion of reaction, the organic solvents were evaporated
completely. The aqueous layer was neutralized to pH 7.0 with 1N NaOH to get a white
solid which was filtered off (0.3g, 69.0%).
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.95(d, J=7.80Hz, 2H), 7.31(d, J=7.29Hz,

2H), 4.47(s,2H), 4.09(d, J=13.89Hz, 2H), 2.72(s,2H), 1.61(s,5H), 1.42(18H) ES+435
Synthesis of (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3hydroxybenzoic acid (38a-c, 39a-b)79
To a solution of 4-Formyl-3-hydroxy benzoic (0.16g, 1mmol) and (S)-tert-butyl 2methylpiperazine-1-carboxylate (0.45g, 2mmol) in 25ml of dichloromethane was added
sodium triacetoxy borohydrate (0.59g, 2.8mmol). The reaction mixture was stirred for 2
days at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65). After
the reaction was completed the reaction mixture was quenched with water and the
reaction mixture was stirred for 10mins. The layers were separated; the aqueous layer
was evaporated to get the crude product which was purified by flash chromatography.

137

1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.45(d, J=7.83Hz, 1H), 7.38(s,1H), 7.17(d,

8.52, 1H), 4.27(d, J=14.07Hz, 1H), 3.75-3.60(m,3H), 3.52(s,1H), 3.09(s,1H), 2.85(d,
J=12.39Hz, 1H), 1.45(s,9H), 1.21(d, J=6.03Hz, 3H) ES+351
3-hydroxy-4-((4-methylpiperazin-1-yl)methyl)benzoic acid (38b)
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.42(d, J=8.01Hz, 1H), 7.38(s,1H), 7.16(d,

J=7.89Hz, 1H), 3.80(s, 2H) 2.79(d, J=25.89Hz, 8H), 2.51(s, 3H) ES+251
3-hydroxy-4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoic acid (38c)
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.44(d, J=8.13Hz, 1H), 7.41(s, 1H), 7.34(d,

J=8.13Hz, 1H, 4.32(s,2H), 3.52(d, J=12.0, 2H), 3.42(s, 4H), 3.27(s, 4H), 2.95(t, J=12.45,
2H), 2.73(s, 3H), 2.24(d, J=12.87Hz, 2H), 1.75(q, J=20.97Hz, 2H) ES+334
4-((4-ethylpiperazin-1-yl)methyl)benzoic acid (39a)
1

H NMR (methanol-d4, 300 MHz) δ (ppm) 7.91(d, J=6.78Hz, 2H), 7.35(d, J=7.08Hz,

2H), 3.65(s, 2H), 3.02(s, 3H), 2.92(q, J=5.10, 3H), 2.68(s, 4H), 1.24(t, J=6.87, 3H),
ES+248.33
4-((4-propylpiperazin-1-yl)methyl)benzoic acid (39b)
1

H NMR (chloroform-D3, 300 MHz) δ (ppm) 7.86(d, J=7.47, 2H), 7.21(d, J=8.04Hz,

2H), 3.77(s, 2H), 2.91(s, 3H), 2.71(s, 4H), 2.60(m, 3H), 1.68(m, 2H), 0.90(t, J=6.75Hz,
3H) ES+262.35
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Synthesis of (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3-methylpiperazine-1carboxylate
Step 1: Synthesis of (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3-methylpiperazine-1carboxylate (40)79
To a solution of 4-Formyl methylbenzoate (0.16g, 1mmol) and (S)-tert-butyl 3methylpiperazine-1-carboxylate (0.20g, 1mmol) in 25ml of dichloromethane was added
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65).
After the reaction was completed the reaction mixture was quenched with 2N sodium
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the
organic layer was evaporated to get the crude product. The crude material was then
purified by flash chromatography (Biotage SP4) using a SNAP 25g column with a
gradient run starting from 6% ethylacetate: 94% hexanes to 25% ethyl acetate and 75%
hexanes over 10 column volumes to yield a white solid (0.34g, 85.3%).
Step 2: Synthesis of (S)-methyl 4-((2-methylpiperazin-1-yl)methyl)benzoate (41)56
The product from step 1 (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3methylpiperazine-1-carboxylate (0.35g, 1mM) was stirred with 20% trifluoroacetic acid
in 5ml of dichloromethane for 2hrs. The reaction was monitored by TLC
(ethylacetate:hexanes-35:65). After the reaction was completed the reaction mixture was
evaporated and the concentrated crude material was purified by flash chromatography
(Biotage SP4) using a RP SNAP 10g column with a gradient run starting from 0%
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Acetonitrile : 60% water over 10 column volumes to yield a reddish semi solid (0.22g,
90%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.50(d, J=7.92Hz, 2H), 7.90(d, J=7.17Hz,

2H), 4.41(s,3H) 3.74(q, J=12.51Hz, 2H), 3.58(t, J=11.74Hz, 3H), 3.43(m,2H), 3.319m,
1H), 3.04(t, J=11.79Hz, 1H), 1.75(s, 3H) ES+248.15
Step 3: (S)-methyl 4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoate (42a)79
To a solution of (S)-methyl 4-((2-methylpiperazin-1-yl)methyl)benzoate (0.24g,
1mmol) and acetaldehyde (0.44g, 10mmol) in 25ml of dichloromethane was added
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65).
After the reaction was completed the reaction mixture was quenched with 2N sodium
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the
organic layer was evaporated to get the crude product. The crude material was then
purified by flash chromatography (Biotage SP4) using a RP SNAP 10g column with a
gradient run starting from 0% acetonitrile: 25% water, to 25% acetonitrile:75% water for
3 column volumes, the gradient was held at 25% acetonitrile:75% water for 5 column
volumes and then proceeded till 100% acetonitrile over 4column volumes to yield a white
semi solid (0.16g, 60%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.92(d, J=7.17Hz, 2H), 7.30(d, J=7.65Hz,

2H), 3.84(s, 3H), 3.33(d, J=12.48Hz, 2H), 3.13(m,2H), 2.96(q, J=5.25Hz, 2H), 2.86(s,
1H), 2.68(m,2H), 2.50(m,2H), 1.26(t, J=7.41Hz, 3H), 1.16(d, J=5.94Hz, 3H) ES+276.18
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(S)-methyl 4-((4-propyl-2-methylpiperazin-1-yl)methyl)benzoate (42b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98 (d, J=7.74Hz, 2H), 7.37(d, J=7.98Hz,

2H), 3.91(s,3H), 3.31(d, J=10.59Hz, 2H), 3.17(d, J=13.89Hz, 1H), 2.88(m,1H),
2.76(m,3H), 2.52(m,4H), 1.72(m, 2H), 1.20(d, J=7.26, 3H), 0.96(t, J=8.82, 3H)
ES+290.41
Synthesis of (S)-4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoic acid (43a)76
Step 4: (S)-methyl 4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoate (0.27g,
1mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol were refluxed at 100oC for 2
hours. The reaction was monitored by TLC (ethylacetate:hexanes-35:65). After the
completion of reaction, the aqueous solution was evaporated completely. The residue was
purified flash chromatography (Biotage SP4) using a RP SNAP 10g column with a
gradient run starting from 0% acetonitrile: 25% water over 10 column volumes, the
gradient was held at 25% acetonitrile:75% water for 3column volumes and then
proceeded till 60% acetonitrile over 4column volumes to yield a white solid (0.17g, 65%)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.89(d, J=7.50Hz, 2H), 7.32(d, J=7.08Hz,

2H), 2.89(m,2H), 2.75(m,2H), 2.52(m,4H), 2.23(m,2H), 2.08(m,1H), 1.21(d, J=7.20Hz,
3H), 1.11(t, J=7.20Hz, 3H) ES+262.17
(S)-4-((2-methyl-4-propylpiperazin-1-yl)methyl)benzoic acid (43b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.00(d, J=7.86Hz, 2H), 7.40(d, J=8.22Hz,

2H), 3.92(s,2H), 3.44(s, 1H), 3.22(m,2H), 2.91(m,3H), 2.78(m, 3H), 1.77(m,2H), 1.29(d,
J=6.81Hz, 3H), 0.97(t, J=7.23Hz, 3H) ES+276.38
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Synthesis of 4-((1-substituted piperidin-4-ylidene)methyl)benzoic acid82
Step 1: Synthesis of methyl 4-((diethoxyphosphoryl)methyl)benzoate (44)
A mixture of methyl 4-(bromomethyl)benzoate (1.39 g, 5mmol) and triethyl phosphite
(1.08g, 5.5 mmol) were stirred at 150°C for 24 h in an oil bath. The mixture was purified
by reverse phase flash chromatography with a gradient of 100% water, 0% acetonitrile
for 3 column volumes, the gradient was slowly changed to 40% water in 2 column
volumes and held at 40% water for 2 column volumes. Then the gradient was slowly
chaged to 0% water, 100% acetonitrile in 3 column volumes. The product was obtained
as a colorless oil (yield-1.11 g, 78%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.96(d, J=8.22Hz, 2H), 7.34(d, J=7.98Hz,

2H), 3.99 (t, J=7.14Hz, 2H), 3.88(s,3H), 3.21(s,1H), 3.14(s,1H), 1.21(t, J=6.42Hz, 6H)
ES+286.28
Step 2: methyl 4-((1-methylpiperidin-4-ylidene)methyl)benzoate (45a) 82
The product 25 (0.29g, 1 mmol) step 1obtained from step 1 is stirred with THF (1.7 ml)
in an ice bath. To this 15-crown-5 (0.018 g, 0.08 mmol) and NaH (60% in oil, 0.04g) was
added and stirred for 30 mins at 0°C. a solution of 1-methylpiperidin-4-one (0.09 g, 0.83
mmol) dissolved in about 1ml of THF was added drop by drop to ice cold stirring mixture
for about 20 mins while maintaining the temperature of the mixture at 0°C. After the
addition of 1-methylpiperidin-4-one, the reaction was stirred at room temperature.
Reaction was monitored with TLC (50% Ethylacetate: 50% Hexanes) for completion.
After the reaction is complete the reaction mixture was poured in ice water and further
partitioned with ethylacetate. Ethylacetate layer was collected and washed with saturated
sodium bicarbonate followed by brine and finally dried over magnesium sulfate. The
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crude product was purified in purified by flash chromatography (Biotage SP4) using a
SNAP 100g column with a gradient 0% to 40% ethylacetate for 5 column volumes, the
concentration of ethyl acetate at 40% was kept constant for 2 column volumes and then
increased to 100% in 5 column volume. The purified product was obtained as white
powder (yield- 0.23g, 94%).
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.97(d, J=7.83Hz, 2H), 7.26(d, J=2.978Hz,

2H), 6.30(s, 1H) 3.90(s,3H), 3.21(s,1H), 2.51(m,4H), 2.40(m,4H), 2.29(s, 3H)
ES+245.14
tert-butyl 4-(4-(methoxycarbonyl)benzylidene)piperidine-1-carboxylate (45b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98(d, J=7.92Hz, 2H), 7.24(d, J=6.60Hz,

2H), 6.36(s, 1H) 3.90(s,3H), 3.51 (t, J=5.97Hz, 2H), 3.40 (J=5.43, 2H), 2.45(t, J=5.40Hz,
2H), 2.35(t, J=2.28Hz, 2H), 1.47(s, 9H)
ES+331.41
4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid (46a)
1

H NMR (D2O, 300MHz) δ (ppm) 7.95(d, J=7.53Hz, 2H), 7.27(d, J=7.53Hz, 2H),

6.57(s,1H), 3.30(s,2H), 3.20(s,1H), 2.85(s,3H), 2.78(t, J=5.55Hz, 2H), 2.70(t, J=5.58Hz,
2H) ES+231.29
4-((1-(tert-butoxycarbonyl)piperidin-4-ylidene)methyl)benzoic acid (46b)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.54(d, J=7.86Hz, 2H), 7.77(d, J=7.328Hz,

2H), 6.87(s, 1H), 4.01(t, J=6.21Hz, 2H) 3.91(t, J=6.66Hz, 2H), 2.96(t, J=2.88Hz, 2H),
2.85(t, J=6.18Hz, 2H), 1.96 (s, 9H) ES+331.41
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tert-butyl 4-(4-(methoxycarbonyl)benzyl)piperidine-1-carboxylate (47) 82
The product 26b ( 0.31 g, 1 mmol) was dissolved in MeOH/THF (1:1, 3 mL) and
hydrogenated at 780 psi over 10% Pd/C(water 50%, 0.02 g) at 70°C for 18 h. The
reaction mixture was filtered to remove Pd/C and concentrated in rotatory evaporator and
dried. The residue was purified by flash chromatography (Biotage SP4) using a SNAP
100g column with a gradient 0% to 60% ethylacetate for 5 column volumes, the
concentration of ethyl acetate at 60% was kept constant for 2 column volumes and then
increased to 100% in 5 column volume. The purified was product obtained as white
powder (yield- 0.32g, 98%)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 7.88(d, J=8.16Hz, 2H), 7.13(d, J=8.13Hz,

2H), 4.02(m, 2H), 3.83(s,3H), 2.52(m, 4H), 1.52(s,4H), 1.37(s, 9H), 1.10 (m,2H)
ES+233.31
4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid (48)
1

H NMR (chloroform-D3, 300MHz) δ (ppm) 8.36(d, J=8.07Hz, 2H), 7.58(d, J=9.18Hz,

2H), 4.42(d, J=14.58Hz, 2H) 2.96(m, 4H), 1.94(d, J=13.86Hz, 2H), 1.79 (s, 9H)
ES+319.40
5.4.2 Fluorescence Polarization Binding Assay
CDK4D1 FP assay: This assay was performed using black 384-well plates using
a previously described procedure55 with the following modifications. To each well were
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-ArgArg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM
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dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with
shaking for 45 min at room temperature. Fluorescence polarization was read on DTX880
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was
calculated for each concentration tested using the equation showing below. IC50 values
were determined by logarithmic regression by correlating relative mp and testing
concentrations.
mP(compound)-mP(DMSO, protein, tracer)

Relative mp = mP( DMSO, protein)-mP(DMSO, protein, tracer)
CDK2A2 FP assay This assay was performed using black 384-well plates. To
each well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-ArgLeu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for
45 mins at room temperature. Fluorescence polarization was read on DTX880 multimode
detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm excitation/emission
filters and a dichroic mirror suitable for fluorescein. Relative mp was calculated for each
concentration tested using the equation showing below. IC50 values were determined by
logarithmic regression by correlating relative mps and testing concentrations.
5.4.3 Docking55
All the N-capping groups were docked in the cyclin A/CDK2 crystal structure
(PDB

ID

2UUE)

using

1-(3,5-

dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-

carbaldehyde as control ligand. The parameters of the LigandFit (Discovery Studio 3.0,
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Accelrys) were PLP1 energy grid, minimization sphere “on”, number of poses 10. All the
docked poses analyzed with PLP1 scoring function, hydrogen bonding and were
subjected to visual analysis for complementarity with second pocket.
5.4.4 Cell culture79
U2OS osteosarcoma cells and DU145 human prostate cancer cells were obtained
from ATCC (Manassas, VA). All cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM , Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS,
USA Scientific) and 100µg/ml of Streptomycin (strep)/ 100 U/ml of Penicillin (pen).
Cells were incubated at 37ºC with 5% CO2.
5.4.5 Viability assay
Cells were seeded in 96-well plates at (2 × 103 cells/ml) and allowed to adhere
overnight in DMEM growth media containing 10% NU serum and 1% Pen/Strep. The
compounds 5965, 5966, 5967, 5968 and 5970 were dissolved in DMSO and added in a
dose dependent manner (1 µM to 100 µM). The diluted compounds were added to the
cells in triplicate and incubated for 72 hours at 37oC with 5% CO2. The cell viability was
determined

using

Bromide) assay4.

MTT (3-(4,5-Dimethylthiazol-2YI)-2,5-Diphenyl

tetrazolium

Absorbance readings were obtained using a DTX880 multimode

detector fitted with 595nm filter. Cell viability results were represented as the ratio of the
absorbance reading in treated vs. untreated cells. IC50 values were obtained using a
nonlinear regression line with 5.0 Graghpad Prism. Experiments performed in triplicates.
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CHAPTER 6
OUTLOOK FOR THE FUTUTRE DVELOPMENT OF NON-ATP COMPETITVE
COMPOUNDS AS CELL CYCLE SPECIFIC CDK INHIBITORS

CDK inhibitors comprise an important class of anticancer agents. CDKs play a
critical role in cell cycle and CDKs are deregulated in majority of human tumors40.
Although there are several drugs in development in this category with interesting
preclinical activity none have yet been approved by the FDA for clinical use41. For the
most part, CDK inhibitors that have been investigated in clinical studies lack selectivity
towards cell cycle CDK targets and have side effects as a result of their cross-reactivity42.
The main goal of this project is to develop non-ATP competitive inhibitors targeting cell
cycle CDKs. This is achieved by targeting CBG which is unique to cyclin A, D and E so
as to avoid inhibition of transcriptional CDKs. Antagonizing protein-protein interactions
at this site leads to selective inhibition of CDK2 and CDK4 that form complexes with the
cyclins A, D and E which can lead to tumor specific killing of cancer cells with
deregulated CDK/Cyclin/Rb/E2F1 pathways. Potent peptidic inhibitors have been
identified in cell permeable forms that have significant anti-tumor activity. In this study,
a novel strategy called REPLACE has been exploited to iteratively convert optimized
peptidic inhibitors which in general do not make good drugs of CDK2/cyclin A as
pharmaceutically appropriate compounds. Targeting protein-protein interactions (PPI) in
drug discovery is highly challenging as these typically involve a large shallow contact
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interface comprised ofnumerous and diffuse contacts83. Furthermore, peptidic
compounds which inhibit PPI’s that are amenable to drug discovery are problematic due
to their metabolic instability, cell permeability and poor bioavailability48. Current
strategies that have been applied for the development of PPI inhibitors include design of
proteomimetics and fragment based design84,85. REPLACE is an iterative strategy
comprised of computational prediction, synthetic organic chemistry and biological
evaluation used to convert peptidic inhibitors into FLIPs and ultimately non-peptidic
drug-like compounds. Using REPLACE, fragment alternatives are designed and
identified to mimic the interactions of binding determinants of a peptidic inhibitor. The
combination of structural analysis along with synthetic methodologies and biological
evaluation results in the efficient design of molecules that interact with hot spots (sites of
critical interaction) and complement the large contact surface area of the PPI binding site.
REPLACE overcomes the disadvantages of conventional fragment based design since the
peptide acts as an affinity and solubility scaffold. Also the iterative nature of REPLACE
means that the inhibitor is gradually converted in several steps therefore minimizing the
possibility of complete potency loss through conformation change. PLAs are optimized in
the context of the peptide prior to further truncation. In this study REPLACE has been
exploited to generate more drug-like inhibitors that selectively inhibit cell cycle
CDK/cyclin complexes and possess significant anti-proliferative activity. Capped
peptides have been identified as more drug-like mimics of the lead octapeptide. Key
fragment alternatives discovered include N-caps based on (i) phenyl heterocyclic
carboxylic acids63, (ii) furan and thiazole carboxylic acids substituted with alkylamino
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groups68 and (iii) pyridine carboxylic acids modified with alkoxy or basic groups68, (iv)
phenylacetic acid derivatives68 and (v) benzoic acid derivatives.
The first stage of the REPLACE49 strategy was identification of fragment
alternatives for key peptide determinants using high-throughput docking. LigandFit55, a
shape based docking method was employed for evaluating binding of fragments in the
cyclin groove. LigandFit55 generates poses that have high complementarity with a
binding site through the use of Monte Carlo conformational search methods in
conjunction with a shape based comparison filter. Use of a LigandFit protocol with the
PLP1 energy grid and a minimization step to refine generated poses, was shown to
reproduce known binding modes of previously determined N-capping groups. An
accurate prediction of the binding affinity of the generated poses was provided by using
the PLP1 scoring function which was shown to obtain the best results since it takes into
account hydrogen bonding between the ligand and receptor. Specific H-bonds and ionpairing interaction of CGI ligands with the cyclin groove have been shown to be
important determinants of high affinity binding. Potential fragment alternatives for the Nterminus were synthesized or obtained from commercial sources and then used to
generate FLIP molecules through coupling to an assembled peptide on a solid support 56.
The ability of FLIPs to recapitulate the affinity of the native peptide is determined in a
competitive binding assay using a known cyclin groove inhibitory peptide which is
fluorescently labeled57. This assay has an important advantage which shows the inhibition
of CDK2/cyclin A and CDK4/cyclin D complexes through specific binding of FLIPs on
target (CBG). After confirmation of the ability of FLIPs to bind with sufficient avidity to
the CBG, the potency of the peptide-fragment hybrids can then be further refined through
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modifications to the N-capping groups. Initial studies examined the SAR of phenyl
heterocyclic carboxylic acids as N-capping groups with these being designed to retain Hbond interactions (Trp217 and Gln 254) and hydrophobic complementarity with
secondary pocket63. Subsequent to this, additional Ncap scaffolds were pursued in order
to provide charge-charge interactions with the acidic regions of CBG in addition to the Hbond and minor pocket complementarity. To achieve this furoic and picolinic acid based
derivatives were exploited and found to be moderately effective68. Benzoic acid based Ncaps easy to synthesize and were used to generate diverse SAR providing interactions
with multiple subsites of CBG with the aim of improving previously developed scaffolds.
Through the N-cap development and optimization critical interactions important for
binding at the CBG was studied. The critical N-terminal residue Arg was replaced so as
to reduce the charge of the overall compound and also to improve metabolic stability of
the FLIP molecule.
After identification of more optimal Ncaps, in order to make the rest of the
peptidic cyclin groove inhibitor more drug-like, REPLACEments for C-terminal motif
interacting with the major hydrophibic pocket were investigated. Non-natural residues
(β-Leu for Leu and Ile, NMePh/3TA for Phe) were incorporated to improve metabolic
stability of the FLIPs along with retaining interactions at the primary pocket71,72. Along
with metabolic stability, modification with a C-terminal amide functionality improved
physicochemical properties such as clogP and polar surface area that contribute to drug
like characteristics. After identifying a more optimal C-terminal motif, these were then
combined with the most effective Ncap to generate FLIPS which should have greater
metabolic stability and cell permeability. After confirming their binding activity, the
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more drug like inhibitors were further tested for their anti-proliferative activity in cancer
cell lines that harbor deregulated CDK/Cyclin/Rb/E2F1 pathways52,54. The effects on cell
cycle distribution for the lead CGI compound, SCCP5964 were determined by FACS
analysis and revealed that this molecule induces a G1 arrest, an observation consistent
with the inhibition of cell cycle CDKs.
Overall significant progress has been achieved in further validating the
REPLACE strategy in the generation of more drug-like cyclin groove inhibitors that are
cell permeable and have anti-proliferative activity. These are the first reported CGI
compounds that are innately drug-like and have anti-tumor activity. These compounds
therefore form a novel class of CDK inhibitors with their unique capability to specifically
inhibit cell cycle specific CDKs unlike clinically investigated compounds that target ATP
binding pocket. The REPLACE strategy has been successfully employed in the iterative
conversion of peptidic inhibitors into more drug like compounds with anti-tumor activity
consistent with on target inhibition demonstrating their potential for drug development.
These compounds therefore have significant potential for further development as antitumor therapeutics that show specificity towards cancer cells and potentially reduce the
toxicities observed with ATP competitive compounds.
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APPENDIX A
CHARACTERIZATION DATA OF REPRESENTATIVE N-CAPS

Figure A.1 MS: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid

Figure A.2 NMR: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid
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Figure A.3 13CNMR: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid

Figure A.4 MS-1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid
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Figure A.5 NMR- 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid

Figure A.6 MS- 5-(3,5-dichlorophenyl)furan-2-carboxylic acid
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Figure A.7 NMR- 5-(3,5-dichlorophenyl)furan-2-carboxylic acid

Figure A.8 MS- 2-(3-propoxyphenyl)acetic acid
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Figure A.9 NMR- 2-(3-propoxyphenyl)acetic acid

Figure A.10 MS: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid
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Figure A.11 1HNMR: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid

Figure A.12 12CNMR: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid
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Figure A.13 MS:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-methoxybenzoic acid

Figure A.14 1HNMR:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-methoxybenzoic
acid
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Figure A.15 13CNMR:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)
-3-methoxybenzoic acid

Figure A.16 MS: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)
-3-hydroxybenzoic acid
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Figure A.17 NMR: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-hydroxybenzoic
acid

Figure A.18 MS: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoicacid

171

Figure A.19 NMR: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoic
acid

Figure A.20 MS:(S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic
acid
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Figure A.21 NMR:(R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1yl)methyl)benzoic acid

Figure A.22 MS: 4-(((1-(tert-butoxycarbonyl)piperidin-4yl)(methyl)amino)methyl)benzoic acid
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Figure A.23 NMR: 4-(((1-(tert-butoxycarbonyl)piperidin-4yl)(methyl)amino)methyl)benzoic acid

Figure A.24 MS: (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3hydroxybenzoic acid
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Figure A.25 NMR: (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3hydroxybenzoic acid

Figure A.26 MS: 4-((4-propylpiperazin-1-yl)methyl)benzoic acid
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Figure A.27 NMR: 4-((4-propylpiperazin-1-yl)methyl)benzoic acid

Figure A.28 MS (S)-4-((2-methyl-4-ethylpiperazin-1-yl)methyl)benzoic acid
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Figure A.29 NMR: (S)-4-((2-methyl-4-ethylpiperazin-1-yl)methyl)benzoic acid

Figure A.30 MS: 4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid
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Figure A.31 NMR: 4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid

Figure A.32 MS: 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid
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Figure A.33 NMR: 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid
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APPENDIX B:
CHARACTERIZATION DATA OF FLIP MOLECULES
Table B.1 Analytical data for FLIPs based on phenyl heterocyclic carboxylic acid
derivatives
FLIP

Purity

Column
Dimensions

Method

Flow rate

HPLC
Retention
Time

Theoretical
MW

Observed
MW

5843

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

23.9

732

732.6

5773

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.4

801.77

800.55

5774

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

24.2

767.33

766.5

5762

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

9.0

731.91

731.65

5763

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

11.2

800.8

799.5

5764

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

10.1

766.34

765.55

5771

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

9.4

749.9

749.6

5765

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

10.1

766.35

755.65

5766

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

9.4

761.9

761.55

5767

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

20.4

761.9

761.55

5776

>75%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

23.3

785.7

784.55

5775

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

9.9

751.34

750.45

5768

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

11.4

786.77

787.55

5769

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.9

752.3

751.55

5772

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

9.7

735.87

735.65

5770

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

10.4

752.32

751.55

5588

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

21.7

747.9

747.4

5587

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.5

731.9

731.4

5760

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.2

731.9

731.6

5852

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

19.2

735.69

735.4

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

23.6

769.37

768.3

5583
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Table B.2 Analytical data for FLIPs based on thiazole, furan carboxylic acid, picolinic
acid, phenylacetic acids
Column
Dimensions

Method

Flow rate

HPLC
Retention
Time

Theoretical Observed
MW
MW

FLIP

Purity

5581

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

18.58

726.9

727.4

5585

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

17.94

721.82

721.45

5584

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

21.48

740.95

740.4

5589

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

17.82

753.95

753.45

5586

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

21.83

721.86

721.35

5582

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

21.10

740.95

740.25

5761

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

7.21

735.9

735.55

5845

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

19.68

666.69

666.55

5856

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

19.81

735.69

737.0

5854

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

19.85

709.69

709.45

5855

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

11.71

737.69

737.45

5853

>90%

4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min

22.42

723.69

723.45
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Table B.3 Analytical data for peptides and FLIPs derived from p21 and p107
Peptide

Purity

Column
Dimensions

Method

Flow rate

HPLC Retention Theoretical Observed
Time
MW
MW

540

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

14.97

722.8

5811

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

16.5

703.88

703.8

5812

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

19.54

704.88

704.45

5831

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.68

704.89

704.9

5832

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.48

644.81

644.45

5833

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

21.05

618.77

618.4

722.4

5871

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

14.81

647.77

647.9

5873

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

18.02

604.74

604.45

5874

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

14.36

590.72

590.45

5875

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

15.15

604.7

605.1

5876

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

14.84

661.5

661.55

5941

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

16.51

618.78

618.25

5925

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

16.8

716.9

717.4

5930

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

16.63

618.72

617.9

5918

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.09

703.87

703.4

5877

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.69

675

676

5878

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

21.22

681

681.4

5879

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.2

689.87

689.6

5815

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

15.71

934.1

934.6

5814

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

13.14

940.14

940
948.2

5820

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

11.13

948.12

5813

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

13.36

953.14

953.9

5816

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

17.1

1046.4

1046.4

444

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

14.84

1040.27

1040.3

5557

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

15.97

1023.22

1023.2

5558

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

1.0ml/min

13.9

891.03

890.5

1.0ml/min

16.5

980.19

980.1

1.0ml/min

15.94

1064.31

1064.45

5559

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)

5564

>90%

4.6X250mm

5-95% acetonitrile(0.05%TFA)/water(0.065%TFA)
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Table B.4 Analytical data for FLIPs based on benzoic acid derivatives
SCCP ID

Purity

Column
Dimensions

Method

Flow rate

HPLC Retention
Time

Theoretical
MW

Observed
MW

5857

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.36

651.69

651.4

5858

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

10.3

681.69

681.4

5844

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

12.93

723.92

723.6

5846

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

21.01

743.5

743.55

5882

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

20.66

695.86

695.5

5883

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

22.65

709.89

709.5

5851

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

20.65

749.69

750.45

5850

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

19..79

734.69

736.4

5896

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

21.22

779.5

780.55

5919

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.74

749.7

749.4

5923

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

19.52

664.59

664.29

5920

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.44

765.7

765.1

5922

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

19.14

808.69

807.5

5921

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.99

763.7

763.2

5965

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

19.55

665.69

665.5

5966

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.02

680.69

708.5

5968

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

18.81

708.69

708.5

5967

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.8

760.69

761.6

5969

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

18.19

678.69

678.75

5970

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.87

679.54

678.55

6033

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

16.37

683.94

684.4

6034

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

16.07

697.97

698.3

6031

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

17.14

653.28

653.2

6032

>90%

4.6 × 250 mm

5-65% acetonitrile/water/0.1%TFA

1ml/min

18.28

722.09

721.25
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